| CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2015;2(4):269-396 | 38617 |
| CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2016;4:262-379 | 18723 |
| THE ALZHEIMER’S PREVENTION CLINIC AT WEILL CORNELL MEDICAL COLLEGE / NEW YORK - PRESBYTERIAN HOSPITAL: RISK STRATIFICATION AND PERSONALIZED EARLY INTERVENTION | J Prev Alz Dis 2015;2(4):254-266 | 8259 |
| ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2015;2(2):128-135 | 7525 |
| RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK | J Prev Alz Dis 2016;3(2):114-120 | 6293 |
| Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020 | J Prev Alz Dis 2020;7(S1):S55-S119 | 6112 |
| CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL | J Prev Alz Dis 2017;4(3):149-156 | 5829 |
| A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) | J Prev Alz Dis 2015;2(4):227-241 | 5382 |
| VITAMIN D AND DEMENTIA | J Prev Alz Dis 2016;3(1):43-52 | 5157 |
| CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT” | J Prev Alz Dis 2016;3(4):219-228 | 4632 |
| A PERSONALIZED 12-WEEK “BRAIN FITNESS PROGRAM” FOR IMPROVING COGNITIVE FUNCTION AND INCREASING THE VOLUME OF HIPPOCAMPUS IN ELDERLY WITH MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2016;3(3):133-137 | 3980 |
| PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER’S DISEASE AND OTHER TAUOPATHIES | J Prev Alz Dis 2017;4(4):236-241 | 3914 |
| REVERSIBLE AND SPECIES-SPECIFIC DEPIGMENTATION EFFECTS OF AZD3293, A BACE INHIBITOR FOR THE TREATMENT OF ALZHEIMER’S DISEASE, ARE RELATED TO BACE2 INHIBITION AND CONFINED TO EPIDERMIS AND HAIR | J Prev Alz Dis 2016;3(4):202-218 | 3227 |
| DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(2):109-115 | 3170 |
| BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE IN ASYMPTOMATIC ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(1):30-42 | 3083 |
| COMBINATION THERAPY OF ANTI-TAU AND ANTI-AMYLOID DRUGS FOR DISEASE MODIFICATION IN EARLY-STAGE ALZHEIMER’S DISEASE: SOCIO-ECONOMIC CONSIDERATIONS MODELED ON TREATMENTS FOR TUBERCULOSIS, HIV/AIDS AND BREAST CANCER | J Prev Alz Dis 2016;3(3):164-172 | 2931 |
| ETHICAL ISSUES IN THE DEVELOPMENT OF READINESS COHORTS IN ALZHEIMER’S DISEASE RESEARCH | J Prev Alz Dis 2017;4(2):125-131 | 2824 |
| NEFLAMAPIMOD: CLINICAL PHASE 2B-READY ORAL SMALL MOLECULE INHIBITOR OF P38? TO REVERSE SYNAPTIC DYSFUNCTION IN EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(4):273-278 | 2728 |
| CLINICAL AND ECONOMIC CHARACTERISTICS OF MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: TRANSFORMING FUNCTIONAL SCORES INTO LEVELS OF DEPENDENCE | J Prev Alz Dis 2015;2(2):115-120 | 2665 |
| THE ALZHEIMER’S PREVENTION INITIATIVE GENERATION PROGRAM: EVALUATING CNP520 EFFICACY IN THE PREVENTION OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(4):242-246 | 2652 |
| EVALUATION OF THE NEUROPROTECTIVE POTENTIAL OF N-ACETYLCYSTEINE FOR PREVENTION AND TREATMENT OF COGNITIVE AGING AND DEMENTIA | J Prev Alz Dis 2017;4(3):201-206 | 2521 |
| BRIDGING THE TRANSLATION GAP: FROM DEMENTIA RISK ASSESSMENT TO ADVICE ON RISK REDUCTION | J Prev Alz Dis 2015;2(3):189-198 | 2503 |
| CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(3):138-144 | 2485 |
| SAFETY AND EFFICACY OF LEMBOREXANT IN PATIENTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND ALZHEIMER’S DISEASE DEMENTIA: RESULTS FROM A PHASE 2 RANDOMIZED CLINICAL TRIAL | J Prev Alz Dis 2021;1(8):7-18 | 2468 |
| THE RELATIONSHIP OF OMEGA 3 POLYUNSATURATED FATTY ACIDS IN RED BLOOD CELL MEMBRANES WITH COGNITIVE FUNCTION AND BRAIN STRUCTURE: A REVIEW FOCUSSED ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(1):78-84 | 2414 |
| POST HOC EVIDENCE FOR AN ADDITIVE EFFECT OF MEMANTINE AND DONEPEZIL: CONSISTENT FINDINGS FROM DOMINO-AD STUDY AND MEMANTINE CLINICAL TRIAL PROGRAM | J Prev Alz Dis 2015;2(3):165-171 | 2406 |
| FROM BRAIN DISEASE TO BRAIN HEALTH: PRIMARY PREVENTION OF ALZHEIMER’S DISEASE AND RELATED DISORDERS IN A HEALTH SYSTEM USING AN ELECTRONIC MEDICAL RECORD-BASED APPROACH | J Prev Alz Dis 2017;4(3):157-164 | 2310 |
| SHORT-TERM IMPACT OF A COMBINED NUTRACEUTICAL ON COGNITIVE FUNCTION, PERCEIVED STRESS AND DEPRESSION IN YOUNG ELDERLY WITH COGNITIVE IMPAIRMENT: A PILOT, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL | J Prev Alz Dis 2017;4(1):12-15 | 2302 |
| MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATA | J Prev Alz Dis 2014;1(1):13-22 | 2221 |
| B-VITAMIN THERAPY FOR KIDNEY TRANSPLANT RECIPIENTS LOWERS HOMOCYSTEINE AND IMPROVES SELECTIVE COGNITIVE OUTCOMES IN THE RANDOMIZED FAVORIT ANCILLARY COGNITIVE TRIAL | J Prev Alz Dis 2017;4(3):174-182 | 2159 |
| 17th Clinical Trials on Alzheimer\'s Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Conference proceedings | | 2114 |
| THE CASE FOR USING ACTIGRAPHY GENERATED SLEEP AND ACTIVITY ENDPOINTS IN ALZHEIMER’S DISEASE CLINICAL TRIALS | J Prev Alz Dis 2016;3(3):173-176 | 2061 |
| INTEGRATED CARE FOR OLDER PEOPLE AND THE IMPLEMENTATION IN THE INSPIRE CARE COHORT | J Prev Alz Dis 2020;7(2):70-74 | 2051 |
| DEPENDENCE LEVELS AS INTERIM CLINICAL MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: 18-MONTH RESULTS FROM THE GERAS OBSERVATIONAL STUDY | J Prev Alz Dis 2017;4(2):72-80 | 1963 |
| ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE 2020 | J Prev Alz Dis 2020;7(2):66-67 | 1918 |
| Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021 | J Prev Alz Dis 2021;8(S1):S73-S170 | 1799 |
| ANTI-TAU TRIALS FOR ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2019;6(3):157-163 | 1792 |
| THE ROSAS COHORT: A PROSPECTIVE, LONGITUDINAL STUDY OF BIOMARKERS FOR ALZHEIMER’S DISEASE. STRATEGY, METHODS AND INITIAL RESULTS | J Prev Alz Dis 2017;4(3):183-193 | 1787 |
| RATIONALE AND STRUCTURE FOR A NEW CENTER FOR STUDIES ON PREVENTION OF ALZHEIMER’S DISEASE (STOP-AD) | J Prev Alz Dis 2016;3(4):236-242 | 1751 |
| ‘ALZHEIMER’S PROGRESSION SCORE’: DEVELOPMENT OF A BIOMARKER SUMMARY OUTCOME FOR AD PREVENTION TRIALS | J Prev Alz Dis 2016;3(4):229-235 | 1731 |
| Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020 | J Prev Alz Dis 2020;7(S1):S2-S54 | 1650 |
| PIMAVANSERIN IN ALZHEIMER’S DISEASE PSYCHOSIS: EFFICACY IN PATIENTS WITH MORE PRONOUNCED PSYCHOTIC SYMPTOMS | J Prev Alz Dis 2019;6(1):27-33 | 1596 |
| WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCE | J Prev Alz Dis 2018;5(3):171-170 | 1587 |
| HEALTH LITERACY IN INDIVIDUALS AT RISK FOR ALZHEIMER’S DEMENTIA: A SYSTEMATIC REVIEW | J Prev Alz Dis 2020;7(1):47-55 | 1587 |
| AN ACTION PLAN TO FACE THE CHALLENGE OF DEMENTIA: INTERNATIONAL STATEMENT ON DEMENTIA FROM IAP FOR HEALTH | J Prev Alz Dis 2018;5(3):207-212 | 1527 |
| FATTY ACIDS AND ALZHEIMER’S DISEASE: EVIDENCE ON COGNITION AND CORTICAL ?-AMYLOID FROM SECONDARY ANALYSES OF THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL | J Prev Alz Dis 2018;5(3):168-170 | 1517 |
| PSYCHOMETRIC PROPERTIES OF THE CLINICAL DEMENTIA RATING – SUM OF BOXES AND OTHER COGNITIVE AND FUNCTIONAL OUTCOMES IN A PRODROMAL ALZHEIMER’S DISEASE POPULATION | J Prev Alz Dis 2021;2(8):151-160 | 1512 |
| VITAMIN E SUPPLEMENTATION REDUCES CELLULAR LOSS IN THE BRAIN OF A PREMATURE AGING MOUSE MODEL | J Prev Alz Dis 2017;4(4):226-235 | 1500 |
| NUTRITION-BASED APPROACHES IN CLINICAL TRIALS TARGETING COGNITIVE FUNCTION: HIGHLIGHTS OF THE CTAD 2020 | J Prev Alz Dis 2021;2(8):118-122 | 1484 |
| NANOROBOTS THE FUTURE OF NEUROLOGY: A PERSPECTIVE ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(2):155-156 | 1481 |
| IDENTIFYING BETTER OUTCOME MEASURES TO IMPROVE TREATMENT OF AGITATION IN DEMENTIA: A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2018;5(2):98-102 | 1445 |
| THE FUTURE OF ANTI-AMYLOID TRIALS | J Prev Alz Dis 2020;3(7):146-151 | 1428 |
| CAN DIGITAL TECHNOLOGY ADVANCE THE DEVELOPMENT OF TREATMENTS FOR ALZHEIMER’S DISEASE? | J Prev Alz Dis 2019;6(4):217-220 | 1402 |
| REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMER’S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMER’S DISEASE TASK FORCE | J Prev Alz Dis 2016;3(2):68-74 | 1401 |
| ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(4):232-236 | 1395 |
| MULTIDOMAIN INTERVENTIONS TO PREVENT COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, AND DEMENTIA: FROM FINGER TO WORLD-WIDE FINGERS | J Prev Alz Dis 2020;7(1):29-36 | 1363 |
| PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORT | J Prev Alz Dis 2019;6(3):169-173 | 1353 |
| RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIES | J Prev Alz Dis 2020;3(7):158-164 | 1293 |
| PIMAVANSERIN: POTENTIAL TREATMENT FOR DEMENTIA-RELATED PSYCHOSIS | J Prev Alz Dis 2018;5(4):253-258 | 1281 |
| EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN PRIMARY CARE | J Prev Alz Dis 2020;3(7):165-170 | 1277 |
| NON-AMYLOID APPROACHES TO DISEASE MODIFICATION FOR ALZHEIMER’S DISEASE: AN EU/US CTAD TASK FORCE REPORT | J Prev Alz Dis 2020;3(7):152-157 | 1274 |
| IMPLICATIONS FOR BACE1 INHIBITOR CLINICAL TRIALS: ADULT CONDITIONAL BACE1 KNOCKOUT MICE EXHIBIT AXONAL ORGANIZATION DEFECTS IN THE HIPPOCAMPUS | J Prev Alz Dis 2019;6(2):78-84 | 1241 |
| TREATABLE VASCULAR RISK AND COGNITIVE PERFORMANCE IN PERSONS AGED 35 YEARS OR OLDER: LONGITUDINAL STUDY OF SIX YEARS | J Prev Alz Dis 2019;6(1):42-49 | 1213 |
| TARGETING LIFESTYLE BEHAVIOR TO IMPROVE BRAIN HEALTH: USER-EXPERIENCES OF AN ONLINE PROGRAM FOR INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE | J Prev Alz Dis 2020;3(7):184-194 | 1210 |
| EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER’S PREVENTION TRIALS | J Prev Alz Dis 2017;4(2):116-124 | 1205 |
| APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMER’S DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDY | J Prev Alz Dis 2019;6(4):248-255 | 1180 |
| THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA (EPAD) LONGITUDINAL COHORT STUDY: BASELINE DATA RELEASE V500.0 | J Prev Alz Dis 2020;7(1):8-13 | 1170 |
| THE INTERRELATIONSHIP BETWEEN INSULIN-LIKE GROWTH FACTOR 1, APOLIPOPROTEIN E Ε4, LIFESTYLE FACTORS, AND THE AGING BODY AND BRAIN | J Prev Alz Dis 2020;4(7):265-273 | 1166 |
| POSSIBLE ENDPOINTS IN A PRODROMAL ALZHEIMER’S DISEASE TRIAL | J Prev Alz Dis 2015;2(2):88-90 | 1154 |
| REVISITING THE HALLMARKS OF AGING TO IDENTIFY MARKERS OF BIOLOGICAL AGE | J Prev Alz Dis 2020;7(1):56-64 | 1148 |
| CORTICAL Β-AMYLOID IN OLDER ADULTS IS ASSOCIATED WITH MULTIDOMAIN INTERVENTIONS WITH AND WITHOUT OMEGA 3 POLYUNSATURATED FATTY ACID SUPPLEMENTATION | J Prev Alz Dis 2020;7(2):128-134 | 1145 |
| A TURNING POINT IN ALZHEIMER’S RESEARCH: HARMONIZED RESEARCH STRATEGIES AND NOVEL INVESTMENTS IN PUBLIC HEALTH INFRASTRUCTURE ARE REENERGIZING THE FIELD, AND REKINDLING HOPE FOR THOSE AFFECTED BY ALZHEIMER’S AND RELATED DEMENTIAS | J Prev Alz Dis 2019;6(4):214-216 | 1139 |
| DOES PLAYING MAHJONG BENEFIT OLDER INDIVIDUALS? A SCOPING REVIEW | J Prev Alz Dis 2024;5(11):1363-1377 | 1124 |
| DIET AS A RISK FACTOR FOR COGNITIVE DECLINE IN AFRICAN AMERICANS AND CAUCASIANS WITH A PARENTAL HISTORY OF ALZHEIMER’S DISEASE: A CROSS- SECTIONAL PILOT STUDY DIETARY PATTERNS | J Prev Alz Dis 2019;6(1):50-55 | 1117 |
| UTILIZATION OF OBSERVATIONAL DATA AS A PROXY COHORT FOR COMPARISON PURPOSES WITH OPEN-LABEL STUDY RESULTS: AN EXAMPLE FROM ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(2):90-99 | 1104 |
| VIEWPOINT: WHEN IT COMES TO LECANEMAB (AND DONANEMAB), HOW MIGHT WE THINK ABOUT ‘REASONABLE AND NECESSARY’? | J Prev Alz Dis 2023;3(10):342-343 | 1067 |
| A MISSED OPPORTUNITY FOR DEMENTIA PREVENTION? CURRENT CHALLENGES FOR EARLY DETECTION AND MODERN-DAY SOLUTIONS | J Prev Alz Dis 2020;4(7):291-293 | 1066 |
| SCREENING FOR MILD COGNITIVE IMPAIRMENT: THERE IS THE WILL BUT IS THERE A WAY? | J Prev Alz Dis 2020;3(7):144-145 | 1050 |
| EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTING | J Prev Alz Dis 2020;3(7):171-178 | 1047 |
| CORRELATION OF CSF- AND MRI-BIOMARKERS AND PROGRESSION OF COGNITIVE DECLINE IN AN OPEN LABEL MCI TRIAL | J Prev Alz Dis 2018;5(3):202-206 | 1044 |
| LIFESTYLE INTERVENTIONS FOR DEMENTIA RISK REDUCTION: A REVIEW ON THE ROLE OF PHYSICAL ACTIVITY AND DIET IN WESTERN AND ASIAN COUNTRIES | J Prev Alz Dis 2025;2(12) | 1023 |
| IMPACT OF THE COVID-19 OUTBREAK ON THE CLINICAL AND RESEARCH ACTIVITIES OF MEMORY CLINICS: AN ALZHEIMER’S DISEASE CENTER FACING THE COVID-19 CRISIS | J Prev Alz Dis 2020;3(7):197-198 | 994 |
| ESTABLISHING CLINICAL RELEVANCE IN PRECLINICAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(2):85-87 | 977 |
| DIGITAL SCREENING FOR COGNITIVE IMPAIRMENT – A PROOF OF CONCEPT STUDY | J Prev Alz Dis 2021;2(8):127-134 | 966 |
| POLYGENIC RISK SCORE ANALYSIS OF ALZHEIMER’S DISEASE IN CASES WITHOUT APOE4 OR APOE2 ALLELES | J Prev Alz Dis 2019;6(1):16-19 | 961 |
| COGNITIVE/CLINICAL ENDPOINTS FOR PRE-DEMENTIA AD TRIALS | J Prev Alz Dis 2015;2(2):82-84 | 944 |
| DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE: CLINICAL PRACTICE IN 2021 | J Prev Alz Dis 2021;3(8):371-386 | 944 |
| ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS | J Prev Alz Dis 2021;4(8):398-410 | 936 |
| PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALS | J Prev Alz Dis 2020;4(7):213-218 | 932 |
| THE ROLE OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER’S DISEASE DRUG DEVELOPMENT PROGRAMS | J Prev Alz Dis 2020;4(7):288-290 | 918 |
| HOW WILL ADUCANUMAB APPROVAL IMPACT AD RESEARCH? | J Prev Alz Dis 2021;4(8):391-392 | 918 |
| APPLICATION OF DIGITAL COGNITIVE BIOMARKERS FOR ALZHEIMER’S DISEASE: IDENTIFYING COGNITIVE PROCESS CHANGES AND IMPENDING COGNITIVE DECLINE | J Prev Alz Dis 2021;2(8):123-126 | 898 |
| EVALUATION OF THE FISCAL COSTS AND CONSEQUENCES OF ALZHEIMER’S DISEASE IN GERMANY: MICROSIMULATION OF PATIENTS’ AND CAREGIVERS’ PATHWAYS | J Prev Alz Dis 2022;4(9):758-768 | 894 |
| THE COMPUTERIZED COGNITIVE COMPOSITE (C3) IN A4, AN ALZHEIMER’S DISEASE SECONDARY PREVENTION TRIAL | J Prev Alz Dis 2021;1(8):59-67 | 883 |
| EDITORIAL: APPROPRIATE USE RECOMMENDATIONS FOR LECANEMAB | J Prev Alz Dis 2023;3(10):356 | 883 |
| TWO RANDOMIZED PHASE 3 STUDIES OF ADUCANUMAB IN EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;2(9):197-210 | 880 |
| THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) PROJECT: AN OVERVIEW | J Prev Alz Dis 2020;4(7):208-212 | 870 |
| IMPACT OF ADUHELM APPROVAL ON CARE AND POLICY | J Prev Alz Dis 2021;4(8):396-397 | 869 |
| A FRAMEWORK FOR DEVELOPING PHARMACOTHERAPY FOR AGITATION IN ALZHEIMER’S DISEASE: RECOMMENDATIONS OF THE ISCTM* WORKING GROUP | J Prev Alz Dis 2020;4(7):274-282 | 866 |
| THIRTY-SIX-MONTH AMYLOID POSITRON EMISSION TOMOGRAPHY RESULTS SHOW CONTINUED REDUCTION IN AMYLOID BURDEN WITH SUBCUTANEOUS GANTENERUMAB | J Prev Alz Dis 2021;1(8):3-6 | 862 |
| THE EPIDEMIOLOGY OF ALZHEIMER’S DISEASE MODIFIABLE RISK FACTORS AND PREVENTION | J Prev Alz Dis 2021;3(8):313-321 | 854 |
| VIEWPOINT: WHAT IS REASONABLE AND NECESSARY FOR PEOPLE LIVING WITH AD AFTER THE FDA APPROVES A TREATMENT? | J Prev Alz Dis 2023;3(10):344-345 | 851 |
| THE ALZHEIMER’S PREVENTION REGISTRY: A LARGE INTERNET-BASED PARTICIPANT RECRUITMENT REGISTRY TO ACCELERATE REFERRALS TO ALZHEIMER’S-FOCUSED STUDIES | J Prev Alz Dis 2020;4(7):242-250 | 839 |
| TRANSLATING THE BIOLOGY OF AGING INTO NEW THERAPEUTICS FOR ALZHEIMER’S DISEASE: SENOLYTICS | J Prev Alz Dis 2023;4(10):633-646 | 833 |
| ACCELERATING PRECLINICAL ALZHEIMER’S CLINICAL TRIALS THROUGH A TRIAL-READY COHORT WITH DIVERSE REPRESENTATION | J Prev Alz Dis 2020;4(7):204-205 | 828 |
| NEXT-GENERATION ALZHEIMER’S THERAPEUTICS: LEVERAGING DEEP BIOLOGY | J Prev Alz Dis 2020;3(7):138-139 | 820 |
| THE US EXPERT PANEL ON THE APPROPRIATE USE RECOMMENDATIONS OF ADUCANUMAB IN CLINICAL PRACTICE | J Prev Alz Dis 2021;4(8):411 | 806 |
| AMYLOID AND APOE STATUS OF SCREENED SUBJECTS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAM | J Prev Alz Dis 2021;2(8):218-223 | 804 |
| TOULOUSE ALZHEIMER’S CLINICAL RESEARCH CENTER RECOVERY AFTER THE COVID-19 CRISIS: TELEMEDICINE AN INNOVATIVE SOLUTION FOR CLINICAL RESEARCH DURING THE CORONAVIRUS PANDEMIC | J Prev Alz Dis 2020;4(7):301-304 | 801 |
| THE TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD): EXPERIENCE FROM THE FIRST 3 YEARS | J Prev Alz Dis 2020;4(7):234-241 | 791 |
| PUBLIC POLICY SHOULD FOSTER ALZHEIMER’S TREATMENT AVAILABILITY: COMMENT ON THE DRAFT US MEDICARE DECISION TO LIMIT PAYMENT FOR ADUCANUMAB (ADUHELMTM) TO PATIENTS PARTICIPATING IN CLINICAL TRIALS | J Prev Alz Dis 2022;2(9):241-246 | 788 |
| LECANEMAB CLARITY AD: QUALITY-OF-LIFE RESULTS FROM A RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIAL IN EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):771-777 | 783 |
| NEUROINFLAMMATION, ITS ROLE IN ALZHEIMER’S DISEASE AND THERAPEUTIC STRATEGIES | J Prev Alz Dis 2023;4(10):686-698 | 782 |
| THE ROLE OF FUTILITY ANALYSES IN AD CLINICAL TRIALS | J Prev Alz Dis 2020;7(1):7 | 781 |
| INTRANASAL INSULIN REDUCES WHITE MATTER HYPERINTENSITY PROGRESSION IN ASSOCIATION WITH IMPROVEMENTS IN COGNITION AND CSF BIOMARKER PROFILES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;3(8):240-248 | 779 |
| Clinical Trials and Aging: 14th Conference Clinical Trials Alzheimer’s Disease, November 9-12, 2021 | J Prev Alz Dis 2021;8(S1):S1-S72 | 773 |
| NEW HOPE FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;3(8):238-239 | 769 |
| GENDER-SPECIFIC DESIGN AND EFFECTIVENESS OF NONPHARMACOLOGICAL INTERVENTIONS AGAINST COGNITIVE DECLINE – SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS | J Prev Alz Dis 2023;1(10):69-82 | 766 |
| CONSEQUENCES OF THE FDA DECISION ON ADUCANUMAB FOR PATIENT CARE AND RESEARCH | J Prev Alz Dis 2021;4(8):393-395 | 759 |
| POLYGENIC RISK SCORING IS AN EFFECTIVE APPROACH TO PREDICT THOSE INDIVIDUALS MOST LIKELY TO DECLINE COGNITIVELY DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;1(8):78-83 | 758 |
| MESENCHYMAL STEM CELLS MODULATE SIRT1/MIR-134/ GSK3Β SIGNALING PATHWAY IN A RAT MODEL OF ALZHEIMER\'S DISEASE | J Prev Alz Dis 2022;3(9):458-468 | 747 |
| RECRUITMENT INTO THE ALZHEIMER PREVENTION TRIALS (APT) WEBSTUDY FOR A TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRCPAD) | J Prev Alz Dis 2020;4(7):219-225 | 735 |
| VALIDATION, DEPLOYMENT, AND REAL-WORLD IMPLEMENTATION OF A MODULAR TOOLBOX FOR ALZHEIMER’S DISEASE DETECTION AND DEMENTIA RISK REDUCTION: THE AD-RIDDLE PROJECT | J Prev Alz Dis 2024;2(11):329-338 | 734 |
| “TIME SAVED” CALCULATIONS TO IMPROVE DECISION-MAKING IN PROGRESSIVE DISEASE STUDIES | J Prev Alz Dis 2024;3(11):529-536 | 724 |
| MODULATION OF MITOCHONDRIAL FUNCTION AS A THERAPEUTIC STRATEGY FOR NEURODEGENERATIVE DISEASES | J Prev Alz Dis 2023;4(10):675-685 | 710 |
| ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS | J Prev Alz Dis 2021;4(8):412-413 | 708 |
| LETTER TO THE EDITOR REFERRING TO AISEN, P.S. AND R. RAMAN, FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020 | J Prev Alz Dis 2020;4(7):299-300 | 704 |
| DIAGNOSTIC BIOMARKERS OF AMYLOID AND TAU PATHOLOGY IN ALZHEIMER’S DISEASE: AN OVERVIEW OF TESTS FOR CLINICAL PRACTICE IN THE UNITED STATES AND EUROPE | J Prev Alz Dis 2023;3(10):426-442 | 694 |
| PROTOCOL FOR THE BRAIN HEALTH SUPPORT PROGRAM STUDY OF THE CANADIAN THERAPEUTIC PLATFORM TRIAL FOR MULTIDOMAIN INTERVENTIONS TO PREVENT DEMENTIA (CANTHUMBS UP): A PROSPECTIVE 12-MONTH INTERVENTION STUDY | J Prev Alz Dis 2023;4(10):875-885 | 691 |
| GEROSCIENCE AND ALZHEIMER’S DISEASE DRUG DEVELOPMENT | J Prev Alz Dis 2023;4(10):620-632 | 688 |
| THE CRITICAL ROLE OF BIOMARKERS FOR DRUG DEVELOPMENT TARGETING THE BIOLOGY OF AGING | J Prev Alz Dis 2023;4(10):729-742 | 685 |
| AUTHORS RESPONSE TO UMBRICHT D, LETTER TO THE EDITOR REFERRING FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020 | J Prev Alz Dis 2020;4(7):300 | 681 |
| EDUCATION AS RISK FACTOR OF MILD COGNITIVE IMPAIRMENT: THE LINK TO THE GUT MICROBIOME | J Prev Alz Dis 2024;3(11):759-768 | 669 |
| MULTIOMICS BLOOD-BASED BIOMARKERS PREDICT ALZHEIMER’S PREDEMENTIA WITH HIGH SPECIFICITY IN A MULTICENTRIC COHORT STUDY | J Prev Alz Dis 2024;3(11):567-581 | 667 |
| ITEM-LEVEL INVESTIGATION OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX FROM THE A4 STUDY SCREENING DATA | J Prev Alz Dis 2021;3(8):257-262 | 666 |
| THE GERAS SOLUTIONS COGNITIVE TEST FOR ASSESSING COGNITIVE IMPAIRMENT: NORMATIVE DATA FROM A POPULATION-BASED COHORT | J Prev Alz Dis 2023;2(10):207-211 | 666 |
| ESTABLISHING A TRIAL READY COHORT TO ACCELERATE ALZHEIMER’S CLINICAL TRIAL ENROLLMENT AND TREATMENTS | J Prev Alz Dis 2020;4(7):202-203 | 664 |
| TACKLING A MAJOR DEFICIENCY OF DIVERSITY IN ALZHEIMER’S DISEASE THERAPEUTIC TRIALS: AN CTAD TASK FORCE REPORT | J Prev Alz Dis 2022;3(9):388-392 | 664 |
| ROLES OF TREM2 IN THE PATHOLOGICAL MECHANISM AND THE THERAPEUTIC STRATEGIES OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;6(11):1682-1695 | 664 |
| ESTIMATES OF CURRENT CAPACITY FOR DIAGNOSING ALZHEIMER’S DISEASE IN SWEDEN AND THE NEED TO EXPAND SPECIALIST NUMBERS | J Prev Alz Dis 2024;1(11):155-161 | 655 |
| SAFETY, TOLERABILITY, PHARMACOKINETICS AND QUANTITATIVE ELECTROENCEPHALOGRAPHY ASSESSMENT OF ACD856, A NOVEL POSITIVE ALLOSTERIC MODULATOR OF TRK-RECEPTORS FOLLOWING MULTIPLE DOSES IN HEALTHY SUBJECTS | J Prev Alz Dis 2023;4(10):778-789 | 654 |
| EDITORIAL: DIETARY CHOLESTEROL AND DEMENTIA RISK | J Prev Alz Dis 2023;4(10):746-747 | 638 |
| PHASE 2A LEARNINGS INCORPORATED INTO REWIND-LB, A PHASE 2B CLINICAL TRIAL OF NEFLAMAPIMOD IN DEMENTIA WITH LEWY BODIES | J Prev Alz Dis 2024;3(11):549-557 | 630 |
| THE SARS-COV-2 PANDEMIC AND THE BRAVE NEW DIGITAL WORLD OF ENVIRONMENTAL ENRICHMENT TO PREVENT BRAIN AGING AND COGNITIVE DECLINE | J Prev Alz Dis 2020;4(7):294-298 | 628 |
| BEYOND VISION: A VIEW FROM EYE TO ALZHEIMER’S DISEASE AND DEMENTIA | J Prev Alz Dis 2024;2(11):469-483 | 628 |
| TRC-PAD: ACCELERATING RECRUITMENT OF AD CLINICAL TRIALS THROUGH INNOVATIVE INFORMATION TECHNOLOGY | J Prev Alz Dis 2020;4(7):226-233 | 627 |
| THE COMMUNITY ENGAGED DIGITAL ALZHEIMER’S RESEARCH (CEDAR) STUDY: A DIGITAL INTERVENTION TO INCREASE RESEARCH PARTICIPATION OF BLACK AMERICAN PARTICIPANTS IN THE BRAIN HEALTH REGISTRY | J Prev Alz Dis 2023;4(10):847-856 | 627 |
| THERAPEUTIC TARGETS FOR ALZHEIMER’S DISEASE: AMYLOID VS. NON-AMYLOID. WHERE DOES CONSENSUS LIE TODAY? AN CTAD TASK FORCE REPORT | J Prev Alz Dis 2022;2(9):231-235 | 625 |
| MULTIMODAL PRECISION PREVENTION - A NEW DIRECTION IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):718-728 | 625 |
| ALZHEIMER’S DISEASE RESEARCH IN JAPAN: A SHORT HISTORY, CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTION | J Prev Alz Dis 2021;4(8):462-464 | 622 |
| VIEWPOINT «COMPOUNDED INTEREST» IN ALZHEIMER’S DISEASE: DO NEW AMYLOID-TARGETING TREATMENTS JUSTIFY THEIR USE | J Prev Alz Dis 2023;3(10):333-335 | 618 |
| LONGITUDINAL COURSE OF AGITATION AND AGGRESSION IN PATIENTS WITH ALZHEIMER’S DISEASE IN A COHORT STUDY: METHODS, BASELINE AND LONGITUDINAL RESULTS OF THE A3C STUDY | J Prev Alz Dis 2021;2(8):199-209 | 602 |
| LONGITUDINAL COGNITIVE DECLINE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR DEMENTIA DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;1(9):178-183 | 595 |
| ANTI-AMYLOID THERAPIES FOR ALZHEIMER’S DISEASE: AN ALZHEIMER EUROPE POSITION PAPER AND CALL TO ACTION | J Prev Alz Dis 2024;2(11):265-273 | 593 |
| MAJOR COST DRIVERS IN ASSESSING THE ECONOMIC BURDEN OF ALZHEIMER’S DISEASE: A STRUCTURED, RAPID REVIEW | J Prev Alz Dis 2021;3(8):362-370 | 588 |
| COST-EFFECTIVENESS OF PREVENTION FOR PEOPLE AT RISK FOR DEMENTIA: A SCOPING REVIEW AND QUALITATIVE SYNTHESIS | J Prev Alz Dis 2024;2(11):402-413 | 588 |
| LOW AMINO ACID SCORE OF BREAKFAST IS ASSOCIATED WITH THE INCIDENCE OF COGNITIVE IMPAIRMENT IN OLDER JAPANESE ADULTS: A COMMUNITY-BASED LONGITUDINAL STUDY | J Prev Alz Dis 2022;1(9):151-157 | 571 |
| CAN VIRTUAL SCIENTIFIC CONFERENCES FACILITATE TWOWAY LEARNING BETWEEN DEMENTIA RESEARCHERS AND PARTICIPANTS? | J Prev Alz Dis 2021;3(8):387-388 | 567 |
| THE COST-EFFECTIVENESS OF THREE PREVENTION STRATEGIES IN ALZHEIMER\'S DISEASE: RESULTS FROM THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIAL (MAPT) | J Prev Alz Dis 2021;4(8):425-435 | 560 |
| ESTIMATED INVESTMENT NEED TO INCREASE ENGLAND’S CAPACITY TO DIAGNOSE ELIGIBILITY FOR AN ALZHEIMER’S TREATMENT TO G7 AVERAGE CAPACITY LEVELS | J Prev Alz Dis 2024;4(11):1022-1029 | 560 |
| LONGITUDINAL IMPACTS OF PRECISION GREENNESS ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;3(11):710-720 | 559 |
| EDITORIAL: CLINICAL IMPLEMENTATION OF LECANEMAB: CHALLENGES, QUESTIONS AND SOLUTIONS | J Prev Alz Dis 2023;3(10):353-355 | 556 |
| THE EFFECTS OF DIFFERENT EXERCISE INTERVENTIONS ON PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS | J Prev Alz Dis 2024;3(11):620-631 | 551 |
| VORTIOXETINE TREATMENT FOR DEPRESSION IN PATIENTS WITH PRODROMAL VS MILD ALZHEIMER’S DISEASE: A SIXMONTH, OPEN-LABEL, OBSERVATIONAL STUDY | J Prev Alz Dis 2024;2(11):375-381 | 548 |
| ADUCANUMAB: APPROPRIATE USE RECOMMENDATIONS UPDATE | J Prev Alz Dis 2022;2(9):221-230 | 541 |
| A PHASE 1 SINGLE-ASCENDING-DOSE TRIAL IN HEALTHY VOLUNTEERS TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF INTRAVENOUS PNT001, A NOVEL MID-DOMAIN TAU ANTIBODY TARGETING CIS-PT231 TAU | J Prev Alz Dis 2024;2(11):366-374 | 540 |
| HOW MODIFIABLE ARE MODIFIABLE DEMENTIA RISK FACTORS? A FRAMEWORK FOR CONSIDERING THE MODIFIABILITY OF DEMENTIA RISK FACTORS | J Prev Alz Dis 2024;1(11):22-37 | 536 |
| CONSISTENCY BETWEEN TREATMENT EFFECTS ON CLINICAL AND BRAIN ATROPHY OUTCOMES IN ALZHEIMER’S DISEASE TRIALS | J Prev Alz Dis 2024;1(11):38-47 | 534 |
| IN VIVO DETECTION OF CHANGES RELATED TO CORTICAL COLUMNAR ORGANIZATION AND NEUROINFLAMMATION ACROSS THE AD CONTINUUM | J Prev Alz Dis 2022;4(9):769-779 | 532 |
| THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) – A FUNDAMENTAL ALLY IN AD PREVENTION RESEARCH | J Prev Alz Dis 2020;4(7):206-207 | 529 |
| HEALTH ECONOMIC CONSIDERATIONS IN THE DEPLOYMENT OF AN ALZHEIMER’S PREVENTION THERAPY | J Prev Alz Dis 2024;2(11):303-309 | 528 |
| A UK-WIDE STUDY EMPLOYING NATURAL LANGUAGE PROCESSING TO DETERMINE WHAT MATTERS TO PEOPLE ABOUT BRAIN HEALTH TO IMPROVE DRUG DEVELOPMENT: THE ELECTRONIC PERSON-SPECIFIC OUTCOME MEASURE (EPSOM) PROGRAMME | J Prev Alz Dis 2021;4(8):448-456 | 525 |
| LECANEMAB: APPROPRIATE USE RECOMMENDATIONS | J Prev Alz Dis 2023;3(10):362-377 | 524 |
| ORAL HEALTH AS A RISK FACTOR FOR ALZHEIMER DISEASE | J Prev Alz Dis 2024;1(11):249-258 | 523 |
| COMPARATIVE ANALYSIS OF DIFFERENT DEFINITIONS OF AMYLOID-Β POSITIVITY TO DETECT EARLY DOWNSTREAM PATHOPHYSIOLOGICAL ALTERATIONS IN PRECLINICAL ALZHEIMER | J Prev Alz Dis 2021;1(8):68-77 | 521 |
| THE FUTURE OF AD CLINICAL TRIALS WITH THE ADVENT OF ANTI-AMYLOID THERAPIES: AN CTAD TASK FORCE REPORT | J Prev Alz Dis 2022;3(9):393-399 | 521 |
| PLATFORM TRIALS TO EXPEDITE DRUG DEVELOPMENT IN ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2021;3(8):306-312 | 518 |
| EXPLORING THE ASSOCIATION BETWEEN AMYLOID-Β AND MEMORY MARKERS FOR ALZHEIMER’S DISEASE IN COGNITIVELY UNIMPAIRED OLDER ADULTS | J Prev Alz Dis 2024;2(11):339-347 | 517 |
| UNSUPERVISED ONLINE PAIRED ASSOCIATES LEARNING TASK FROM THE CAMBRIDGE NEUROPSYCHOLOGICAL TEST AUTOMATED BATTERY (CANTAB®) IN THE BRAIN HEALTH REGISTRY | J Prev Alz Dis 2024;2(11):514-524 | 516 |
| SEX MODERATES THE ASSOCIATION BETWEEN FRAILTY AND MILD BEHAVIORAL IMPAIRMENT | J Prev Alz Dis 2022;4(9):692-700 | 515 |
| DETECTION AND MANAGEMENT OF AMYLOID-RELATED IMAGING ABNORMALITIES IN PATIENTS WITH ALZHEIMER’S DISEASE TREATED WITH ANTI-AMYLOID BETA THERAPY | J Prev Alz Dis 2022;2(9):211-220 | 514 |
| DEMENTIA PREVENTION: A GLOBAL CHALLENGE IN URGENT NEED OF SOLUTIONS | J Prev Alz Dis 2022;1(9):1-2 | 512 |
| THE INSTITUTE ON METHODS AND PROTOCOLS FOR ADVANCEMENT OF CLINICAL TRIALS IN ADRD (IMPACT-AD): A NOVEL CLINICAL TRIALS TRAINING PROGRAM | J Prev Alz Dis 2021;3(8):286-291 | 509 |
| AMYLOID AND TAU PREDICTION OF COGNITIVE AND FUNCTIONAL DECLINE IN UNIMPAIRED OLDER INDIVIDUALS: LONGITUDINAL DATA FROM THE A4 AND LEARN STUDIES | J Prev Alz Dis 2024;4(11):802-813 | 507 |
| MECHANISMS UNDERLYING NON-PHARMACOLOGICAL DEMENTIA PREVENTION STRATEGIES: A TRANSLATIONAL PERSPECTIVE | J Prev Alz Dis 2022;1(9):3-11 | 504 |
| CAN WE USE BLOOD BIOMARKERS AS ENTRY CRITERIA AND FOR MONITORING DRUG TREATMENT EFFECTS IN CLINICAL TRIALS? A REPORT FROM THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2023;3(10):418-425 | 504 |
| PUSHING THROUGH THE BARRIERS: PEER ADVICE TO INCREASE PHYSICAL ACTIVITY AND REDUCE DEMENTIA RISK FROM PARTICIPANTS IN A MASSIVE OPEN ONLINE ALZHEIMER’S FOCUSED COURSE | J Prev Alz Dis 2023;3(10):503-512 | 499 |
| DONANEMAB (LY3002813) PHASE 1B STUDY IN ALZHEIMER’S DISEASE: RAPID AND SUSTAINED REDUCTION OF BRAIN AMYLOID MEASURED BY FLORBETAPIR F18 IMAGING | J Prev Alz Dis 2021;4(8):414-424 | 495 |
| THE SCOTTISH BRAIN HEALTH SERVICE MODEL: RATIONALE AND SCIENTIFIC BASIS FOR A NATIONAL CARE PATHWAY OF BRAIN HEALTH SERVICES IN SCOTLAND | J Prev Alz Dis 2022;2(9):348-358 | 489 |
| ELECSYS CEREBROSPINAL FLUID ASSAYS ACCURATELY DISTINGUISH ALZHEIMER’S DISEASE FROM FRONTOTEMPORAL LOBAR DEGENERATION | J Prev Alz Dis 2022;3(9):491-498 | 489 |
| SEX-DRIVEN DIFFERENCES IN THE EFFECTIVENESS OF INDIVIDUALIZED CLINICAL MANAGEMENT OF ALZHEIMER’S DISEASE RISK | J Prev Alz Dis 2022;4(9):731-742 | 487 |
| DECREASED GRAY–WHITE MATTER CONTRAST OF [11C]-PIB UPTAKE IN COGNITIVELY UNIMPAIRED SUBJECTS WITH SEVERE OBSTRUCTIVE SLEEP APNEA | J Prev Alz Dis 2022;3(9):499-506 | 486 |
| ULTRA-PROCESSED FOOD CONSUMPTION AND RISK OF DEMENTIA AND ALZHEIMER\'S DISEASE: THE FRAMINGHAM HEART STUDY | J Prev Alz Dis 2025;2(12) | 486 |
| BLOOD DERIVED AMYLOID BIOMARKERS FOR ALZHEIMER’S DISEASE PREVENTION | J Prev Alz Dis 2022;1(9):12-21 | 485 |
| TARGETING ENDOGENOUS MECHANISMS OF BRAIN RESILIENCE FOR THE TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):699-705 | 483 |
| “BACK TO BRAAK”: ROLE OF NUCLEUS REUNIENS AND SUBCORTICAL PATHWAYS IN ALZHEIMER’S DISEASE PROGRESSION | J Prev Alz Dis 2024;4(11):1030-1040 | 483 |
| NOVEL BLOOD-BASED BIOMARKERS AND DISEASE MODIFYING THERAPIES FOR ALZHEIMER’S DISEASE. ARE WE READY FOR THE NEW ERA? | J Prev Alz Dis 2024;4(11):897-902 | 481 |
| BASELINE FINDINGS OF PREVENTE4: A DOUBLE-BLIND PLACEBO CONTROLLED CLINICAL TRIAL TESTING HIGH DOSE DHA IN APOE4 CARRIERS BEFORE THE ONSET OF DEMENTIA | J Prev Alz Dis 2023;4(10):810-820 | 480 |
| GLOBAL ENERGY METABOLISM DEFICIT IN ALZHEIMER DISEASE BRAIN | J Prev Alz Dis 2024;1(11):171-178 | 479 |
| CLINICAL MEANINGFULNESS IN ALZHEIMER’S DISEASE CLINICAL TRIALS. A REPORT FROM THE EU-US CTAD TASK FORCE | J Prev Alz Dis 2024;5(11):1219-1227 | 479 |
| DIGITAL THERAPEUTICS FOR MCI AND ALZHEIMER’S DISEASE: A REGULATORY PERSPECTIVE - HIGHLIGHTS FROM THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE (CTAD) | J Prev Alz Dis 2022;2(9):236-240 | 476 |
| A POLYMORPHISM CLUSTER AT THE 2Q12 LOCUS MAY PREDICT RESPONSE TO PIROMELATINE IN PATIENTS WITH MILD ALZHEIMER\'S DISEASE | J Prev Alz Dis 2022;2(9):255-261 | 475 |
| UNSUPERVISED PERFORMANCE OF THE COGSTATE BRIEF BATTERY IN THE BRAIN HEALTH REGISTRY: IMPLICATIONS FOR DETECTING COGNITIVE DECLINE | J Prev Alz Dis 2022;2(9):262-268 | 474 |
| OPTIMISING ALZHEIMER’S DISEASE DIAGNOSIS AND TREATMENT: ASSESSING COST-UTILITY OF INTEGRATING BLOOD BIOMARKERS IN CLINICAL PRACTICE FOR DISEASEMODIFYING TREATMENT | J Prev Alz Dis 2024;4(11):928-942 | 474 |
| THE ROLE OF THYROID DYSFUNCTION IN ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2023;2(10):276-286 | 473 |
| ORAL TAU AGGREGATION INHIBITOR FOR ALZHEIMER’S DISEASE: DESIGN, PROGRESS AND BASIS FOR SELECTION OF THE 16 MG/DAY DOSE IN A PHASE 3, RANDOMIZED, PLACEBOCONTROLLED TRIAL OF HYDROMETHYLTHIONINE MESYLATE | J Prev Alz Dis 2022;4(9):780-790 | 472 |
| USING DIGITAL TOOLS TO ADVANCE ALZHEIMER’S DRUG TRIALS DURING A PANDEMIC: THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2021;4(8):513-519 | 462 |
| MULTIMODAL PREVENTIVE TRIAL FOR ALZHEIMER’S DISEASE: MIND-ADMINI PILOT TRIAL STUDY DESIGN AND PROGRESS | J Prev Alz Dis 2022;1(9):30-39 | 462 |
| FIBRIN-TARGETING IMMUNOTHERAPY FOR DEMENTIA | J Prev Alz Dis 2023;4(10):647-660 | 461 |
| MODIFIABLE RISK FACTORS FOR ACCELERATED DECLINE IN PROCESSING SPEED: RESULTS FROM THREE DUTCH POPULATION COHORTS | J Prev Alz Dis 2024;1(11):108-116 | 458 |
| ASSOCIATION OF BLOOD MICRORNA EXPRESSION AND POLYMORPHISMS WITH COGNITIVE AND BIOMARKER CHANGES IN OLDER ADULTS | J Prev Alz Dis 2024;1(11):230-240 | 457 |
| 24-HOUR BLOOD PRESSURE VARIABILITY VIA AMBULATORY MONITORING AND RISK FOR PROBABLE DEMENTIA IN THE SPRINT TRIAL | J Prev Alz Dis 2024;3(11):684-692 | 457 |
| BLOOD BIOMARKERS FROM RESEARCH USE TO CLINICAL PRACTICE: WHAT MUST BE DONE? A REPORT FROM THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2022;4(9):569-579 | 456 |
| WHAT MATTERS TO PATIENTS WITH ALZHEIMER’S DISEASE AND THEIR CARE PARTNERS? IMPLICATIONS FOR UNDERSTANDING THE VALUE OF FUTURE INTERVENTIONS | J Prev Alz Dis 2022;3(9):550-555 | 454 |
| VALIDATION OF A COMMUNITY-BASED APPROACH TOWARD PERSONALIZED DEMENTIA RISK REDUCTION: THE KIMEL FAMILY CENTRE FOR BRAIN HEALTH AND WELLNESS | J Prev Alz Dis 2024;5(11):1455-1466 | 449 |
| AMYLOID-RELATED IMAGING ABNORMALITIES AND OTHER MRI FINDINGS IN A COGNITIVELY UNIMPAIRED POPULATION WITH AND WITHOUT CEREBRAL AMYLOID | J Prev Alz Dis 2022;4(9):617-624 | 448 |
| BLARCAMESINE FOR THE TREATMENT OF EARLY ALZHEIMER\'S DISEASE: RESULTS FROM THE ANAVEX2-73-AD-004 PHASE IIB/III TRIAL | J Prev Alz Dis 2025;1(12) | 448 |
| SITE READINESS FRAMEWORK TO IMPROVE HEALTH SYSTEM PREPAREDNESS FOR A POTENTIAL NEW ALZHEIMER’S DISEASE TREATMENT PARADIGM | J Prev Alz Dis 2022;3(9):542-549 | 446 |
| EDITORIAL: THE DAWN OF A NEW ERA OF ALZHEIMER’S RESEARCH AND DRUG DEVELOPMENT | J Prev Alz Dis 2022;3(9):385-386 | 445 |
| ADUCANUMAB TRIALS EMERGE BUT DON’T ENGAGE | J Prev Alz Dis 2022;2(9):193-196 | 444 |
| CLINICAL TRIAL ENDPOINTS AND THEIR CLINICAL MEANINGFULNESS IN EARLY STAGES OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;3(9):507-522 | 440 |
| FEMALE REPRODUCTIVE FACTORS AND RISK OF MILD COGNITIVE IMPAIRMENT AND DEMENTIA: THE HUNT STUDY | J Prev Alz Dis 2024;4(11):1063-1072 | 435 |
| EXAMINING THE ROLE OF COMMUNITY ENGAGEMENT IN ENHANCING THE PARTICIPATION OF RACIAL AND ETHNIC MINORITIZED COMMUNITIES IN ALZHEIMER’S DISEASE CLINICAL TRIALS; A RAPID REVIEW | J Prev Alz Dis 2024;6(11):1647-1672 | 435 |
| PLASMA BIOMARKERS OF ALZHEIMER’S DISEASE AND NEURODEGENERATION ACCORDING TO SOCIODEMOGRAPHIC CHARACTERISTICS AND CHRONIC HEALTH CONDITIONS | J Prev Alz Dis 2024;5(11):1189-1197 | 427 |
| COMPARATIVE EFFICACY, SAFETY, TOLERABILITY, AND EFFECTIVENESS OF ANTIPSYCHOTICS IN THE TREATMENT OF DEMENTIA-RELATED PSYCHOSIS (DRP): A SYSTEMATIC LITERATURE REVIEW | J Prev Alz Dis 2021;4(8):520-533 | 426 |
| EDITORIAL: THE STATE OF ALZHEIMER’S RESEARCH AND THE PATH FORWARD | J Prev Alz Dis 2023;4(10):617-619 | 425 |
| MULTISENSORY STIMULATION REDUCES NEUROPSYCHIATRIC SYMPTOMS AND ENHANCES COGNITIVE FUNCTION IN OLDER ADULTS WITH DEMENTIA: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS | J Prev Alz Dis 2025;5(12) | 425 |
| DATA-DRIVEN THRESHOLDING STATISTICALLY BIASES ATN PROFILING ACROSS COHORT DATASETS | J Prev Alz Dis 2024;1(11):185-195 | 424 |
| ERRATUM TO: EDUCATION AS RISK FACTOR OF MILD COGNITIVE IMPAIRMENT: THE LINK TO THE GUT MICROBIOME | J Prev Alz Dis 2024;3(11):798 | 422 |
| EVALUATION OF CLINICAL MEANINGFULNESS OF FORTASYN CONNECT IN TERMS OF “TIME SAVED” | J Prev Alz Dis 2024;4(11):992-997 | 422 |
| LONGITUDINAL PHOSPHO-TAU217 PREDICTS AMYLOID POSITRON EMISSION TOMOGRAPHY IN ASYMPTOMATIC ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;4(11):823-830 | 422 |
| COGNITIVE PERFORMANCE AND INCIDENT ALZHEIMER’S DEMENTIA IN MEN VERSUS WOMEN | J Prev Alz Dis 2024;1(11):162-170 | 419 |
| KEY CONSIDERATIONS FOR COMBINATION THERAPY IN ALZHEIMER\'S CLINICAL TRIALS: PERSPECTIVES FROM AN EXPERT ADVISORY BOARD CONVENED BY THE ALZHEIMER\'S DRUG DISCOVERY FOUNDATION | J Prev Alz Dis 2025;1(12) | 419 |
| BUNTANETAP, A NOVEL TRANSLATIONAL INHIBITOR OF MULTIPLE NEUROTOXIC PROTEINS, PROVES TO BE SAFE AND PROMISING IN BOTH ALZHEIMER’S AND PARKINSON’S PATIENTS | J Prev Alz Dis 2023;1(10):25-33 | 417 |
| WHO BENEFITED MOST FROM THE INTERNET-BASED CONVERSATIONAL ENGAGEMENT RCT (I-CONECT)? APPLICATION OF THE PERSONALIZED MEDICINE APPROACH TO A BEHAVIORAL INTERVENTION STUDY | J Prev Alz Dis 2024;3(11):639-648 | 417 |
| PERFORMANCE OF FULLY-AUTOMATED HIGH-THROUGHPUT PLASMA BIOMARKER ASSAYS FOR ALZHEIMER’S DISEASE IN AMNESTIC MILD COGNITIVE IMPAIRMENT SUBJECTS | J Prev Alz Dis 2024;4(11):1073-1078 | 417 |
| THE EFFECT OF MULTIDOMAIN INTERVENTIONS ON GLOBAL COGNITION, SYMPTOMS OF DEPRESSION AND APATHY – A POOLED ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS | J Prev Alz Dis 2022;1(9):96-103 | 412 |
| WHERE DO WE GO FROM HERE? | J Prev Alz Dis 2022;2(9):188-189 | 412 |
| PROTOCOL OF A PHASE II RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF S-ADENOSYL METHIONINE IN PARTICIPANTS WITH MILD COGNITIVE IMPAIRMENT OR DEMENTIA DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;4(10):800-809 | 412 |
| VALIDITY OF ONLINE VERSUS IN-CLINIC SELF-REPORTED EVERYDAY COGNITION SCALE | J Prev Alz Dis 2022;2(9):269-276 | 409 |
| THE ‘ADUCANUMAB STORY’: WILL THE LAST CHAPTER SPELL THE END OF THE ‘AMYLOID HYPOTHESIS’ OR MARK A NEW BEGINNING? | J Prev Alz Dis 2022;2(9):190-192 | 409 |
| EVIDENCE-BASED TOOLS FOR DIETARY ASSESSMENTS IN NUTRITION EPIDEMIOLOGY STUDIES FOR DEMENTIA PREVENTION | J Prev Alz Dis 2022;1(9):49-53 | 405 |
| ASURE CLINICAL TRIAL PROTOCOL: A RANDOMIZED, PLACEBOCONTROLLED, PROOF-OF-CONCEPT STUDY AIMING TO EVALUATE SAFETY AND TARGET ENGAGEMENT FOLLOWING ADMINISTRATION OF TW001 IN EARLY ALZHEIMER’S DISEASE PATIENTS | J Prev Alz Dis 2023;4(10):669-674 | 404 |
| PROJECTED SAVINGS TO CANADIAN PROVINCIAL BUDGETS FROM REDUCED LONG-TERM CARE HOME UTILIZATION DUE TO A DISEASE-MODIFYING ALZHEIMER’S TREATMENT | J Prev Alz Dis 2024;1(11):179-184 | 404 |
| THE USE OF EPISODIC MEMORY TESTS FOR SCREENING IN CLINICAL TRIALS FOR EARLY ALZHEIMER’S DISEASE: A COMPARISON OF THE FREE AND CUED SELECTIVE REMINDING TEST (FCSRT) AND THE REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS (RBANS) | J Prev Alz Dis 2023;1(10):41-49 | 403 |
| DEVELOPMENT OF A MOBILE-FIRST REGISTRY TO RECRUIT HEALTHY VOLUNTEERS AND MEMBERS OF UNDERREPRESENTED COMMUNITIES FOR ALZHEIMER’S DISEASE PREVENTION STUDIES | J Prev Alz Dis 2023;4(10):857-864 | 403 |
| NON-GENETIC RISK FACTORS OF ALZHEIMER’S DISEASE: AN UPDATED UMBRELLA REVIEW | J Prev Alz Dis 2024;4(11):917-927 | 403 |
| EFFECTIVENESS OF RESISTANCE EXERCISE ON COGNITIVE FUNCTION IN ANIMAL MODELS OF ALZHEIMER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2024;4(11):998-1012 | 400 |
| PERIODONTAL DISEASE AND ALZHEIMER’S: INSIGHTS FROM A SYSTEMATIC LITERATURE NETWORK ANALYSIS | J Prev Alz Dis 2024;4(11):1148-1165 | 400 |
| BURDEN OF ILLNESS IN PEOPLE WITH ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW OF EPIDEMIOLOGY, COMORBIDITIES AND MORTALITY | J Prev Alz Dis 2024;1(11):97-107 | 395 |
| THE SHAPE TRAIL TEST IS SENSITIVE IN DIFFERENTIATING OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: A CULTURE-NEUTRAL FIVE-MINUTE TEST | J Prev Alz Dis 2024;4(11):1166-1176 | 394 |
| EDITORIAL: INTRODUCTION TO THE SPECIAL ISSUE ON THE A4 STUDY | J Prev Alz Dis 2024;4(11):801 | 394 |
| MULTIDOMAIN INTERVENTION TRIAL FOR PREVENTING COGNITIVE DECLINE AMONG OLDER ADULTS WITH TYPE 2 DIABETES: J-MIND-DIABETES | J Prev Alz Dis 2024;6(11):1604-1614 | 394 |
| ARE POPULATION-LEVEL APPROACHES TO DEMENTIA RISK REDUCTION UNDER-RESEARCHED? A RAPID REVIEW OF THE DEMENTIA PREVENTION LITERATURE | J Prev Alz Dis 2024;1(11):241-248 | 392 |
| PERFORMANCE OF A SHORT VERSION OF THE EVERYDAY COGNITION SCALE (ECOG-12) TO DETECT COGNITIVE IMPAIRMENT | J Prev Alz Dis 2024;6(11):1741-1750 | 392 |
| 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA | J Prev Alz Dis 2022;9(S1):S51-S248 | 391 |
| NEUROPROTECTIVE EFFECTS OF IVIG AGAINST ALZHEIMER’ S DISEASE VIA REGULATION OF ANTIGEN PROCESSING AND PRESENTATION BY MHC CLASS I MOLECULES IN 3XTG-AD MICE | J Prev Alz Dis 2023;3(10):581-594 | 390 |
| TWO-YEAR PROGNOSTIC UTILITY OF PLASMA P217+TAU ACROSS THE ALZHEIMER’S CONTINUUM | J Prev Alz Dis 2023;4(10):828-836 | 390 |
| ASSOCIATIONS OF CARDIOVASCULAR AND NONCARDIOVASCULAR COMORBIDITIES WITH DEMENTIA RISK IN PATIENTS WITH DIABETES: RESULTS FROM A LARGE UK COHORT STUDY | J Prev Alz Dis 2022;1(9):86-91 | 386 |
| LETTER TO THE EDITOR: BEYOND FRAILTY IN ALZHEIMER’S DISEASE: SHOULD WE MOVE TO THE CONCEPT OF INTRINSIC CAPACITY? | J Prev Alz Dis 2022;4(9):813-815 | 386 |
| ESTIMATING SOCIO-ECONOMIC STATUS FOR ALZHEIMER’S DISEASE TRIALS | J Prev Alz Dis 2024;5(11):1418-1425 | 385 |
| 15th Conference Clinical Trials Alzheimer’s Disease, November 29- December 2, 2022, San Francisco, CA, USA | J Prev Alz Dis 2022;9(S1):S8-S50 | 383 |
| HEIGHTENED PREVALENCE OF COMMON HOSPITAL-TREATED INFECTIONS PRECEDING DEMENTIA DIAGNOSIS WITH ACCELERATED DEMENTIA ONSET AFTER INFLUENZA | J Prev Alz Dis 2024;5(11):1445-1454 | 383 |
| EXAMINING DEMOGRAPHIC FACTORS, PSYCHOSOCIAL WELLBEING AND CARDIOVASCULAR HEALTH IN SUBJECTIVE COGNITIVE DECLINE IN THE BRAIN HEALTH REGISTRY COHORT | J Prev Alz Dis 2024;3(11):787-797 | 380 |
| Editorial: Current Themes and Controversies in the Alzheimer’s Disease Field: Looking Ahead to the ctad Meeting in San Francisco, November 29-December 2 2022 | J Prev Alz Dis 2022;9(S1):S3-S4 | 379 |
| INITIAL EXPERIENCE WITH LECANEMAB AND LESSONS LEARNED IN 71 PATIENTS IN A REGIONAL MEDICAL CENTER | J Prev Alz Dis 2024;6(11):1549-1562 | 379 |
| SOCIAL ISOLATION, LONELINESS, AND THEIR JOINT EFFECTS ON COGNITIVE DECLINE AND INCIDENT ALZHEIMER\'S DISEASE: FINDINGS FROM THE CHICAGO HEALTH AND AGING PROJECT | J Prev Alz Dis 2025;3(12) | 377 |
| INVESTIGATING PARTIALLY DISCORDANT RESULTS IN PHASE 3 STUDIES OF ADUCANUMAB | J Prev Alz Dis 2023;2(10):171-177 | 376 |
| OPPORTUNITIES FOR CELLULAR REJUVENATION IN ALZHEIMER’S DISEASE: HOW EPIGENETIC REPROGRAMMING AND CHAPERONE-MEDIATED AUTOPHAGY ARE ENABLING NEXT GENERATION THERAPEUTIC APPROACHES | J Prev Alz Dis 2023;4(10):661-668 | 375 |
| LONGITUDINAL TRAJECTORIES OF THE COGNITIVE FUNCTION INDEX IN THE A4 STUDY | J Prev Alz Dis 2024;4(11):838-845 | 375 |
| A CONFORMATIONAL VARIANT OF P53 (U-P53AZ) AS BLOODBASED BIOMARKER FOR THE PREDICTION OF THE ONSET OF SYMPTOMATIC ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;3(9):469-479 | 373 |
| COGNITIVE TRAINING WITH OLDER ADULTS USING SMARTPHONE AND WEB-BASED APPLICATIONS: A SCOPING REVIEW | J Prev Alz Dis 2024;3(11):693-700 | 373 |
| EDITORIAL: WHAT ARE THE REMAINING CHALLENGES BEFORE BLOODBASED BIOMARKERS FOR ALZHEIMER’S DISEASE CAN BE USED IN CLINICAL PRACTICE? | J Prev Alz Dis 2022;4(9):567-568 | 372 |
| WHO BENEFITED THE MOST? EFFECTIVENESS OF A LIFESTYLE INTERVENTION AGAINST COGNITIVE DECLINE IN OLDER WOMEN AND MEN – SECONDARY ANALYSIS OF THE AGEWELL. DE-TRIAL | J Prev Alz Dis 2024;2(11):348-355 | 372 |
| DEVELOPMENT AND VALIDATION THE MOBILE TOOLBOX (MTB) SPELLING TEST | J Prev Alz Dis 2024;6(11):1673-1681 | 372 |
| CORE BLOOD BIOMARKERS OF ALZHEIMER\'S DISEASE: A SINGLE-CENTER REAL-WORLD PERFORMANCE STUDY | J Prev Alz Dis 2025;2(12) | 371 |
| BIOMARKERS AND COGNITION STUDY, SINGAPORE (BIOCIS): PROTOCOL, STUDY DESIGN, AND PRELIMINARY FINDINGS | J Prev Alz Dis 2024;4(11):1093-1105 | 369 |
| LIVING ENVIRONMENT, BUILT ENVIRONMENT AND COGNITIVE FUNCTION AMONG OLDER CHINESE ADULTS: RESULTS FROM A CROSS-SECTIONAL STUDY | J Prev Alz Dis 2022;1(9):126-135 | 368 |
| ASSOCIATION BETWEEN RESTING HEART RATE AND MACHINE LEARNING-BASED BRAIN AGE IN MIDDLE- AND OLDER-AGE | J Prev Alz Dis 2024;4(11):1140-1147 | 368 |
| PRE-RANDOMIZATION PREDICTORS OF STUDY DISCONTINUATION IN A PRECLINICAL ALZHEIMER’S DISEASE RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2024;4(11):874-880 | 368 |
| RELATIONSHIP BETWEEN PLASMA P-TAU217 AND AMYLOID PET IN RACIAL AND ETHNIC UNDERREPRESENTED GROUPS (REURG) COMPARED WITH NON RE-URG IN LEARN AND A4 | J Prev Alz Dis 2024;4(11):831-837 | 359 |
| ACU193, A MONOCLONAL ANTIBODY THAT SELECTIVELY BINDS SOLUBLE ASS OLIGOMERS: DEVELOPMENT RATIONALE, PHASE 1 TRIAL DESIGN, AND CLINICAL DEVELOPMENT PLAN | J Prev Alz Dis 2023;1(10):19-24 | 358 |
| DEVELOPMENT AND CONCURRENT VALIDITY OF THE SHORTFORM COGDRISK DEMENTIA RISK ASSESSMENT TOOL | J Prev Alz Dis 2024;6(11):1751-1758 | 358 |
| UNDERSTANDING ONLINE REGISTRY FACILITATORS AND BARRIERS EXPERIENCED BY BLACK BRAIN HEALTH REGISTRY PARTICIPANTS: THE COMMUNITY ENGAGED DIGITAL ALZHEIMER’S RESEARCH (CEDAR) STUDY | J Prev Alz Dis 2023;3(10):551-561 | 357 |
| CHANGE IN DIGITAL COGNITIVE TEST PERFORMANCE BETWEEN SOLANEZUMAB AND PLACEBO GROUPS IN PRECLINICAL ALZHEIMER’S DISEASE: SECONDARY ANALYSES FROM THE A4 STUDY | J Prev Alz Dis 2024;4(11):846-856 | 356 |
| EDITORIAL: ICOPE HEALTHY LONGEVITY INTEGRATIVE PREVENTIVE CARE, ALZHEIMER’S DISEASE PREVENTION AND EARLY DIAGNOSIS | J Prev Alz Dis 2024;6(11):1523-1524 | 355 |
| EDITORIAL: THE FUTURE IS NOW: ADVANCING BLOOD-BASED MARKERS | J Prev Alz Dis 2022;4(9):563-564 | 354 |
| ASSOCIATION BETWEEN NEUROPSYCHOLOGICAL PERFORMANCE AND CSF PROFILE IN SUBJECTIVE COGNITIVE DECLINE: TOWARDS THE DIAGNOSIS OF PRECLINICAL AD | J Prev Alz Dis 2023;3(10):523-529 | 354 |
| LETTER TO THE EDITOR: UPDATE TO: TWO RANDOMIZED PHASE 3 STUDIES OF ADUCANUMAB IN EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;4(11):1178-1179 | 354 |
| PREVALENCE ESTIMATION OF DEMENTIA/ALZHEIMER’S DISEASE USING HEALTH AND RETIREMENT STUDY DATABASE IN THE UNITED STATES | J Prev Alz Dis 2024;5(11):1183-1188 | 354 |
| ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW PREVENTION CLINICAL TRIAL | J Prev Alz Dis 2022;4(9):625-634 | 353 |
| PERFORMANCE OF PLASMA BIOMARKERS COMBINED WITH STRUCTURAL MRI TO IDENTIFY CANDIDATE PARTICIPANTS FOR ALZHEIMER’S DISEASE-MODIFYING THERAPY | J Prev Alz Dis 2024;5(11):1198-1205 | 353 |
| THE ROLE OF AΒ IN ALZHEIMER’S DISEASE AS AN EVOLUTIONARY OUTCOME OF OPTIMIZED INNATE IMMUNE DEFENSE | J Prev Alz Dis 2022;4(9):580-588 | 352 |
| DIGITAL CLOCK DRAWING AS AN ALZHEIMER’S DISEASE SUSCEPTIBILITY BIOMARKER: ASSOCIATIONS WITH GENETIC RISK SCORE AND APOE IN OLDER ADULTS | J Prev Alz Dis 2024;1(11):79-87 | 352 |
| EDITORIAL: BLOOD-BASED BIOMARKERS FOR ALZHEIMER’S DISEASE: ARE WE THERE YET? | J Prev Alz Dis 2022;4(9):565-566 | 351 |
| REDUCING THE EFFECTS OF AGEING ON COGNITION WITH THERAPEUTIC INTERVENTION OF AN ORAL MULTI-NUTRIENT: THE REACTION PILOT TRIAL STUDY DESIGN | J Prev Alz Dis 2023;4(10):821-827 | 350 |
| COGNITIVE DIGITAL BIOMARKERS FROM AUTOMATED TRANSCRIPTION OF SPOKEN LANGUAGE | J Prev Alz Dis 2022;4(9):791-800 | 349 |
| PROGRESS IN THE TREATMENT OF ALZHEIMER’S DISEASE IS NEEDED – POSITION STATEMENT OF EUROPEAN ALZHEIMER’S DISEASE CONSORTIUM (EADC) INVESTIGATORS | J Prev Alz Dis 2024;5(11):1212-1218 | 349 |
| VIEWPOINT: AMYLOID-TARGETING NEW THERAPIES FOR ALZHEIMER’S DISEASE: A HEALTH ECONOMICS PERSPECTIVE | J Prev Alz Dis 2023;3(10):349-352 | 348 |
| A STATISTICAL FRAMEWORK FOR ASSESSING THE RELATIONSHIP BETWEEN BIOMARKERS AND CLINICAL ENDPOINTS IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;5(11):1228-1240 | 347 |
| VALIDATION OF THE COGDRISK INSTRUMENT AS PREDICTIVE OF DEMENTIA IN FOUR GENERAL COMMUNITY-DWELLING POPULATIONS | J Prev Alz Dis 2023;3(10):478-487 | 345 |
| MEDICAL COSTS AND CAREGIVER BURDEN OF DELIVERING DISEASE-MODIFYING ALZHEIMER’S TREATMENTS WITH DIFFERENT DURATION AND ROUTE OF ADMINISTRATION | J Prev Alz Dis 2024;5(11):1384-1389 | 344 |
| GREATER WHITE MATTER HYPERINTENSITY VOLUME IS ASSOCIATED WITH THE NUMBER OF MICROHEMORRHAGES IN PRECLINICAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;4(11):869-873 | 341 |
| LOWER INCIDENCE OF DEMENTIA FOLLOWING CANCER DIAGNOSES: EVIDENCE FROM A LARGE COHORT AND MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2024;5(11):1397-1405 | 339 |
| DIAGNOSTIC ACCURACY OF PLASMA P-TAU217 FOR DETECTING PATHOLOGICAL CEREBROSPINAL FLUID CHANGES IN COGNITIVELY UNIMPAIRED SUBJECTS USING THE LUMIPULSE PLATFORM | J Prev Alz Dis 2024;6(11):1581-1591 | 338 |
| COMMENTARY: CLINICAL EFFICACY IN INDIVIDUAL PATIENTS TREATED WITH LECANEMAB | J Prev Alz Dis 2023;3(10):378-379 | 337 |
| EDITORIAL: WHAT IS REASONABLE AND NECESSARY FOR ALZHEIMER PATIENTS FROM RANDOMIZED CLINICAL TRIALS TO CLINICAL PRACTICE? | J Prev Alz Dis 2023;3(10):331-332 | 337 |
| EDITORIAL: USEFULNESS OF ANCHOR BASED METHODS FOR DETERMINING CLINICALLY MEANINGFUL CHANGE IN MCI DUE TO AD | J Prev Alz Dis 2023;1(10):7-8 | 336 |
| ACOUSTIC SPEECH ANALYSIS IN ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2024;6(11):1789-1797 | 336 |
| NO ASSOCIATION FOUND: ADVERSE CHILDHOOD EXPERIENCES AND COGNITIVE IMPAIRMENT IN OLDER AUSTRALIAN ADULTS | J Prev Alz Dis 2024;6(11):1818-1825 | 334 |
| SAFETY PROFILE OF A COGNITIVELY UNIMPAIRED OLDER POPULATION WITH ELEVATED CEREBRAL AMYLOID IN A 4.5- YEAR CLINICAL TRIAL | J Prev Alz Dis 2024;4(11):857-868 | 333 |
| EFFECTS OF THE COVID-19 PANDEMIC ON THE NUMBER OF NEW DEMENTIA DIAGNOSES AND THE QUALITY OF DEMENTIA DIAGNOSTICS AND TREATMENT | J Prev Alz Dis 2024;6(11):1703-1711 | 333 |
| ESTABLISHING CLINICALLY MEANINGFUL CHANGE ON OUTCOME ASSESSMENTS FREQUENTLY USED IN TRIALS OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;1(10):9-18 | 332 |
| JAPANESE SUBGROUP ANALYSES FROM EMERGE AND ENGAGE, PHASE 3 CLINICAL TRIALS OF ADUCANUMAB IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;5(11):1260-1269 | 332 |
| VIEWPOINT: BALANCING THE CONFLICTING GOALS FOR TREATMENT OF ALZHEIMER’S DISEASE WITH MONOCLONAL ANTIBODIES | J Prev Alz Dis 2023;3(10):336-338 | 330 |
| ASSOCIATION OF COGNITIVE RESERVE INDICATOR WITH COGNITIVE DECLINE AND STRUCTURAL BRAIN DIFFERENCES IN MIDDLE AND OLDER AGE: FINDINGS FROM THE UK BIOBANK | J Prev Alz Dis 2024;3(11):739-748 | 330 |
| EDITORIAL: CHANGE ON CLINICAL TRIAL OUTCOME ASSESSMENTS: THE SEARCH FOR MEANINGFULNESS | J Prev Alz Dis 2023;1(10):5-6 | 329 |
| ECONOMIC IMPACT OF PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER DISEASE IN THE UNITED STATES | J Prev Alz Dis 2024;4(11):983-991 | 329 |
| MAXIMIZING THE UTILITY OF ALZHEIMER’S DISEASE TRIAL DATA: SHARING OF BASELINE A4 AND LEARN DATA | J Prev Alz Dis 2024;4(11):889-894 | 329 |
| PREDICTING PROGRESSION FROM NORMAL TO MCI AND FROM MCI TO AD USING CLINICAL VARIABLES IN THE NATIONAL ALZHEIMER’S COORDINATING CENTER UNIFORM DATA SET VERSION 3: APPLICATION OF MACHINE LEARNING MODELS AND A PROBABILITY CALCULATOR | J Prev Alz Dis 2023;2(10):301-313 | 326 |
| ASSOCIATIONS BETWEEN PARTICIPANT CHARACTERISTICS AND PARTICIPANT FEEDBACK ABOUT AN UNSUPERVISED ONLINE COGNITIVE ASSESSMENT IN A RESEARCH REGISTRY | J Prev Alz Dis 2023;3(10):607-614 | 325 |
| PREFERENCES ABOUT FUTURE ALZHEIMER’S DISEASE TREATMENTS ELICITED THROUGH AN ONLINE SURVEY USING THE THRESHOLD TECHNIQUE | J Prev Alz Dis 2023;4(10):756-764 | 324 |
| CORRELATES OF SUBJECTIVE COGNITIVE DECLINE IN BLACK AMERICAN MEN | J Prev Alz Dis 2024;6(11):1734-1740 | 324 |
| SYSTEMATIC AND COMPARATIVE ANALYSIS OF THE BURDEN OF ALZHEIMER´S DISEASE AND OTHER DEMENTIAS IN MEXICO. RESULTS AT THE NATIONAL AND SUBNATIONAL LEVELS, 1990- 2019 | J Prev Alz Dis 2023;1(10):120-129 | 322 |
| POINT OF VIEW: CHALLENGES IN IMPLEMENTATION OF NEW IMMUNOTHERAPIES FOR ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;1(12) | 321 |
| UNDERSTANDING BARRIERS AND FACILITATORS TO SIGNING UP FOR A MOBILE-RESPONSIVE REGISTRY TO RECRUIT HEALTHY VOLUNTEERS AND MEMBERS OF UNDERREPRESENTED COMMUNITIES FOR ALZHEIMER’S DISEASE PREVENTION STUDIES | J Prev Alz Dis 2023;4(10):865-874 | 319 |
| UTILITY OF ENVIRONMENTAL COMPLEXITY AS A PREDICTOR OF ALZHEIMER’S DISEASE DIAGNOSIS: A BIG-DATA MACHINE LEARNING APPROACH | J Prev Alz Dis 2023;2(10):223-235 | 317 |
| ERRATUM TO: DIGITAL CLOCK DRAWING AS AN ALZHEIMER’S DISEASE SUSCEPTIBILITY BIOMARKER: ASSOCIATIONS WITH GENETIC RISK SCORE AND APOE IN OLDER ADULTS | J Prev Alz Dis 2024;1(11):263 | 317 |
| EDITORIAL: THE CLINICAL TRIALS ALZHEIMER’S DISEASE (CTAD) MEETING IN SAN FRANCISCO, FALL 2022, WILL BE A VERY EXCITING EVENT! | J Prev Alz Dis 2022;3(9):387 | 316 |
| CHARACTERIZING CLINICAL PROGRESSION IN COGNITIVELY UNIMPAIRED OLDER INDIVIDUALS WITH BRAIN AMYLOID: RESULTS FROM THE A4 STUDY | J Prev Alz Dis 2024;4(11):814-822 | 315 |
| BLOOD CATHEPSINS ON THE RISK OF ALZHEIMER’S DISEASE AND RELATED PATHOLOGICAL BIOMARKERS: RESULTS FROM OBSERVATIONAL COHORT AND MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2024;6(11):1834-1842 | 315 |
| EDITORIAL: ACCELERATING INNOVATIONS FOR ENHANCED BRAIN HEALTH. CAN ARTIFICIAL INTELLIGENCE ADVANCE NEW PATHWAYS FOR DRUG DISCOVERY FOR ALZHEIMER’S AND OTHER NEURODEGENERATIVE DISORDERS? | J Prev Alz Dis 2023;1(10):1-4 | 311 |
| LETTER TO THE EDITOR: AMBAR: A THERAPEUTICAL APPROACH FOR ALZHEIMER’S DISEASE PATIENTS REGARDLESS OF AMYLOID STATUS | J Prev Alz Dis 2023;1(10):148-149 | 309 |
| RISK OF DEMENTIA IN KOREAN VIETNAM WAR VETERANS | J Prev Alz Dis 2024;5(11):1378-1383 | 308 |
| METABOLIC SYNDROME STATUS CHANGES AND COGNITIVE FUNCTIONING: INSIGHTS FROM THE LIFELINES COHORT STUDY | J Prev Alz Dis 2024;5(11):1283-1290 | 306 |
| ‘TIME SAVED’ AS A DEMONSTRATION OF CLINICAL MEANINGFULNESS AND ILLUSTRATED USING THE DONANEMAB TRAILBLAZER-ALZ STUDY FINDINGS | J Prev Alz Dis 2023;3(10):595-599 | 305 |
| EDITORIAL: EXPANDING THE ATN FRAMEWORK TO FURTHER PERSONALIZE THERAPIES | J Prev Alz Dis 2023;3(10):380 | 302 |
| POTENTIALLY MODIFIABLE DEMENTIA RISK FACTORS IN CANADA: AN ANALYSIS OF CANADIAN LONGITUDINAL STUDY ON AGING WITH A MULTI-COUNTRY COMPARISON | J Prev Alz Dis 2024;5(11):1490-1499 | 301 |
| EDITORIAL: IMPLICATIONS OF EMERGING USES OF GENETIC TESTING FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;3(10):359-361 | 300 |
| FLAVONOID-RICH FRUIT INTAKE IN MIDLIFE AND LATE-LIFE AND ASSOCIATIONS WITH RISK OF DEMENTIA: THE FRAMINGHAM HEART STUDY | J Prev Alz Dis 2024;5(11):1270-1279 | 300 |
| DETECTION RATES OF MILD COGNITIVE IMPAIRMENT IN PRIMARY CARE FOR THE UNITED STATES MEDICARE POPULATION | J Prev Alz Dis 2024;1(11):7-12 | 299 |
| EDITORIAL: LECANEMAB: APPROPRIATE USE RECOMMENDATIONS – A COMMENTARY FROM A EUROPEAN PERSPECTIVE | J Prev Alz Dis 2023;3(10):357-358 | 298 |
| CONTINUOUS ASSOCIATIONS BETWEEN REMOTE SELFADMINISTERED COGNITIVE MEASURES AND IMAGING BIOMARKERS OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;5(11):1467-1479 | 297 |
| A PILOT STUDY OF BRAIN BOOTCAMP, A LOW-INTENSITY INTERVENTION ON DIET, EXERCISE, COGNITIVE ACTIVITY, AND SOCIAL INTERACTION TO IMPROVE OLDER ADULTS’ DEMENTIA RISK SCORES | J Prev Alz Dis 2024;5(11):1500-1512 | 297 |
| HIGH DEFINITION TRANSCRANIAL DIRECT CURRENT STIMULATION AS AN INTERVENTION FOR COGNITIVE DEFICITS IN ALZHEIMER\'S DEMENTIA: A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2025;2(12) | 297 |
| ANTIHYPERTENSIVE AGENTS AND INCIDENT ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES | J Prev Alz Dis 2022;4(9):715-724 | 293 |
| Editorial: We Have Turned the Corner | J Prev Alz Dis 2022;9(S1):S5-S6 | 293 |
| LEVERAGING DIVERSE REGULATED CELL DEATH PATTERNS TO IDENTIFY DIAGNOSIS BIOMARKERS FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;6(11):1775-1788 | 293 |
| COHORT EFFECTS IN ALZHEIMER’S DISEASE TRIALS: AN EMPIRICAL ASSESSMENT UTILIZING DATA FROM THE ALZHEIMER’S DISEASE COOPERATIVE STUDY | J Prev Alz Dis 2023;3(10):471-477 | 292 |
| COMPUTERIZED COGNITIVE TRAINING IN MILD COGNITIVE IMPAIRMENT: FINDINGS IN AFRICAN AMERICANS AND CAUCASIANS | J Prev Alz Dis 2024;1(11):149-154 | 292 |
| VIEWPOINT: CLINICIANS’ PERSPECTIVES ON HOW DISEASE MODIFYING DRUGS FOR ALZHEIMER’S DISEASE IMPACT SPECIALTY CARE | J Prev Alz Dis 2023;3(10):339-341 | 291 |
| USE OF LECANEMAB AND DONANEMAB IN THE CANADIAN HEALTHCARE SYSTEM: EVIDENCE, CHALLENGES, AND AREAS FOR FUTURE RESEARCH | J Prev Alz Dis 2025;3(12) | 291 |
| CROSS-SECTIONAL AND LONGITUDINAL COMPARISON OF TAU IMAGING WITH 18F-MK6240 AND 18F-FLORTAUCIPIR IN POPULATIONS MATCHED FOR AGE, MMSE AND BRAIN BETA-AMYLOID BURDEN | J Prev Alz Dis 2023;2(10):251-258 | 290 |
| PREVENTING DEMENTIA IN ITALY: ESTIMATIONS OF MODIFIABLE RISK FACTORS AND PUBLIC HEALTH IMPLICATIONS | J Prev Alz Dis 2025;3(12) | 289 |
| ARTIFICIAL INTELLIGENCE-ENABLED SAFETY MONITORING IN ALZHEIMER\'S DISEASE CLINICAL TRIALS | J Prev Alz Dis 2025;1(12) | 288 |
| OUTREACH, SCREENING, AND RANDOMIZATION OF APOE Ε4 CARRIERS INTO AN ALZHEIMER’S PREVENTION TRIAL: A GLOBAL PERSPECTIVE FROM THE API GENERATION PROGRAM | J Prev Alz Dis 2023;3(10):453-463 | 287 |
| DIGITAL HEALTH TECHNOLOGIES FOR ALZHEIMER’S DISEASE AND RELATED DEMENTIAS: INITIAL RESULTS FROM A LANDSCAPE ANALYSIS AND COMMUNITY COLLABORATIVE EFFORT | J Prev Alz Dis 2024;5(11):1480-1489 | 287 |
| EFFICACY OF A GROUP-BASED 8-WEEK MULTICOMPONENT COGNITIVE TRAINING ON COGNITION, MOOD AND ACTIVITIES OF DAILY LIVING AMONG HEALTHY OLDER ADULTS: A TWO-YEAR FOLLOW-UP OF A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2025;2(12) | 287 |
| QUANTIFYING PERSONALIZED SHIFT-WORK MOLECULAR PORTRAITS UNDERLYING ALZHEIMER’S DISEASE THROUGH COMPUTATIONAL BIOLOGY | J Prev Alz Dis 2024;6(11):1721-1733 | 285 |
| COMBINED EVIDENCE FOR A LONG-TERM, CLINICAL SLOWING EFFECT OF MULTINUTRIENT INTERVENTION IN PRODROMAL ALZHEIMER’S DISEASE: POST-HOC ANALYSIS OF 3-YEAR DATA FROM THE LIPIDIDIET TRIAL | J Prev Alz Dis 2023;3(10):464-470 | 281 |
| LECANEMAB FOR EARLY ALZHEIMER\'S DISEASE: APPROPRIATE USE RECOMMENDATIONS FROM THE FRENCH FEDERATION OF MEMORY CLINICS | J Prev Alz Dis 2025;4(12) | 275 |
| ENHANCING DEMENTIA PREDICTION: A 19-YEAR VALIDATION OF THE CAIDE RISK SCORE WITH INSULIN RESISTANCE AND APOE Ε4 INTEGRATION IN A POPULATION-BASED COHORT | J Prev Alz Dis 2025;2(12) | 260 |
| MACHINE LEARNING TO DETECT ALZHEIMER\'S DISEASE WITH DATA ON DRUGS AND DIAGNOSES | J Prev Alz Dis 2025;5(12) | 258 |
| THE ALZMATCH PILOT STUDY - FEASIBILITY OF REMOTE BLOOD COLLECTION OF PLASMA BIOMARKERS FOR PRECLINICAL ALZHEIMER’S DISEASE TRIALS | J Prev Alz Dis 2024;5(11):1435-1444 | 254 |
| UNIVERSAL PREVENTION OF DEMENTIA IN ITALY: A DOCUMENT ANALYSIS OF THE 21 ITALIAN REGIONAL PREVENTION PLANS | J Prev Alz Dis 2024;6(11):1525-1533 | 251 |
| VIEWPOINT: DEFINING FDA APPROVED TREATMENTS AS REASONABLE AND NECESSARY: PERSPECTIVES OF INDIVIDUALS LIVING WITH ALZHEIMER’S DISEASE AND CARE PARTNERS | J Prev Alz Dis 2023;3(10):346-348 | 247 |
| PHYSICAL AND MENTAL DEMANDS OF WORK ASSOCIATED WITH DEMENTIA RISK IN LATER LIFE | J Prev Alz Dis 2025;4(12) | 239 |
| PHASE 1 STUDIES OF THE ANTI-TAU MONOCLONAL ANTIBODY JNJ-63733657 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;6(11):1592-1603 | 235 |
| A PILOT ELECTROENCEPHALOGRAPHY STUDY OF THE EFFECT OF CT1812 TREATMENT ON SYNAPTIC ACTIVITY IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;6(11):1809-1817 | 232 |
| IDENTIFYING PROTEOMIC PROGNOSTIC MARKERS FOR ALZHEIMER\'S DISEASE WITH SURVIVAL MACHINE LEARNING: THE FRAMINGHAM HEART STUDY | J Prev Alz Dis 2025;2(12) | 230 |
| DAYTIME SLEEPINESS, APNEA, NEUROIMAGING CORRELATES AND CORTISOL DYSREGULATION IN A MEMORY CLINIC COHORT | J Prev Alz Dis 2024;6(11):1798-1808 | 227 |
| EDITORIAL: ON THE 2024 ALZHEIMER’S ASSOCIATION CRITERIA: STILL NOT READY FOR CLINICAL USE | J Prev Alz Dis 2024;4(11):895-896 | 220 |
| EXPERT OPINION ON CENTILOID THRESHOLDS SUITABLE FOR INITIATING ANTI-AMYLOID THERAPY. SUMMARY OF DISCUSSION AT THE 2024 SPRING ALZHEIMER’S ASSOCIATION RESEARCH ROUNDTABLE | J Prev Alz Dis 2025;1(12) | 217 |
| CUTTING THROUGH THE NOISE: A NARRATIVE REVIEW OF ALZHEIMER\'S DISEASE PLASMA BIOMARKERS FOR ROUTINE CLINICAL USE | J Prev Alz Dis 2025;4(12) | 213 |
| PREDICTING COGNITIVE DECLINE: DEEP-LEARNING REVEALS SUBTLE BRAIN CHANGES IN PRE-MCI STAGE | J Prev Alz Dis 2025;5(12) | 213 |
| MODULATORY EFFECT OF BLOOD LDL CHOLESTEROL ON THE ASSOCIATION BETWEEN CEREBRAL AΒ AND TAU DEPOSITION IN OLDER ADULTS | J Prev Alz Dis 2024;6(11):1767-1774 | 209 |
| ANTI-HYPERTENSIVES REDUCE THE RATE OF ALZHEIMER’S DISEASE PROGRESSION: A COHORT STUDY LINKED WITH GENETIC AND NEUROPATHOLOGICAL ANALYSES | J Prev Alz Dis 2024;6(11):1634-1646 | 209 |
| FREE RECALL OUTPERFORMS STORY RECALL IN ASSOCIATIONS WITH PLASMA BIOMARKERS IN PRECLINICAL ALZHEIMER DISEASE | J Prev Alz Dis 2024;6(11):1696-1702 | 208 |
| ASSOCIATIONS OF ISCHEMIC HEART DISEASE WITH BRAIN GLYMPHATIC MRI INDICES AND RISK OF ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;3(12) | 208 |
| INFORMAL CARE FOR PEOPLE WITH DEMENTIA IN EUROPE | J Prev Alz Dis 2025;1(12) | 207 |
| DETERMINANTS OF DEMENTIA DIAGNOSIS IN U.S. PRIMARY CARE IN THE PAST DECADE: A SCOPING REVIEW | J Prev Alz Dis 2025;2(12) | 206 |
| THE IMPACT OF HYPERTENSION PREVENTION AND MODIFICATION ON DEMENTIA BURDEN: A SYSTEMATIC REVIEW OF ECONOMIC STUDIES | J Prev Alz Dis 2025;1(12) | 204 |
| BLOOD-BRAIN BARRIER INTEGRITY DISRUPTION IS ASSOCIATED WITH BOTH CHRONIC VASCULAR RISK FACTORS AND WHITE MATTER HYPERINTENSITIES | J Prev Alz Dis 2025;2(12) | 203 |
| THE ASSOCIATIONS BETWEEN FRESH VEGETABLE AND FRUIT CONSUMPTION AND PLASMA AND PET BIOMARKERS IN PRECLINICAL ALZHEIMER\'S DISEASE: A CROSS-SECTIONAL AND LONGITUDINAL STUDY OF CHINESE POPULATION | J Prev Alz Dis 2025;5(12) | 203 |
| THE EFFECT OF SLEEP DISTURBANCES ON THE INCIDENCE OF DEMENTIA FOR VARYING LAG TIMES | J Prev Alz Dis 2025;2(12) | 202 |
| DIAGNOSTIC AND DISCRIMINATIVE ACCURACY OF PLASMA PHOSPHORYLATED TAU 217 FOR SYMPTOMATIC ALZHEIMERʼS DISEASE IN A CHINESE COHORT | J Prev Alz Dis 2025;5(12) | 202 |
| EFFECTIVENESS OF A META-COGNITIVE GROUP INTERVENTION FOR OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE OR MILD COGNITIVE IMPAIRMENT: THE ASPIRE RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2024;6(11):1534-1548 | 199 |
| INFORMING ALZHEIMER’S BIOMARKER COMMUNICATION: CONCERNS AND UNDERSTANDING OF COGNITIVELY UNIMPAIRED ADULTS DURING AMYLOID RESULTS DISCLOSURE | J Prev Alz Dis 2024;6(11):1572-1580 | 198 |
| EFFECTS OF TRADITIONAL THAI FOLK DANCE COMBINED WITH COGNITIVE STIMULATION PROGRAM ON BEHAVIOR AND COGNITION AMONG OLDER ADULTS WITH COGNITIVE DECLINE: A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2025;4(12) | 198 |
| VALIDATION OF THE MULTI-DAY BOSTON REMOTE ASSESSMENT OF NEUROCOGNITIVE HEALTH (BRANCH) AMONG COGNITIVELY IMPAIRED & UNIMPAIRED OLDER ADULTS | J Prev Alz Dis 2025;3(12) | 197 |
| CLINICAL DEVELOPMENT OF ADUCANUMAB, AN ANTI-A? HUMAN MONOCLONAL ANTIBODY BEING INVESTIGATED FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(4):255-263 | 196 |
| ELIGIBILITY FOR DONANEMAB TRIAL IN A POPULATION-BASED STUDY OF COGNITIVE AGING | J Prev Alz Dis 2025;4(12) | 194 |
| USEFULNESS OF CEREBROSPINAL FLUID ALZHEIMER\'S DISEASE BIOMARKERS IN OLDER PATIENTS: EVIDENCE FROM A NATIONAL MULTICENTER PROSPECTIVE STUDY | J Prev Alz Dis 2025;1(12) | 192 |
| HYPOTHETICAL INTERVENTIONS ON CARDIOVASCULAR HEALTH METRICS FOR ABNORMAL COGNITIVE AGING: AN APPLICATION OF THE PARAMETRIC G-FORMULA IN THE CLHLS COHORT STUDY WITH 12 YEARS FOLLOW-UP | J Prev Alz Dis 2024;6(11):1615-1625 | 191 |
| ASSOCIATION BETWEEN COGNITIVE RESERVE INDICATOR AND CHRONIC DISEASE-FREE SURVIVAL: A LARGE COMMUNITYBASED LONGITUDINAL STUDY | J Prev Alz Dis 2024;6(11):1712-1720 | 187 |
| INFORMING ETIOLOGICAL HETEROGENEITY OF MILD COGNITIVE IMPAIRMENT AND RISK FOR PROGRESSION TO DEMENTIA WITH PLASMA P-TAU217 | J Prev Alz Dis 2025;1(12) | 186 |
| PLASMA NEUROFILAMENT LIGHT MEDIATES THE EFFECTS OF APOLIPOPROTEIN E ON BRAIN ATROPHY AND COGNITIVE DECLINE IN THE COMORBID ALZHEIMER\'S DISEASE AND CEREBRAL SMALL VESSEL DISEASE | J Prev Alz Dis 2025;3(12) | 186 |
| VIEWS AND PERCEPTIONS OF AMYLOID IMAGING IN A PRECLINICAL ALZHEIMER’S DISEASE TRIAL | J Prev Alz Dis 2024;6(11):1563-1571 | 184 |
| THE INTERACTION BETWEEN CIRCADIAN SYNDROME AND GENETIC SUSCEPTIBILITY IN THE RISK OF INCIDENT DEMENTIA: A LONGITUDINAL COHORT STUDY | J Prev Alz Dis 2025;5(12) | 184 |
| EDITORIAL: AMPLIFYING EFFICIENCY AND ACCURACY IN DEMENTIA DRUG DEVELOPMENT | J Prev Alz Dis 2024;5(11):1180-1182 | 183 |
| HEARING LOSS, DIET, AND COGNITIVE DECLINE: INTERCONNECTIONS FOR DEMENTIA PREVENTION | J Prev Alz Dis 2025;3(12) | 183 |
| PROTOCOL FOR AN INTERGENERATIONAL RANDOMIZED CONTROLLED TRIAL TO ENHANCE PHYSICAL ACTIVITY IN OLDER ADULTS AT RISK FOR ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;3(12) | 182 |
| ASSOCIATIONS OF GLYCEMIC STATUS WITH DYNAMIC DISEASE TRAJECTORIES OF ATRIAL FIBRILLATION AND DEMENTIA | J Prev Alz Dis 2025;3(12) | 181 |
| BRAIN HEALTH SERVICES FOR THE SECONDARY PREVENTION OF COGNITIVE IMPAIRMENT AND DEMENTIA: OPPORTUNITIES, CHALLENGES, AND THE BUSINESS CASE FOR EXISTING AND FUTURE FACILITIES | J Prev Alz Dis 2025;5(12) | 178 |
| EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT? | J Prev Alz Dis 2019;6(3):150 | 177 |
| BASAL FOREBRAIN GLOBAL FUNCTIONAL CONNECTIVITY IS PRESERVED IN ASYMPTOMATIC PRESENILIN-1 E280A MUTATION CARRIERS: RESULTS FROM THE COLOMBIA COHORT | J Prev Alz Dis 2025;2(12) | 177 |
| EFFECTS OF THE DAVOS ALZHEIMER\'S COLLABORATIVE EARLY DETECTION OF COGNITIVE IMPAIRMENT PROGRAM ON CLINICIAN ATTITUDES, ENGAGEMENT, AND CONFIDENCE | J Prev Alz Dis 2025;3(12) | 177 |
| MEMSCREEN: A SMARTPHONE APPLICATION FOR DETECTION OF MILD COGNITIVE IMPAIRMENT: A VALIDATION STUDY: SMARTPHONE APP FOR MCI DETECTION | J Prev Alz Dis 2025;3(12) | 174 |
| ASSOCIATIONS OF EARLY-ONSET CORONARY HEART DISEASE AND GENETIC SUSCEPTIBILITY WITH INCIDENT DEMENTIA AND WHITE MATTER HYPERINTENSITY: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;2(12) | 172 |
| A POINT-BASED COGNITIVE IMPAIRMENT SCORING SYSTEM FOR SOUTHEAST ASIAN ADULTS | J Prev Alz Dis 2025;4(12) | 172 |
| WHITE MATTER HYPERINTENSITY SEVERITY MODIFIES GUT METABOLITE ASSOCIATION WITH COGNITIVE OUTCOMES | J Prev Alz Dis 2025;4(12) | 165 |
| INTERACTIONS OF PHYSICAL ACTIVITY AND LUNG FUNCTION ON COGNITIVE HEALTH IN OLDER ADULTS: JOINT ASSOCIATION AND MEDIATION ANALYSIS | J Prev Alz Dis 2025;5(12) | 164 |
| DISTINCT CSF Α-SYNUCLEIN AGGREGATION PROFILES ASSOCIATED WITH ALZHEIMER\'S DISEASE PHENOTYPES AND MCI-TO-AD CONVERSION | J Prev Alz Dis 2025;2(12) | 160 |
| FEASIBILITY OF COMPUTERIZED MOTOR, COGNITIVE AND SPEECH TESTS IN THE HOME: ANALYSIS OF TAS TEST IN 2,300 OLDER ADULTS | J Prev Alz Dis 2025;4(12) | 160 |
| AMERICAN\'S OVERALL AND EQUITY-BASED SOCIETAL VALUATION OF A DISEASE-MODIFYING ALZHEIMER\'S TREATMENT: RESULTS FROM A DISCRETE CHOICE EXPERIMENT | J Prev Alz Dis 2025;3(12) | 158 |
| EFFECT OF A SINGLE NONPHARMACOLOGICAL INTERVENTION ON COGNITIVE FUNCTIONING IN OLDER ADULTS WITH MILD-TO-MODERATE ALZHEIMER\'S DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS: NON-DRUG INTERVENTIONS FOR ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;3(12) | 158 |
| INFLUENCE OF APOE Ε4 ON PERFORMANCE OF CSF BIOMARKERS IN DIFFERENTIATING CLINICAL ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;4(12) | 158 |
| THE IMPACT OF PRE-ANALYTICAL FACTORS ON PLASMA BIOMARKERS FOR ALZHEIMER\'S DISEASE: THE ASPREE HEALTHY AGEING BIOBANK | J Prev Alz Dis 2025;4(12) | 156 |
| REAL-WORLD DATASETS FOR THE INTERNATIONAL REGISTRY FOR ALZHEIMER\'S DISEASE AND OTHER DEMENTIAS (INRAD) AND OTHER REGISTRIES: AN INTERNATIONAL CONSENSUS | J Prev Alz Dis 2025;4(12) | 156 |
| CORRIGENDUM TO “MULTIOMICS BLOOD-BASED BIOMARKERS PREDICT ALZHEIMER\'S PREDEMENTIA WITH HIGH SPECIFICITY IN A MULTICENTRIC COHORT STUDY” [THE JOURNAL OF PREVENTION OF ALZHEIMER\'S DISEASE 2024;11(3):567–581] | J Prev Alz Dis 2025;2(12) | 152 |
| BRAIN HEALTH CLINICS – AN EVOLVING CLINICAL PATHWAY? | J Prev Alz Dis 2025;3(12) | 150 |
| LIVER FUNCTION AND ALZHEIMER\'S BRAIN PATHOLOGIES: A LONGITUDINAL STUDY: LIVER AND ALZHEIMER\'S PATHOLOGIES | J Prev Alz Dis 2025;1(12) | 149 |
| MICROSTRUCTURAL WHITE MATTER INJURY CONTRIBUTES TO COGNITIVE DECLINE: BESIDES AMYLOID AND TAU | J Prev Alz Dis 2025;2(12) | 149 |
| MODIFIABLE RISK FACTORS FOR EARLY- AND LATE-ONSET DEMENTIA USING THE KOREAN NATIONAL HEALTH INSURANCE SERVICE DATABASE | J Prev Alz Dis 2025;3(12) | 148 |
| EDITORIAL: VISION, COURAGE, AND ACADEMIC FREEDOM | J Prev Alz Dis 2025;3(12) | 148 |
| PATIENT ELIGIBILITY FOR AMYLOID-TARGETING IMMUNOTHERAPIES IN ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;4(12) | 147 |
| ASSESSING THE CAUSAL ROLE OF LIPID METABOLITES IN ALZHEIMER\'S DISEASE: A MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2025;4(12) | 145 |
| JOINT ENSEMBLE LEARNING-BASED RISK PREDICTION OF ALZHEIMER\'S DISEASE AMONG MILD COGNITIVE IMPAIRMENT PATIENTS | J Prev Alz Dis 2025;4(12) | 145 |
| CLARITY AD: ASIAN REGIONAL ANALYSIS OF A PHASE III TRIAL OF LECANEMAB IN EARLY ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;5(12) | 144 |
| TAILORING IMPLEMENTATION STRATEGIES FOR THE HEALTHY ACTIONS AND LIFESTYLES TO AVOID DEMENTIA OR HISPANOS Y EL ALTO A LA DEMENCIA PROGRAM: LESSONS LEARNED FROM A SURVEY STUDY | J Prev Alz Dis 2025;3(12) | 142 |
| CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME AND INCIDENCE OF DEMENTIA AMONG OLDER ADULTS | J Prev Alz Dis 2025;5(12) | 142 |
| LIFESTYLE FACTORS AND PLASMA BIOMARKERS OF ALZHEIMER\'S DISEASE: A NARRATIVE REVIEW | | 142 |
| CHARACTERIZING AND VALIDATING 12-MONTH RELIABLE COGNITIVE CHANGE IN EARLY-ONSET ALZHEIMER\'S DISEASE FOR USE IN CLINICAL TRIALS | J Prev Alz Dis 2025;4(12) | 141 |
| ASSOCIATION OF STATINS USE AND GENETIC SUSCEPTIBILITY WITH INCIDENCE OF ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;2(12) | 140 |
| MOTOR ABILITIES AND COGNITIVE PERFORMANCE IN LATINOS WITH AUTOSOMAL DOMINANT ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;1(12) | 139 |
| FEASIBILITY AND ACCEPTABILITY OF REMOTE APOE-GENOTYPING AMONG RESEARCH VOLUNTEERS OF AN ONLINE RECRUITMENT REGISTRY (THE DUTCH BRAIN RESEARCH REGISTRY) | J Prev Alz Dis 2025;5(12) | 139 |
| CARDIOVASCULAR HEALTH, GENETIC PREDISPOSITION, AND DEMENTIA RISK AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS | J Prev Alz Dis 2025;1(12) | 138 |
| QUALITATIVE RESEARCH AND LITERATURE REVIEW SUPPORT THE INTEGRATED ALZHEIMER\'S DISEASE RATING SCALE (IADRS) CONTENT VALIDITY IN EARLY SYMPTOMATIC AD | J Prev Alz Dis 2025;4(12) | 137 |
| LETTER TO THE EDITOR: REEVALUATING THE SLEEP-DEMENTIA LINK: METHODOLOGICAL GAPS AND FUTURE DIRECTIONS | J Prev Alz Dis 2025;4(12) | 134 |
| INTERCEPT-AD, A PHASE 1 STUDY OF INTRAVENOUS SABIRNETUG IN PARTICIPANTS WITH MILD COGNITIVE IMPAIRMENT OR MILD DEMENTIA DUE TO ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;1(12) | 131 |
| ASSOCIATION BETWEEN L-Α GLYCERYLPHOSPHORYLCHOLINE USE AND DELAYED DEMENTIA CONVERSION: A NATIONWIDE LONGITUDINAL STUDY IN SOUTH KOREA | J Prev Alz Dis 2025;4(12) | 129 |
| PLASMA AMYLOID-Β PRECURSOR PROTEIN 669–711/AMYLOID-Β1–42 RATIO IS ASSOCIATED WITH COGNITION IN ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;1(12) | 128 |
| LMTK2 AND CRB1 ARE TWO NOVEL RISK GENES FOR ALZHEIMER\'S DISEASE IN HAN CHINESE | J Prev Alz Dis 2025;5(12) | 128 |
| BIOFLUID BIOMARKER CHANGES FOLLOWING TREATMENT WITH SABIRNETUG (ACU193) IN INTERCEPT-AD, A PHASE 1 TRIAL IN EARLY ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;4(12) | 127 |
| DEVELOPING DISEASE-MODIFYING TREATMENTS IN ALZHEIMER’S DISEASE – A PERSPECTIVE FROM ROCHE AND GENENTECH | J Prev Alz Dis 2017;4(4):264-272 | 124 |
| BEHAVIOUR CHANGE TECHNIQUES USED IN INTERVENTIONS TARGETING DEMENTIA RISK FACTORS AMONGST OLDER ADULTS IN RURAL AND REMOTE AREAS: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2025;4(12) | 122 |
| CURRENT STATUS AND FUTURE DIRECTIONS FOR THE DIAGNOSIS AND MANAGEMENT OF MILD COGNITIVE IMPAIRMENT IN SOUTHEAST ASIA: A SEACURE CONSENSUS PAPER | J Prev Alz Dis 2025;5(12) | 122 |
| ASSOCIATION OF DIETARY DIVERSITY, GENETIC SUSCEPTIBILITY, AND THE RISK OF INCIDENT DEMENTIA: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;4(12) | 121 |
| MAINTAINING LEVEL OF MODIFIABLE DEMENTIA RISK SCORES IS ASSOCIATED WITH BETTER COGNITIVE OUTCOMES THAN INCREASING RISK SCORES: A POPULATION-BASED PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2025;1(12) | 120 |
| DIETARY SUPPLEMENTATION AND THE ROLE OF PHYTOCHEMICALS AGAINST THE ALZHEIMER\'S DISEASE: FOCUS ON POLYPHENOLIC COMPOUNDS | J Prev Alz Dis 2025;1(12) | 118 |
| LONGITUDINAL ASSOCIATIONS OF CAROTID ARTERY STIFFNESS WITH PROGRESSION OF CEREBROVASCULAR DISEASE, INCIDENT DEMENTIA AND COGNITIVE DECLINE IN OLDER ADULTS | | 117 |
| DISTINCT TRAJECTORIES OF SUBJECTIVE COGNITIVE DECLINE BEFORE DIAGNOSIS OF NEUROCOGNITIVE DISORDERS: LONGITUDINAL MODELLING OVER 18 YEARS | J Prev Alz Dis 2025;5(12) | 116 |
| MICROGLIAL ACTIVATION STATES AND THEIR IMPLICATIONS FOR ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;1(12) | 113 |
| CHRONOTYPE AS A POTENTIAL RISK FACTOR FOR COGNITIVE DECLINE: THE MEDIATING ROLE OF SLEEP QUALITY AND HEALTH BEHAVIOURS IN A 10-YEAR FOLLOW-UP STUDY | | 113 |
| LETTER TO THE EDITOR: MITOCHONDRIAL DYSFUNCTION AS THE MISSING LINK BETWEEN CIRCADIAN SYNDROME AND DEMENTIA | J Prev Alz Dis 2025;4(12) | 112 |
| HEALTHY DIETARY PATTERNS IN RELATION TO COGNITIVE PERFORMANCE AND ALZHEIMER\'S DISEASE MORTALITY | J Prev Alz Dis 2025;5(12) | 111 |
| OPPOSITE CAUSAL EFFECTS OF TYPE 2 DIABETES AND METFORMIN ON ALZHEIMER\'S DISEASE | | 111 |
| REPLY TO THE LETTER TO THE EDITOR: ENHANCING STATIN RESEARCH FOR ALZHEIMER\'S PREVENTION: SUGGESTIONS FOR FUTURE STUDIES AND POLICY IMPLICATIONS | J Prev Alz Dis 2025;5(12) | 109 |
| GENETIC PREDISPOSITION TO HIGH CIRCULATING LEVELS OF INTERLEUKIN 6 AND RISK FOR ALZHEIMER\'S DISEASE. DISCOVERY AND REPLICATION | J Prev Alz Dis 2025;1(12) | 106 |
| INTEGRATIVE SINGLE-CELL RNA SEQUENCING AND MENDELIAN RANDOMIZATION ANALYSIS REVEAL THE POTENTIAL ROLE OF SYNAPTIC VESICLE CYCLING-RELATED GENES IN ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;5(12) | 106 |
| LETTER TO THE EDITOR: ENHANCING STATIN RESEARCH FOR ALZHEIMER\'S PREVENTION: SUGGESTIONS FOR FUTURE STUDIES AND POLICY IMPLICATIONS | J Prev Alz Dis 2025;5(12) | 103 |
| CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2017;4(4):282-428 | 101 |
| PATIENT MANAGEMENT PATHWAYS IN DEMENTIA – RESOURCE UTILISATION, DIAGNOSIS AND DRUG TREATMENT IN THE STOCKHOLM REGION, SWEDEN | | 94 |
| THE DISEASE BURDEN, RISK FACTORS AND FUTURE PREDICTIONS OF ALZHEIMER\'S DISEASE AND OTHER TYPES OF DEMENTIA IN ASIA FROM 1990 TO 2021 | J Prev Alz Dis 2025;5(12) | 93 |
| CEREBRAL PERFUSION CORRELATES WITH AMYLOID DEPOSITION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;2(12) | 92 |
| ASSOCIATION BETWEEN THE USE OF INFORMATION AND COMMUNICATION TECHNOLOGY AND COGNITIVE DECLINE STRATIFIED BY SOCIAL ISOLATION: THE OTASSHA STUDY | | 89 |
| MULTI-OMICS ANALYSIS OF DRUGGABLE GENES TO FACILITATE ALZHEIMER\'S DISEASE THERAPY: A MULTI-COHORT MACHINE LEARNING STUDY | | 88 |
| CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2018;5(S1):S1-S196 | 86 |
| COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2019;6(3):164-168 | 86 |
| DEVELOPMENT REVIEW OF THE BACE1 INHIBITOR LANABECESTAT (AZD3293/LY3314814) | J Prev Alz Dis 2017;4(4):247-254 | 85 |
| EDITORIAL: TAU BASED THERAPEUTICS: ALTERNATIVE APPROACHES IN THE WAR ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(3):151-152 | 82 |
| WHAT WE LEARN FROM THE CTAD 2018 (CLINICAL TRIALS ALZHEIMER’S DISEASE) | J Prev Alz Dis 2018;5(4):214-215 | 81 |
| THE 2018 REVISED FDA GUIDANCE FOR EARLY ALZHEIMER’S DISEASE: ESTABLISHING THE MEANINGFULNESS OF TREATMENT EFFECTS | J Prev Alz Dis 2019;6(4):223-227 | 81 |
| REPLY TO THE LETTER TO THE EDITOR: MITOCHONDRIAL DYSFUNCTION AS THE MISSING LINK BETWEEN CIRCADIAN SYNDROME AND DEMENTIA | J Prev Alz Dis 2025;4(12) | 81 |
| BRAIN HEALTH PRO/SANTE CERVEAU PRO: THE DEVELOPMENT OF A WEB-BASED PROGRAM FOR DEMENTIA LITERACY AND RISK FACTOR REDUCTION | | 81 |
| THE COST-EFFECTIVENESS OF AN ONLINE INTERVENTION TO PREVENT DEMENTIA: RESULTS FROM THE MAINTAIN YOUR BRAIN (MYB) RANDOMISED CONTROLLED TRIAL | | 81 |
| EFFECTIVENESS OF DIGITAL SCREENING TOOLS IN DETECTING COGNITIVE IMPAIRMENT AMONG COMMUNITY-DWELLING ELDERLY IN NORTHERN CHINA: A LARGE COHORT STUDY | J Prev Alz Dis 2025;3(12) | 80 |
| TREATMENT EFFECTS OF VORTIOXETINE ON COGNITIVE FUNCTIONS IN MILD ALZHEIMER’S DISEASE PATIENTS WITH DEPRESSIVE SYMPTOMS: A 12 MONTH, OPEN-LABEL, OBSERVATIONAL STUDY | J Prev Alz Dis 2019;6(3):192-197 | 78 |
| COMPARATIVE EFFICACY AND SAFETY OF ANTIDIABETIC AGENTS IN ALZHEIMER\'S DISEASE: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS | J Prev Alz Dis 2025;5(12) | 78 |
| CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERS | J Prev Alz Dis 2014;1(3):214-296 | 75 |
| EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE? | J Prev Alz Dis 2019;6(3):153-154 | 75 |
| EDITORIAL: BLOOD TESTS FOR ALZHEIMER’S DISEASE AND RELATED DISORDERS | J Prev Alz Dis 2019;6(3):155-156 | 70 |
| CORRIGENDUM TO “17TH CLINICAL TRIALS ON ALZHEIMER\'S DISEASE (CTAD) MADRID, SPAIN, OCTOBER 29 - NOVEMBER 1, 2024: SYMPOSIA, ORAL COMMUNICATIONS” [J PREV ALZHEIMERS DIS 2025;12(1S):100043]. | J Prev Alz Dis 2025;4(12) | 69 |
| 17th Clinical Trials on Alzheimer\'s Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Conference proceedings | | 68 |
| DETECTING TREATMENT GROUP DIFFERENCES IN ALZHEIMER’S DISEASE CLINICAL TRIALS: A COMPARISON OF ALZHEIMER’S DISEASE ASSESSMENT SCALE - COGNITIVE SUBSCALE (ADAS-COG) AND THE CLINICAL DEMENTIA RATING - SUM OF BOXES (CDR-SB) | J Prev Alz Dis 2018;5(1):15-20 | 67 |
| DIETARY PATTERNS AND BLOOD-BASED BIOMARKERS OF ALZHEIMER\'S DISEASE IN COGNITIVELY INTACT OLDER ADULTS: FINDINGS FROM A POPULATION-BASED STUDY | | 66 |
| BIOMARKER AND CLINICAL TRIAL DESIGN SUPPORT FOR DISEASE-MODIFYING THERAPIES: REPORT OF A SURVEY OF THE EU/US: ALZHEIMER’S DISEASE TASK FORCE | J Prev Alz Dis 2018;5(2):103-109 | 64 |
| THE ROLE OF SERUM VITAMINS IN MEDIATING THE EFFECT OF NEURODEGENERATIVE DISEASES ON SUBCORTICAL BRAIN VOLUME | | 63 |
| LETTER TO THE EDITOR: CONCERNS ABOUT ANAVEX\'S CLINICAL TRIAL OF BLARCAMESINE | J Prev Alz Dis 2025;5(12) | 62 |
| PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCE | J Prev Alz Dis 2015;2(3):184-188 | 58 |
| TRAJECTORY OF THE MAPT-PACC-PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE IN THE PLACEBO GROUP OF A RANDOMIZED CONTROL TRIAL: RESULTS FROM THE MAPT STUDY: LESSONS FOR FURTHER TRIALS | J Prev Alz Dis 2018;5(1):31-35 | 58 |
| PHENOTYPIC ALTERATIONS IN PERIPHERAL BLOOD B LYMPHOCYTES OF PATIENTS WITH ALZHEIMER\'S DISEASE | | 58 |
| DONANEMAB: APPROPRIATE USE RECOMMENDATIONS | J Prev Alz Dis 2025;5(12) | 58 |
| CORRIGENDUM TO “ENHANCING DEMENTIA PREDICTION: A 19-YEAR VALIDATION OF THE CAIDE RISK SCORE WITH INSULIN RESISTANCE AND APOE ε4 INTEGRATION IN A POPULATION-BASED COHORT” [THE JOURNAL OF PREVENTION OF ALZHEIMER\'S DISEASE (2024) 100034] | J Prev Alz Dis 2025;5(12) | 58 |
| POOR GLYMPHATIC FUNCTION IS ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT AND ITS PROGRESSION TO ALZHEIMER\'S DISEASE: A DTI-ALPS STUDY | | 58 |
| ASSOCIATION OF DIETARY FATTY ACIDS WITH LONGITUDINAL CHANGE IN PLASMA-BASED BIOMARKERS OF ALZHEIMER\'S DISEASE | J Prev Alz Dis 2025;5(12) | 55 |
| COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE | J Prev Alz Dis 2019;6(3):180-181 | 54 |
| RESULTS FROM A PHASE II STUDY TO ASSESS THE CLINICAL AND IMMUNOLOGICAL ACTIVITY OF AFFITOPE® AD02 IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(2):103-114 | 53 |
| A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF THE EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY, SAFETY AND AMYLOID IMAGING IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(4):192-201 | 53 |
| A KETO-MEDIET APPROACH WITH COCONUT SUBSTITUTION AND EXERCISE MAY DELAY THE ONSET OF ALZHEIMER’S DISEASE AMONG MIDDLE-AGED | J Prev Alz Dis 2017;4(1):51-57 | 52 |
| DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(1):8-14 | 52 |
| THE ROAD AHEAD TO CURE ALZHEIMER\'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS | J Prev Alz Dis 2014;1(3):181-202 | 51 |
| ADVANCING ALZHEIMER’S DISEASE TREATMENT: LESSONS FROM CTAD 2018 | J Prev Alz Dis 2019;6(3):198-203 | 49 |
| EDITORIAL: ARE APPROPRIATE USE RECOMMENDATIONS USEFUL IN CLINICAL PRACTICE? | J Prev Alz Dis 2025;5(12) | 49 |
| CONTINUING PROGRESS IN ALZHEIMER’S DISEASE TRIALS: CAUSE FOR OPTIMISM | J Prev Alz Dis 2017;4(4):211-212 | 48 |
| COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMER’S DISEASE LIQUID BIOPSY | J Prev Alz Dis 2019;6(3):182-184 | 48 |
| SAMPLE SIZE ESTIMATES FOR BIOMARKER-BASED OUTCOME MEASURES IN CLINICAL TRIALS IN AUTOSOMAL DOMINANT ALZHEIMER\'S DISEASE | | 48 |
| FINGOLIMOD AMELIORATES AMYLOID DEPOSITION AND NEURODEGENERATION IN APP/PS1 MOUSE MODEL OF ALZHEIMER\'S DISEASE | | 48 |
| OVERSIMPLIFICATION OF DEMENTIA RISK REDUCTION MESSAGING IS A THREAT TO KNOWLEDGE TRANSLATION IN DEMENTIA PREVENTION RESEARCH | J Prev Alz Dis 2018;5(1):2-4 | 47 |
| PLASMA BIOMARKER FOR ALZHEIMER’S DISEASE: ARE WE READY NOW FOR CLINICAL PRACTICE AND DRUG TRIALS? | J Prev Alz Dis 2018;5(3):158-159 | 47 |
| MACHINE LEARNING ALGORITHM HELPS IDENTIFY NONDIAGNOSED PRODROMAL ALZHEIMER’S DISEASE PATIENTS IN THE GENERAL POPULATION | J Prev Alz Dis 2019;6(3):185-191 | 47 |
| ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: THE ROAD AHEAD | J Prev Alz Dis 2015;2(2):78-79 | 46 |
| IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED | J Prev Alz Dis 2014;1(1):40-45 | 45 |
| ASSESSMENT OF CLINICAL MEANINGFULNESS OF ENDPOINTS IN THE GENERATION PROGRAM BY THE INSIGHTS TO MODEL ALZHEIMER’S PROGRESSION IN REAL LIFE (IMAP) STUDY | J Prev Alz Dis 2019;6(2):85-89 | 45 |
| E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS | J Prev Alz Dis 2014;1(2):110-116 | 43 |
| LONGITUDINAL TRAJECTORIES OF CLINICAL DECLINE IN AMYLOID POSITIVE AND NEGATIVE POPULATIONS | J Prev Alz Dis 2016;3(2):92-100 | 43 |
| GLOBAL ALZHEIMER’S PLATFORM TRIAL READY COHORTS FOR THE PREVENTION OF ALZHEIMER’S DEMENTIA | J Prev Alz Dis 2016;3(4):185-187 | 43 |
| COMMENTARY: TREATING ALZHEIMER’S DISEASE : COMBINE OR FAIL ? | J Prev Alz Dis 2019;6(3):174-176 | 43 |
| COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE – THE NEXT STEP | J Prev Alz Dis 2019;6(3):179 | 43 |
| LATENT COGNITIVE PROFILES AND THEIR ASSOCIATIONS WITH INSTRUMENTAL ACTIVITIES OF DAILY LIVING AMONG OLDER ADULTS WITHOUT DEMENTIA: A UNITED STATES NATIONAL CROSS-SECTIONAL STUDY | | 43 |
| DRUG DEVELOPMENT IN AD: POINT OF VIEW FROM THE INDUSTRY | J Prev Alz Dis 2015;2(4):216-218 | 41 |
| VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDY | J Prev Alz Dis 2016;3(2):75-84 | 41 |
| UPDATE ON PREVENTION TRIALS IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(3):168-175 | 40 |
| ESTABLISHING COMPOSITE COGNITIVE ENDPOINTS FOR USE IN PRECLINICAL ALZHEIMER’S DISEASE TRIALS | J Prev Alz Dis 2015;2(1):2-3 | 39 |
| RECRUITMENT OF AT-RISK PARTICIPANTS FOR CLINICAL TRIALS: A MAJOR PARADIGM SHIFT FOR ALZHEIMER’S DISEASE PREVENTION | J Prev Alz Dis 2017;4(4):213-214 | 39 |
| THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) FINDINGS FROM THE EXPEDITION3 TRIAL | J Prev Alz Dis 2018;5(2):134-136 | 39 |
| LETTER TO THE EDITOR: REBUTTAL LETTER ON BEHALF OF ALL AUTHORS IN RESPONSE TO THE LETTER TO THE EDITOR | J Prev Alz Dis 2025;5(12) | 39 |
| THE ROAD AHEAD TO CURE AND PREVENT ALZHEIMER’S DISEASE: IMPLEMENTING PREVENTION INTO PRIMARY CARE | J Prev Alz Dis 2015;2(3):199-211 | 38 |
| PREVENTION: HOW THE PARADIGM IS SHIFTING | J Prev Alz Dis 2014;1(1):51-55 | 37 |
| COMMENTARY: OPPORTUNITIES FOR COMBINATION TRIALS | J Prev Alz Dis 2019;6(3):177-178 | 37 |
| ASSOCIATIONS BETWEEN THE EAT-LANCET PLANETARY HEALTH DIET AND INCIDENT DEMENTIA | | 37 |
| EDITORIAL: JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE (JPAD): BUILDING A “FLEET” AGAINST ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(1):2-3 | 36 |
| PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(4):243-259 | 36 |
| PRIMARY PREVENTION OF DEMENTIA: THE FUTURE OF POPULATION-BASED MULTIDOMAIN LIFESTYLE INTERVENTIONS | J Prev Alz Dis 2018;5(1):5-7 | 36 |
| BASELINE HABITUAL DIETARY NITRATE INTAKE AND ALZHEIMER\'S DISEASE RELATED NEUROIMAGING BIOMARKERS IN THE AUSTRALIAN IMAGING, BIOMARKERS AND LIFESTYLE STUDY OF AGEING | | 36 |
| FACEHBI: A PROSPECTIVE STUDY OF RISK FACTORS, BIOMARKERS AND COGNITION IN A COHORT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. STUDY RATIONALE AND RESEARCH PROTOCOLS | J Prev Alz Dis 2017;4(2):100-108 | 35 |
| NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA: OVERVIEW AND MEASUREMENT CHALLENGES | J Prev Alz Dis 2015;2(3):155-156 | 34 |
| HEALTHYBRAINS.ORG: FROM REGISTRY TO RANDOMIZATION | J Prev Alz Dis 2016;3(3):123-126 | 34 |
| GETTING MORE CLINICALLY MEANINGFUL MEASURES OF FUNCTIONAL IMPAIRMENT FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2017;4(2):67-68 | 34 |
| EDITORIAL : DEMENTIA PREVENTION STRATEGIES – BEYOND THE RANDOMIZED CONTROLLED TRIAL? | J Prev Alz Dis 2014;1(2):62-64 | 33 |
| INTERVENTIONS TO PREVENT COGNITIVE DECLINE AND DEMENTIA IN ADULTS WITHOUT COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEW | J Prev Alz Dis 2015;2(1):38-45 | 33 |
| METHODOLOGICAL ASPECTS OF THE PHASE II STUDY AFF006 EVALUATING AMYLOID-BETA -TARGETING VACCINE AFFITOPE® AD02 IN EARLY ALZHEIMER’S DISEASE – PROSPECTIVE USE OF NOVEL COMPOSITE SCALES | J Prev Alz Dis 2015;2(2):91-102 | 33 |
| LIFESTYLE AND COGNITION: SEPARATING THE EFFECTS OF AVERAGE LIFESTYLE AND LIFESTYLE CHANGES BASED ON THE LIBRA SCORE | | 33 |
| HERPES ZOSTER AS RISK FACTOR FOR DEMENTIA: A MATCHED COHORT STUDY OVER 20 YEARS IN A 10-MILLION POPULATION IN ITALY | | 33 |
| ASSOCIATION OF THE DIFFERENCE BETWEEN CYSTATIN C- AND CREATININE-BASED ESTIMATED GLOMERULAR FILTRATION RATE WITH CEREBRAL SMALL VESSEL DISEASE: A LARGE PROSPECTIVE COHORT STUDY | | 33 |
| BEYOND THE CONTROVERSY ON Aß BLOOD-BASED BIOMARKERS | J Prev Alz Dis 2015;2(1):51-55 | 32 |
| TRIAL DESIGN FOR THE EVALUATION OF NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: CONSIDERATIONS AND RECOMMENDATIONS | J Prev Alz Dis 2015;2(3):163-164 | 32 |
| AT A CROSSROADS: A PERSPECTIVE ON DRUG DEVELOPMENT FOR ALZHEIMER’S DISEASE IN 2016 | J Prev Alz Dis 2016;3(4):181-184 | 31 |
| PROSPECTIVE EVALUATION OF COGNITIVE HEALTH AND RELATED FACTORS IN ELDERLY AT RISK FOR DEVELOPING ALZHEIMER’S DEMENTIA: A LONGITUDINAL COHORT STUDY | J Prev Alz Dis 2019;6(4):256-266 | 31 |
| EDITORIAL : THE BRAINHEALTHREGISTRY.ORG: USING THE INTERNET FOR IDENTIFICATION, ASSESSMENT, SCREENING, RECRUITMENT, AND LONGITUDINAL MONITORING OF SUBJECTS FOR NEUROSCIENCE AND ALZHEIMER’S DISEASE STU | J Prev Alz Dis 2014;1(2):59-61 | 30 |
| THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS | J Prev Alz Dis 2016;3(1):8-12 | 30 |
| PRIMARY PREVENTION OF DEMENTIA: AN EPIDEMIOLOGICAL POINT OF VIEW | J Prev Alz Dis 2016;3(3):160-163 | 30 |
| CTAD 2016 abstract: EXPEDITION3: A PHASE 3 TRIAL OF SOLANEZUMAB IN MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE | | 30 |
| EFFECTS OF OMEGA-3 FATTY ACIDS ON RESTING CEREBRAL PERFUSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2018;5(1):26-30 | 30 |
| IS A LARGE-SCALE SCREENING FOR ALZHEIMER’S DISEASE POSSIBLE? YES, IN A FEW YEARS | J Prev Alz Dis 2019;6(4):221-222 | 30 |
| RANDOMIZED, PLACEBO CONTROLLED TRIAL OF NPT088, A PHAGE-DERIVED, AMYLOID-TARGETED TREATMENT FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(4):228-231 | 30 |
| EDITORIAL : MULTI-DOMAIN PREVENTION FOR A MULTI-FACTORIAL DISEASE | J Prev Alz Dis 2014;1(1):4-5 | 29 |
| PHYSICAL ACTIVITY AND ß-AMYLOID BRAIN LEVELS IN HUMANS: A SYSTEMATIC REVIEW | J Prev Alz Dis 2015;2(1):56-63 | 29 |
| USING MACHINE LEARNING AND ELECTRONIC HEALTH RECORD (EHR) DATA FOR THE EARLY PREDICTION OF ALZHEIMER\'S DISEASE AND RELATED DEMENTIAS | | 29 |
| LETTER TO THE EDITOR: DISPARITIES IN OUT-OF-POCKET COSTS FOR DISEASE-MODIFYING THERAPY UNDER JAPAN\'S UNIVERSAL HEALTH INSURANCE SYSTEM | | 29 |
| COMMENT : A NEW ERA: DISEASE MODIFYING ALZHEIMER DISEASE PREVENTION TRIALS | J Prev Alz Dis 2014;1(2):68 | 28 |
| STUDIES OF AGITATION / AGGRESSION IN ALZHEIMER’S DISEASE – SCIENTIFIC AND OPERATIONAL CHALLENGES | J Prev Alz Dis 2015;2(3):157-159 | 28 |
| DIETARY FACTORS AND COGNITIVE DECLINE | J Prev Alz Dis 2016;3(1):53-64 | 28 |
| LESSONS TO BE LEARNED ABOUT CLINICAL TRIALS IN PRECLINICAL AD FROM ONGOING LONGITUDINAL STUDIES | J Prev Alz Dis 2015;2(4):214-215 | 28 |
| PREVENTION OF ALZHEIMER’S DISEASE IN CHINESE POPULATIONS: STATUS, CHALLENGES AND DIRECTIONS | J Prev Alz Dis 2018;5(2):90-94 | 28 |
| MINIMIZING THE SAMPLE SIZES OF CLINICAL TRIALS ON PRECLINICAL AND EARLY SYMPTOMATIC STAGE OF ALZHEIMER DISEASE | J Prev Alz Dis 2018;5(2):110-119 | 28 |
| A LITERATURE REVIEW OF METHODOLOGIES USED IN RANDOMIZED CLINICAL TRIALS OF AGITATION IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(2):120-133 | 28 |
| COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED | J Prev Alz Dis 2014;1(1):8-10 | 27 |
| BLOOD-BRAIN BARRIER PERMEABILITY IN AGING AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(3):138-140 | 27 |
| AMYLOID AND TAU BIOMARKERS IN CSF | J Prev Alz Dis 2015;2(1):46-50 | 27 |
| INVESTIGATING FUNCTIONAL IMPAIRMENT IN PRECLINICAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(1):4-6 | 27 |
| MRI FOR PRE-DEMENTIA TRIALS | J Prev Alz Dis 2016;3(1):5-7 | 27 |
| A SIX-YEAR RISK ASSESSMENT FOR DEMENTIA AND ALZHEIMER\'S DISEASE IN THE GENERAL POPULATION THROUGH IMMUNOPRECIPITATION-MASS SPECTROMETRY PLASMA AMYLOID QUANTIFICATION | | 27 |
| MULTIMORBIDITY AND RISK OF DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF LONGITUDINAL COHORT STUDIES | | 27 |
| DEVELOPMENT OF AZELIRAGON, AN ORAL SMALL MOLECULE ANTAGONIST OF THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS, FOR THE POTENTIAL SLOWING OF LOSS OF COGNITION IN MILD ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(2):149-154 | 26 |
| CLINICAL APPLICATION OF APOE IN ALZHEIMER’S PREVENTION: A PRECISION MEDICINE APPROACH | J Prev Alz Dis 2018;5(4):245-252 | 26 |
| LONGITUDINAL COMPARISON OF IN CLINIC AND AT HOME ADMINISTRATION OF THE COGSTATE BRIEF BATTERY AND DEMONSTRATED PRACTICE EFFECTS IN THE MAYO CLINIC STUDY OF AGING | J Prev Alz Dis 2020;7(1):21-28 | 26 |
| COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED? | J Prev Alz Dis 2014;1(1):6-7 | 25 |
| BASELINE SUBJECTIVE MEMORY COMPLAINTS ASSOCIATE WITH INCREASED RISK OF INCIDENT DEMENTIA: THE PREADVISE TRIAL | J Prev Alz Dis 2015;2(1):11-16 | 25 |
| IMMUNOTHERAPY OF AD: ALUM DEMAIN? | J Prev Alz Dis 2015;2(2):80-81 | 25 |
| COMPUTERIZED COGNITIVE TESTING FOR USE IN CLINICAL TRIALS: A COMPARISON OF THE NIH TOOLBOX AND COGSTATE C3 BATTERIES | J Prev Alz Dis 2017;4(1):3-11 | 25 |
| REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMER’S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCH | J Prev Alz Dis 2019;6(1):2-15 | 25 |
| FACTORS ASSOCIATED WITH ALZHEIMER’S DISEASE: AN OVERVIEW OF REVIEWS | J Prev Alz Dis 2019;6(2):121-134 | 25 |
| IMPACT OF DIETARY FACTORS AND INFLAMMATION ON COGNITION AMONG OLDER ADULTS | J Prev Alz Dis 2015;2(4):220-226 | 24 |
| NEW IPA CRITERIA FOR AGITATION IN COGNITIVE IMPAIRMENT | J Prev Alz Dis 2015;2(3):160-162 | 24 |
| BARRIERS FOR PREVENTION AND PRODROMAL AD TRIALS | J Prev Alz Dis 2016;3(2):66-67 | 24 |
| TURNING POINT TOWARDS BLOOD BIOMARKER-GUIDED TARGETED THERAPY FOR PRECISION MEDICINE IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2018;5(3):160-164 | 24 |
| WEB-BASED SOFTWARE FOR REAL-TIME SIMULATION-ASSISTED TRIAL DESIGN IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(1):20-23 | 23 |
| TEA FOR ALZHEIMER PREVENTION | J Prev Alz Dis 2015;2(2):136-141 | 23 |
| SELF-REPORTED MEMORY COMPLAINTS: A COMPARISON OF DEMENTED AND UNIMPAIRED OUTCOMES | J Prev Alz Dis 2016;3(1):13-19 | 23 |
| THE VALUE OF PRE-SCREENING IN THE ALZHEIMER’S PREVENTION INITIATIVE (API) AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE TRIAL | J Prev Alz Dis 2018;5(1):49-54 | 23 |
| ALZHEIMER’S PREVENTION EDUCATION: IF WE BUILD IT, WILL THEY COME? www.AlzU.org | J Prev Alz Dis 2014;1(2):91-98 | 22 |
| COMMENT : ALZHEIMER’S DISEASE DRUG DEVELOPMENT: TRIAL-READY COHORTS SHOULD HELP | J Prev Alz Dis 2014;1(2):69-70 | 22 |
| ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA? | J Prev Alz Dis 2014;1(3):141-142 | 22 |
| FOREWORD: AD DRUG DEVELOPMENT IS NOT BROKEN: CLINICAL TRIALS IN ALZHEIMER’S DISEASE 2014 CONFERENCE, PHILADELPHIA | J Prev Alz Dis 2014;1(3):212-213 | 22 |
| COGNITIVE REHABILITATION IN ALZHEIMER’S DISEASE – A CONCEPTUAL AND METHODOLOGICAL REVIEW | J Prev Alz Dis 2015;2(2):142-152 | 22 |
| DEMENTIA PREVENTION BY DISEASE-MODIFICATION THROUGH NUTRITION | J Prev Alz Dis 2017;4(3):138-139 | 22 |
| A NOVEL STUDY PARADIGM FOR LONG-TERM PREVENTION TRIALS IN ALZHEIMER DISEASE: THE PLACEBO GROUP SIMULATION APPROACH (PGSA). APPLICATION TO MCI DATA FROM THE NACC DATABASE | J Prev Alz Dis 2014;1(2):99-109 | 21 |
| DEMENTIA PREVENTION: OPTIMIZING THE USE OF OBSERVATIONAL DATA FOR PERSONAL, CLINICAL, AND PUBLIC HEALTH DECISION-MAKING | J Prev Alz Dis 2014;1(2):117-123 | 21 |
| COMMUNITY-BASED INTERVENTION FOR PREVENTION OF DEMENTIA IN JAPAN | J Prev Alz Dis 2015;2(1):71-76 | 21 |
| ASSESSMENT OF AGE-RELATED DIFFERENCES IN FUNCTIONAL CAPACITY USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT) | J Prev Alz Dis 2015;2(2):121-127 | 21 |
| AN OPEN-LABEL TRIAL OF YOKUKANSAN ON SLEEP DISTURBANCE IN ALZHEIMER’S DISEASE AND OTHER DEMENTIA | J Prev Alz Dis 2015;2(3):172-177 | 21 |
| THE HARVARD AUTOMATED PHONE TASK: NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING TESTS FOR EARLY ALZHEIMER’S DISEASE | J Prev Alz Dis 2015;2(4):242-253 | 21 |
| ALZHEIMER’S ASSOCIATION: INITIATIVES & PUBLIC HEALTH PERSPECTIVE | J Prev Alz Dis 2016;3(4):178-180 | 21 |
| ALBUMIN, HEMOGLOBIN, AND THE TRAJECTORY OF COGNITIVE FUNCTION IN COMMUNITY-DWELLING OLDER JAPANESE: A 13-YEAR LONGITUDINAL STUDY | J Prev Alz Dis 2017;4(2):93-99 | 21 |
| ADHERENCE TO THE MEDITERRANEAN DIET IS NOT RELATED TO BETA-AMYLOID DEPOSITION: DATA FROM THE WOMEN’S HEALTHY AGEING PROJECT | J Prev Alz Dis 2018;5(2):137-141 | 21 |
| PTI-125 REDUCES BIOMARKERS OF ALZHEIMER’S DISEASE IN PATIENTS | J Prev Alz Dis 2020;4(7):256-264 | 21 |
| COMMENT : E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS FOR STUDY | J Prev Alz Dis 2014;1(2):66-67 | 20 |
| A PATIENT-CENTERED ANALYSIS OF ENROLLMENT AND RETENTION IN A RANDOMIZED BEHAVIORAL TRIAL OF TWO COGNITIVE REHABILITATION INTERVENTIONS FOR MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2014;1(3):143-150 | 20 |
| GINKGO BILOBA EXTRACT CONSUMPTION AND LONG-TERM OCCURRENCE OF DEATH AND DEMENTIA | J Prev Alz Dis 2017;4(1):16-20 | 20 |
| PLASMA A?42/40 RATIO DETECTS EARLY STAGES OF ALZHEIMER’S DISEASE AND CORRELATES WITH CSF AND NEUROIMAGING BIOMARKERS IN THE AB255 STUDY | J Prev Alz Dis 2019;6(1):34-41 | 20 |
| ARIZONA ALZHEIMER’S REGISTRY: STRATEGY AND OUTCOMES OF A STATEWIDE RESEARCH RECRUITMENT REGISTRY | J Prev Alz Dis 2014;1(2):74-79 | 19 |
| COSTS AND RESOURCE USE ASSOCIATED WITH ALZHEIMER’S DISEASE IN ITALY: RESULTS FROM AN OBSERVATIONAL STUDY | J Prev Alz Dis 2018;5(1):55-64 | 19 |
| AADVAC1, AN ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE AND NON ALZHEIMER TAUOPATHIES: AN OVERVIEW OF PRECLINICAL AND CLINICAL DEVELOPMENT | J Prev Alz Dis 2019;6(1):63-69 | 19 |
| THINKING ABOUT COGNITIVE FRAILTY | J Prev Alz Dis 2015;2(1):7-10 | 18 |
| A NOVEL EIGENVECTOR-BASED METHOD TO DETECT MILD ALZHEIMER’S DISEASE USING EVENT-RELATED POTENTIALS | J Prev Alz Dis 2016;3(2):101-104 | 18 |
| PSYCHOMETRIC EVALUATION OF THE NEUROPSYCHOLOGICAL TEST BATTERY IN INDIVIDUALS WITH NORMAL COGNITION, MILD COGNITIVE IMPAIRMENT, OR MILD TO MODERATE ALZHEIMER’S DISEASE: RESULTS FROM A LONGITUDINAL STUDY | J Prev Alz Dis 2018;5(4):236-244 | 18 |
| DESIGNING TRIALS OF DISEASE MODIFYING AGENTS FOR EARLY AND PRECLINICAL ALZHEIMER’S DISEASE INTERVENTION: WHAT EVIDENCE IS MEANINGFUL TO PATIENTS, PROVIDERS, AND PAYERS? | J Prev Alz Dis 2019;6(1):20-26 | 18 |
| COMMENT: HIGH ALZHEIMER’S DISEASE STUDY COMPLEXITY - LOW SUCCESS RATE | J Prev Alz Dis 2014;1(1):11-12 | 17 |
| CEREAL INTAKE INCREASES AND DAIRY PRODUCTS DECREASE RISK OF COGNITIVE DECLINE AMONG ELDERLY FEMALE JAPANESE | J Prev Alz Dis 2014;1(3):160-167 | 17 |
| THREE CARDINAL LESSONS FROM ADAPT – 10 YEARS ON | J Prev Alz Dis 2014;1(3):176-180 | 17 |
| NEUROPSYCHOLOGICAL PROFILE OF “COGNITIVE FRAILTY” SUBJECTS IN MAPT STUDY | J Prev Alz Dis 2016;3(3):151-159 | 17 |
| THE PARADOX OF RESEARCH ON DEMENTIA-ALZHEIMER’S DISEASE | J Prev Alz Dis 2016;3(4):189-191 | 17 |
| SWINGS AND ROUNDABOUTS IN CNS DRUG BIOMARKERS | J Prev Alz Dis 2017;4(3):134-135 | 17 |
| BRAIN DONATION BY PROXY: ARE THERE PREDICTORS IN NEURODEGENERATIVE DEMENTIA? | J Prev Alz Dis 2014;1(3):151-159 | 16 |
| INTEGRATING INFORMATION FROM FDG - AND AMYLOID PET FOR DETECTING DIFFERENT TYPES OF DEMENTIA IN OLDER PERSONS. A CASE-SERIES STUDY | J Prev Alz Dis 2016;3(3):127-132 | 16 |
| FEMALE SEX AND ALZHEIMER’S RISK: THE MENOPAUSE CONNECTION | J Prev Alz Dis 2018;5(4):225-230 | 16 |
| REPORT FROM THE FIRST CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) ASIA-CHINA 2018 : BRINGING TOGETHER GLOBAL LEADERS | J Prev Alz Dis 2019;6(2):144-147 | 16 |
| DIETARY FAT INTAKE AND COGNITIVE FUNCTION AMONG OLDER POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2019;6(3):204-211 | 16 |
| COMPARING THE STANDARD AND ELECTRONIC VERSIONS OF THE ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITIVE SUBSCALE: A VALIDATION STUDY | J Prev Alz Dis 2019;6(4):237-241 | 16 |
| COMMENT : CLINICAL TRIALS FOR ALZHEIMER’S DISEASE TURNED A CORNER IN 2013’ | J Prev Alz Dis 2014;1(2):71-73 | 15 |
| CLINICAL EFFECTS OF ORAL TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION | J Prev Alz Dis 2017;4(3):136-137 | 15 |
| AURAPTENE IN THE PEELS OF CITRUS KAWACHIENSIS (KAWACHIBANKAN) CONTRIBUTES TO THE PRESERVATION OF COGNITIVE FUNCTION: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERS | J Prev Alz Dis 2018;5(3):197-201 | 15 |
| DIABETES MELLITUS AND COGNITIVE DECLINE – PREVENTION SHOULD NOT BE DELAYED! | J Prev Alz Dis 2018;5(2):95-97 | 15 |
| FEASIBILITY OF USING A WEARABLE BIOSENSOR DEVICE IN PATIENTS AT RISK FOR ALZHEIMER’S DISEASE DEMENTIA | J Prev Alz Dis 2020;7(2):104-111 | 15 |
| MEDITERRANEAN DIET AND MAGNETIC RESONANCE IMAGING-ASSESSED BRAIN ATROPHY IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(1):23-32 | 14 |
| HIPPOCAMPAL ASTROCYTES AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(2):124-128 | 14 |
| JPAD IS MOVING FAST | J Prev Alz Dis 2016;3(1):3-4 | 14 |
| ANTIOXIDANTS IN THE DIET AND COGNITIVE FUNCTION: WHICH ROLE FOR THE MEDITERRANEAN LIFE-STYLE? | J Prev Alz Dis 2017;4(1):58-64 | 14 |
| EPIGALLOCATECHIN 3-GALLATE AS AN INHIBITOR OF TAU PHOSPHORYLATION AND AGGREGATION: A MOLECULAR AND STRUCTURAL INSIGHT | J Prev Alz Dis 2017;4(4):218-225 | 14 |
| WHO GUIDELINES ON COMMUNITY-LEVEL INTERVENTIONS TO MANAGE DECLINES IN INTRINSIC CAPACITY: THE ROAD TO PREVENTION COGNITIVE DECLINE IN OLDER AGE? | J Prev Alz Dis 2018;5(3):165-167 | 14 |
| INCREASED FUNCTIONAL CONNECTIVITY AFTER LISTENING TO FAVORED MUSIC IN ADULTS WITH ALZHEIMER DEMENTIA | J Prev Alz Dis 2019;6(1):56-62 | 14 |
| IMPLEMENTING A MEMORY CLINIC MODEL TO FACILITATE RECRUITMENT INTO EARLY PHASE CLINICAL TRIALS FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE | J Prev Alz Dis 2019;6(2):135-138 | 14 |
| OVERTREATING ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;2(8):234-236 | 14 |
| PREDICTION OF COGNITIVE DECLINE FOR ENRICHMENT OF ALZHEIMER’S DISEASE CLINICAL TRIALS | J Prev Alz Dis 2022;3(9):400-409 | 14 |
| HIGHER COGNITIVE PERFORMANCE IS PROSPECTIVELY ASSOCIATED WITH HEALTHY DIETARY CHOICES: THE MAINE SYRACUSE LONGITUDINAL STUDY | J Prev Alz Dis 2015;2(1):24-32 | 13 |
| DIABETES MITIGATES THE ROLE OF MEMORY COMPLAINT IN PREDICTING DEMENTIA RISK: RESULTS FROM THE PREVENTION OF ALZHEIMER’S DISEASE WITH VITAMIN E AND SELENIUM STUDY | J Prev Alz Dis 2017;4(3):143-148 | 13 |
| CARE MANAGEMENT TO PROMOTE TREATMENT ADHERENCE IN PATIENTS WITH COGNITIVE IMPAIRMENT AND VASCULAR RISK FACTORS: A DEMONSTRATION PROJECT | J Prev Alz Dis 2018;5(1):36-41 | 13 |
| COGNITIVE FRAILTY AND INCIDENCE OF DEMENTIA IN OLDER PERSONS | J Prev Alz Dis 2018;5(1):42-48 | 13 |
| ANALYSIS OF THE RELATIONSHIP OF COGNITIVE IMPAIRMENT AND FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER’S DISEASE IN EXPEDITION 3 | J Prev Alz Dis 2018;5(3):184-187 | 13 |
| EFFECTIVENESS OF THE OPEN SCREENING PROGRAMS IN RECRUITING SUBJECTS TO PRODROMAL AND MILD ALZHEIMER’S DISEASE CLINICAL TRIALS | J Prev Alz Dis 2020;4(7):251-255 | 13 |
| COST-EFFECTIVENESS OF DEMENTIA PREVENTION INTERVENTIONS | J Prev Alz Dis 2021;2(8):210-217 | 13 |
| MEMORY BROUGHT TO MIND. FIVE-YEAR FOLLOW-UP OF CASE FINDING AND INTERVENTION OF DEMENTIA IN A SWEDISH PRIMARY HEALTH CARE DISTRICT | J Prev Alz Dis 2015;2(1):17-23 | 12 |
| IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENT | J Prev Alz Dis 2015;2(1):64-70 | 12 |
| THE EFFECT OF VASCULAR NEUROPATHOLOGY ON LATE-LIFE COGNITION: RESULTS FROM THE SMART PROJECT | J Prev Alz Dis 2016;3(2):85-91 | 12 |
| SHORT-TERM PRACTICE EFFECTS AND AMYLOID DEPOSITION: PROVIDING INFORMATION ABOVE AND BEYOND BASELINE COGNITION | J Prev Alz Dis 2017;4(2):87-92 | 12 |
| COMBINING GEOSPATIAL ANALYSIS WITH DEMENTIA RISK UTILISING GENERAL PRACTICE DATA: A SYSTEMATIC REVIEW | J Prev Alz Dis 2018;5(1):71-77 | 12 |
| PROSPECTS FOR EFFECTIVE TREATMENT OF THE DEMENTIA-ALZHEIMER SYNDROME: A RENEWED ODYSSEY IN SEARCH OF THE MAGIC ELIXIR | J Prev Alz Dis 2017;4(4):215-217 | 12 |
| ASSESSMENT OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT) | J Prev Alz Dis 2018;5(4):216-224 | 12 |
| BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDRED | J Prev Alz Dis 2019;6(2):112-120 | 12 |
| GEROSCIENCE AND THE ROLE OF AGING IN THE ETIOLOGY AND MANAGEMENT OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2020;7(1):2-3 | 12 |
| DATA-DRIVEN PARTICIPANT RECRUITMENT: FINDINGS FROM THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE 3 | J Prev Alz Dis 2020;7(2):122-127 | 12 |
| A MACHINE LEARNING FRAMEWORK FOR ASSESSMENT OF COGNITIVE AND FUNCTIONAL IMPAIRMENTS IN ALZHEIMER’S DISEASE: DATA PREPROCESSING AND ANALYSIS | J Prev Alz Dis 2020;7(2):87-94 | 12 |
| CURRENT STATE OF SELF-ADMINISTERED BRIEF COMPUTERIZED COGNITIVE ASSESSMENTS FOR DETECTION OF COGNITIVE DISORDERS IN OLDER ADULTS: A SYSTEMATIC REVIEW | J Prev Alz Dis 2021;3(8):267-276 | 12 |
| THE UPS AND DOWNS OF AMYLOID IN ALZHEIMER’S | J Prev Alz Dis 2022;1(9):92-95 | 12 |
| THE TIMECOURSE OF GLOBAL COGNITIVE GAINS FROM SUPERVISED COMPUTER-ASSISTED COGNITIVE TRAINING: A RANDOMISED, ACTIVE-CONTROLLED TRIAL IN ELDERLY WITH MULTIPLE DEMENTIA RISK FACTORS | J Prev Alz Dis 2014;1(1):33-39 | 11 |
| THE RELATIONSHIP OF HEMOGLOBIN LEVELS, DELIRIUM AND COGNITIVE STATUS IN HOSPITALIZED GERIATRIC PATIENTS: RESULTS FROM THE CRIME STUDY | J Prev Alz Dis 2015;2(3):178-183 | 11 |
| NEW FINDINGS WITH REANALYSIS OF THE DOMINO TRIAL ? | J Prev Alz Dis 2015;2(3):212 | 11 |
| ASSESSING THE RELATIONSHIP BETWEEN VITAMIN D STATUS AND IMPAIRMENTS IN COGNITIVE AND PHYSICAL PERFORMANCE IN OLDER ADULTS USING A DUAL TASK PHYSICAL PERFORMANCE TEST | J Prev Alz Dis 2017;4(1):29-36 | 11 |
| ASSOCIATIONS OF LONG-TERM TEA CONSUMPTION WITH DEPRESSIVE AND ANXIETY SYMPTOMS IN COMMUNITY-LIVING ELDERLY: FINDINGS FROM THE DIET AND HEALTHY AGING STUDY | J Prev Alz Dis 2018;5(1):21-25 | 11 |
| EFFECTS OF A SIX-MONTH MULTI-INGREDIENT NUTRITION SUPPLEMENT INTERVENTION OF OMEGA-3 POLYUNSATURATED FATTY ACIDS, VITAMIN D, RESVERATROL, AND WHEY PROTEIN ON COGNITIVE FUNCTION IN OLDER ADULTS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIAL | J Prev Alz Dis 2018;5(3):175-183 | 11 |
| MEDITERRANEAN-DASH INTERVENTION FOR NEURODEGENERATIVE DELAY (MIND) DIET SLOWS COGNITIVE DECLINE AFTER STROKE | J Prev Alz Dis 2019;6(4):267-273 | 11 |
| FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS | J Prev Alz Dis 2020;3(7):195-196 | 11 |
| IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: CURRENT SCENARIO AND FUTURE PERSPECTIVES | J Prev Alz Dis 2021;4(8):534-551 | 11 |
| STIMULUS-LOCKED LATERALIZED READINESS POTENTIAL AND PERFORMANCE: USEFUL MARKERS FOR DIFFERENTIATING BETWEEN AMNESTIC SUBTYPES OF MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2017;4(1):21-28 | 10 |
| COGNITIVE PERFORMANCE DOES NOT LIMIT PHYSICAL ACTIVITY PARTICIPATION IN THE LIFESTYLE INTERVENTIONS AND INDEPENDENCE FOR ELDERS PILOT STUDY (LIFE-P) | J Prev Alz Dis 2017;4(1):44-50 | 10 |
| SEX AND AGE DIFFERENCES IN THE ASSOCIATION OF BLOOD PRESSURE AND HYPERTENSION WITH COGNITIVE FUNCTION IN THE ELDERLY: THE RANCHO BERNARDO STUDY | J Prev Alz Dis 2017;4(3):165-173 | 10 |
| ACTIVITIES OF DAILY LIVING MEASURED BY THE HARVARD AUTOMATED PHONE TASK TRACK WITH COGNITIVE DECLINE OVER TIME IN NON-DEMENTED ELDERLY | J Prev Alz Dis 2017;4(2):81-86 | 10 |
| DEMENTIA: CREATING A KNOWLEDGE-BASED HEALTHCARE PROFESSION | J Prev Alz Dis 2018;5(1):85-86 | 10 |
| LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLY | J Prev Alz Dis 2018;5(1):87 | 10 |
| DETECTION OF RATER ERRORS ON COGNITIVE INSTRUMENTS IN A CLINICAL TRIAL SETTING | J Prev Alz Dis 2018;5(3):188-196 | 10 |
| BIFIDOBACTERIUM BREVE A1 SUPPLEMENTATION IMPROVED COGNITIVE DECLINE IN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: AN OPEN-LABEL, SINGLE-ARM STUDY | J Prev Alz Dis 2019;6(1):70-75 | 10 |
| INTER-SPECIES GLIA DIFFERENCES: IMPLICATIONS FOR SUCCESSFUL TRANSLATION OF TRANSGENIC RODENT ALZHEIMER’S DISEASE MODEL TREATMENT USING BEXAROTENE | J Prev Alz Dis 2014;1(1):46-50 | 9 |
| CURCUMIN MICELLES IMPROVE MITOCHONDRIAL FUNCTION IN A MOUSE MODEL OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2014;1(2):80-83 | 9 |
| MODERATE, REGULAR ALCOHOL CONSUMPTION IS ASSOCIATED WITH HIGHER COGNITIVE FUNCTION IN OLDER COMMUNITY-DWELLING ADULTS | J Prev Alz Dis 2016;3(2):105-113 | 9 |
| EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY | J Prev Alz Dis 2016;3(4):188 | 9 |
| MODEST OVERWEIGHT AND HEALTHY DIETARY HABITS REDUCE RISK OF DEMENTIA: A NATIONWIDE SURVEY IN TAIWAN | J Prev Alz Dis 2017;4(1):37-43 | 9 |
| OBJECTIVE COGNITIVE IMPAIRMENT AND PROGRESSION TO DEMENTIA IN WOMEN: THE PROSPECTIVE EPIDEMIOLOGICAL RISK FACTOR STUDY | J Prev Alz Dis 2017;4(3):194-200 | 9 |
| EXPANDING THE TOOLKIT FOR STUDIES OF AGING | J Prev Alz Dis 2017;4(2):69-70 | 9 |
| FINANCIAL MANAGEMENT SKILLS IN AGING, MCI AND DEMENTIA: CROSS SECTIONAL RELATIONSHIP TO 18F-FLORBETAPIR PET CORTICAL Β-AMYLOID DEPOSITION | J Prev Alz Dis 2019;6(4):274-282 | 9 |
| LINKING GEROSCIENCE AND INTEGRATED CARE TO REINFORCE PREVENTION | J Prev Alz Dis 2020;7(2):68-69 | 9 |
| ELEVATED BLOOD HOMOCYSTEINE AND RISK OF ALZHEIMER’S DEMENTIA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS BASED ON PROSPECTIVE STUDIES | J Prev Alz Dis 2021;3(8):329-334 | 9 |
| COMMENTARY: FUTURE OF ALZHEIMER’S DISEASE TREATMENT: COMBINATION THERAPY AND PRECISION MEDICINE | J Prev Alz Dis 2023;4(10):743-745 | 9 |
| REPLY TO THE LETTER TO THE EDITOR: RESPONSE TO CONCERNS RAISED ON MRI SURVEILLANCE AND CLINICAL IMPLICATIONS OF ARIA IN DISEASE MODIFYING TREATMENT | J Prev Alz Dis 2024;1(11):261-262 | 9 |
| VALIDATION OF AN ULTRA-SENSITIVE METHOD FOR QUANTITATION OF PHOSPHO-TAU 217 (PTAU217) IN HUMAN PLASMA, SERUM, AND CSF USING THE ALZPATH PTAU217 ASSAY ON THE QUANTERIX HD-X PLATFORM | J Prev Alz Dis 2024;5(11):1206-1211 | 9 |
| EFFECT OF PUNICALAGIN AND RESVERATROL ON METHIONINE SULFOXIDE REDUCTASE: A POSSIBLE PROTECTIVE CONTRIBUTION AGAINST ALZHEIMER DISEASE | J Prev Alz Dis 2015;2(1):33-37 | 8 |
| GINKGETIN AMELIORATES NEUROPATHOLOGICAL CHANGES IN APP/PS1 TRANSGENICAL MICE MODEL | J Prev Alz Dis 2016;3(1):24-29 | 8 |
| POTENTIAL UTILITY OF PRACTICE EFFECTS IN PREVENTIVE TRIALS | J Prev Alz Dis 2017;4(3):140-142 | 8 |
| STRONG RELATIONSHIP BETWEEN MALNUTRITION AND COGNITIVE FRAILTY IN THE SINGAPORE LONGITUDINAL AGEING STUDIES (SLAS-1 AND SLAS-2) | J Prev Alz Dis 2018;5(2):142-148 | 8 |
| RESPONSES: LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLY | J Prev Alz Dis 2018;5(1):87 | 8 |
| CROSS-SECTIONAL CHARACTERIZATION OF ALBUMIN GLYCATION STATE IN CEREBROSPINAL FLUID AND PLASMA FROM ALZHEIMER’S DISEASE PATIENTS | J Prev Alz Dis 2019;6(2):139-143 | 8 |
| SHIFT IN HOSPITALIZATIONS FOR ALZHEIMER’S DISEASE TO RELATED DEMENTIAS IN FRANCE BETWEEN 2007 AND 2017 | J Prev Alz Dis 2019;6(2):108-111 | 8 |
| NEUROPSYCHOLOGICAL, PSYCHIATRIC, AND FUNCTIONAL CORRELATES OF CLINICAL TRIAL ENROLLMENT | J Prev Alz Dis 2019;6(4):242-247 | 8 |
| SENSITIVITY OF THE PRECLINICAL ALZHEIMER’S COGNITIVE COMPOSITE (PACC), PACC5, AND REPEATABLE BATTERY FOR NEUROPSYCHOLOGICAL STATUS (RBANS) TO AMYLOID STATUS IN PRECLINICAL ALZHEIMER’S DISEASE -ATABECESTAT PHASE 2B/3 EARLY CLINICAL TRIAL | J Prev Alz Dis 2022;2(9):255-261 | 8 |
| EFFECTIVENESS OF PHYSICAL EXERCISE ON ALZHEIMER’S DISEASE. A SYSTEMATIC REVIEW | J Prev Alz Dis 2022;4(9):601-616 | 8 |
| ASSOCIATIONS OF STAGES OF OBJECTIVE MEMORY IMPAIRMENT WITH CEREBROSPINAL FLUID AND NEUROIMAGING BIOMARKERS OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;1(10):112-119 | 8 |
| FORECASTING THE PREVALENCE OF ALZHEIMER’S DISEASE AT MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA STAGES IN FRANCE IN 2022 | J Prev Alz Dis 2023;2(10):259-266 | 8 |
| INITIAL EXPERIENCES WITH AMYLOID-RELATED IMAGING ABNORMALITIES IN PATIENTS RECEIVING ADUCANUMAB FOLLOWING ACCELERATED APPROVAL | J Prev Alz Dis 2023;4(10):765-770 | 8 |
| THE ROOM WHERE IT HAPPENS: CLINICIAN REFLECTIONS ON RETURNING PRECLINICAL ALZHEIMER’S BIOMARKER RESULTS TO RESEARCH PARTICIPANTS | J Prev Alz Dis 2024;1(11):1-6 | 8 |
| BRAIN PHOTOBIOMODULATION: A POTENTIAL TREATMENT IN ALZHEIMER’S AND PARKINSON’S DISEASES | | 8 |
| LONG-TERM CUMULATIVE PHYSICAL ACTIVITY ASSOCIATED WITH LESS COGNITIVE DECLINE: EVIDENCE FROM A 16-YEAR COHORT STUDY | | 8 |
| NEUROPROTECTIVE EFFECTS OF A VARIETY OF POMEGRANATE JUICE EXTRACTS (PJE) AGAINST THE EXCITOTOXIN QUINOLINIC ACID IN HUMAN PRIMARY NEURONS | J Prev Alz Dis 2014;1(2):84-90 | 7 |
| LETTER TO THE EDITOR: PREVENTING DEMENTIA THROUGH COMMUNITY INVOLVEMENT AND ALTRUISTIC BEHAVIORS | J Prev Alz Dis 2018;5(4):259-260 | 7 |
| GEOGRAPHIC CLUSTERS OF ALZHEIMER’S DISEASE MORTALITY RATES IN THE USA: 2008-2012 | J Prev Alz Dis 2018;5(4):231-235 | 7 |
| MRI CLINICAL RATINGS AND COGNITIVE FUNCTION IN A CROSS-SECTIONAL POPULATION STUDY OF DEMENTIA: THE CACHE COUNTY MEMORY STUDY | J Prev Alz Dis 2019;6(2):100-107 | 7 |
| SELF-ADMINISTERED COGNITIVE TESTING BY OLDER ADULTS AT-RISK FOR COGNITIVE DECLINE | J Prev Alz Dis 2020;4(7):283-287 | 7 |
| THE EU/US TASK FORCE’S FUTURE FOR ANTI-AMYLOID TRIALS: FAITES VOS JEUX | J Prev Alz Dis 2020;3(7):199-200 | 7 |
| NUTRITION TO PREVENT OR TREAT COGNITIVE IMPAIRMENT IN OLDER ADULTS: A GRADE RECOMMENDATION | J Prev Alz Dis 2021;1(8):110-116 | 7 |
| PROSPECTIVE ASSOCIATIONS BETWEEN PLASMA AMYLOIDBETA 42/40 AND FRAILTY IN COMMUNITY-DWELLING OLDER ADULTS | J Prev Alz Dis 2021;1(8):41-47 | 7 |
| SUGAR IN BEVERAGE AND THE RISK OF INCIDENT DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2021;2(8):188-193 | 7 |
| A WEB-BASED MULTIDOMAIN LIFESTYLE INTERVENTION FOR OLDER ADULTS: THE EMIND RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2021;2(8):142-150 | 7 |
| EFFECTS OF FOLIC ACID AND VITAMIN B12 SUPPLEMENTATION ON COGNITIVE IMPAIRMENT AND INFLAMMATION IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMIZED, SINGLE-BLINDED, PLACEBO-CONTROLLED TRIAL | J Prev Alz Dis 2021;3(8):249-256 | 7 |
| PREVENTION OF ALZHEIMER’S DISEASE AND COGNITIVE DECLINE WITH DIET & LIFESTYLE: PROCEEDINGS OF THE A. G. LEVENTIS FOUNDATION CONFERENCE | J Prev Alz Dis 2023;1(10):137-143 | 7 |
| PREDICTIVE UTILITY OF PLASMA AMYLOID AND TAU FOR COGNITIVE DECLINE IN COGNITIVELY NORMAL ADULTS | J Prev Alz Dis 2023;2(10):178-185 | 7 |
| CTAD TASK FORCE PAPER - NEUROPSYCHIATRIC SYMPTOMS IN AD: CLINICAL TRIALS TARGETING MILD BEHAVIORAL IMPAIRMENT: A REPORT FROM THE INTERNATIONAL CTAD TASK FORCE | J Prev Alz Dis 2024;1(11):56-64 | 7 |
| EFFECTS OF COMPUTERIZED COGNITIVE TRAINING ON GAIT SPEED IN COMMUNITY DWELLING OLDER ADULTS, A PILOT STUDY | J Prev Alz Dis 2016;3(3):145-150 | 6 |
| AGING, SENESCENCE, AND DEMENTIA | J Prev Alz Dis 2022;3(9):523-531 | 6 |
| THE EFFECTS OF SUBJECTIVE COGNITIVE DECLINE ON APOE GENOTYPE DISCLOSURE IN THE BUTLER HOSPITAL ALZHEIMER’S PREVENTION REGISTRY | J Prev Alz Dis 2023;2(10):152-161 | 6 |
| A PRAGMATIC, INVESTIGATOR-DRIVEN PROCESS FOR DISCLOSURE OF AMYLOID PET SCAN RESULTS TO ADNI-4 RESEARCH PARTICIPANTS | J Prev Alz Dis 2024;2(11):294-302 | 6 |
| CLINICAL CORRELATES OF THE PET-BASED BRAAK STAGING FRAMEWORK IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;2(11):414-421 | 6 |
| VALUE OF BLOOD NEURAL CELL-DERIVED SMALL EXTRACELLULAR VESICLES IN THE DIAGNOSIS AND PREDICTION OF ALZHEIMER\'S DISEASE: A SYSTEMATIC REVIEW | | 6 |
| DEVELOPMENT OF AN UPSA SHORT FORM FOR USE IN LONGITUDINAL STUDIES IN THE EARLY ALZHEIMER’S DISEASE SPECTRUM | J Prev Alz Dis 2020;3(7):179-183 | 5 |
| AN INDUSTRY PERSPECTIVE: FUTURE OF ANTI-AMYLOID TRIALS | J Prev Alz Dis 2020;3(7):142-143 | 5 |
| A IS FOR AMYLOID | J Prev Alz Dis 2020;3(7):140-141 | 5 |
| A JAPANESE MULTICENTER STUDY ON PET AND OTHER BIOMARKERS FOR SUBJECTS WITH POTENTIAL PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;4(8):495-502 | 5 |
| COHORT-SPECIFIC OPTIMIZATION OF MODELS PREDICTING PRECLINICAL ALZHEIMER’S DISEASE, TO ENHANCE SCREENING PERFORMANCE IN THE MIDDLE OF PRECLINICAL ALZHEIMER’S DISEASE CLINICAL STUDIES | J Prev Alz Dis 2021;4(8):503-512 | 5 |
| DISEASE BURDEN AND ATTRIBUTABLE RISK FACTORS OF ALZHEIMER’S DISEASE AND DEMENTIA IN CHINA FROM 1990 TO 2019 | J Prev Alz Dis 2022;2(9):306-314 | 5 |
| CLINICAL RESEARCH INVESTIGATING ALZHEIMER’S DISEASE IN CHINA: CURRENT STATUS AND FUTURE PERSPECTIVES TOWARD PREVENTION | J Prev Alz Dis 2022;3(9):532-541 | 5 |
| DEMOGRAPHIC ANALYSIS OF INDUSTRY-SPONSORED ALZHEIMER’S DISEASE TRIAL POPULATIONS IN THE UNITED STATES | J Prev Alz Dis 2023;1(10):130-132 | 5 |
| PHARMACOLOGICAL INVENTIONS FOR ALZHEIMER TREATMENT IN THE UNITED STATES OF AMERICA: A REVISION PATENT FROM 2010 – 2020 | J Prev Alz Dis 2023;1(10):50-68 | 5 |
| MEDICAL JOURNEY OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD ALZHEIMER’S DISEASE DEMENTIA: A CROSS-SECTIONAL SURVEY OF PATIENTS, CARE PARTNERS, AND NEUROLOGISTS | J Prev Alz Dis 2023;2(10):162-170 | 5 |
| LONGITUDINAL EXPOSURE–RESPONSE MODELING OF MULTIPLE INDICATORS OF ALZHEIMER’S DISEASE PROGRESSION | J Prev Alz Dis 2023;2(10):212-222 | 5 |
| SCREENING OVER SPEECH IN UNSELECTED POPULATIONS FOR CLINICAL TRIALS IN AD (PROSPECT-AD): STUDY DESIGN AND PROTOCOL | J Prev Alz Dis 2023;2(10):314-321 | 5 |
| NEUROINFLAMMATION BIOMARKERS IN THE AT(N) FRAMEWORK ACROSS THE ALZHEIMER’S DISEASE CONTINUUM | J Prev Alz Dis 2023;3(10):401-417 | 5 |
| LETTER TO THE EDITOR: FIRST EXPERIENCES WITH AMYLOID-RELATED IMAGING ABNORMALITIES – YET WITHOUT IMAGING THAT CAN RULE OUT CEREBRAL INJURY OR MONITOR EFFICACY OF RECOMMENDED MANAGEMENT | J Prev Alz Dis 2024;1(11):259-260 | 5 |
| EFFECTS OF A GROUP-BASED 8-WEEK MULTICOMPONENT COGNITIVE TRAINING ON COGNITION, MOOD AND ACTIVITIES OF DAILY LIVING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP OF A RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2020;7(2):112-121 | 4 |
| SEARCHING FOR THE HOLY GRAIL WILL NEED BIOMARKERS | J Prev Alz Dis 2020;7(1):4-6 | 4 |
| IS RELUCTANCE TO SHARE ALZHEIMER’S DISEASE BIOMARKER STATUS WITH A STUDY PARTNER A BARRIER TO PRECLINICAL TRIAL RECRUITMENT? | J Prev Alz Dis 2021;1(8):52-58 | 4 |
| A NOVEL COMPUTERIZED COGNITIVE STRESS TEST TO DETECT MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2021;2(8):135-141 | 4 |
| ENVIRONMENTAL DISTRACTIONS DURING UNSUPERVISED REMOTE DIGITAL COGNITIVE ASSESSMENT | J Prev Alz Dis 2021;3(8):263-266 | 4 |
| QUANTIFYING RECRUITMENT SOURCE AND PARTICIPANT COMMUNICATION PREFERENCES FOR ALZHEIMER’S DISEASE PREVENTION RESEARCH | J Prev Alz Dis 2021;3(8):299-305 | 4 |
| PERIPHERAL BLOOD BRCA1 METHYLATION POSITIVELY CORRELATES WITH MAJOR ALZHEIMER’S DISEASE RISK FACTORS | J Prev Alz Dis 2021;4(8):477-482 | 4 |
| THE ASSOCIATION BETWEEN PEANUT AND PEANUT BUTTER CONSUMPTION AND COGNITIVE FUNCTION AMONG COMMUNITY-DWELLING OLDER ADULTS | J Prev Alz Dis 2021;4(8):436-441 | 4 |
| RECRUITMENT OF OLDER AFRICAN AMERICANS IN ALZHEIMER’S DISEASE CLINICAL TRIALS USING A COMMUNITY EDUCATION APPROACH | J Prev Alz Dis 2022;4(9):672-678 | 4 |
| US ADULTS’ LIKELIHOOD TO PARTICIPATE IN DEMENTIA PREVENTION DRUG TRIALS: RESULTS FROM THE NATIONAL POLL ON HEALTHY AGING | J Prev Alz Dis 2023;1(10):34-40 | 4 |
| FRUCTOSE CONSUMPTION IS ASSOCIATED WITH A HIGHER RISK OF DEMENTIA AND ALZHEIMER’S DISEASE: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2023;2(10):186-192 | 4 |
| EXPECTANCY DOES NOT PREDICT 18-MONTH TREATMENT OUTCOMES WITH COGNITIVE TRAINING IN MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2024;1(11):71-78 | 4 |
| ADDING THE TOPOGRAPHICAL INFORMATION FROM TAU-PET TO THE A/T/(N) FRAMEWORK: STEPS TOWARDS STAGING AD IN VIVO | J Prev Alz Dis 2023;3(10):381-386 | 4 |
| REPRODUCTIVE MARKERS IN ALZHEIMER’S DISEASE PROGRESSION: THE FRAMINGHAM HEART STUDY | J Prev Alz Dis 2023;3(10):530-535 | 4 |
| ASSOCIATION BETWEEN LONGITUDINAL CEREBROSPINAL FLUID ALZHEIMER’S BIOMARKERS AND THE LIFESTYLE FOR BRAIN HEALTH (LIBRA) INDEX: FINDINGS FROM THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA COHORT STUDY (EPAD LCS) | J Prev Alz Dis 2023;3(10):543-550 | 4 |
| METFORMIN IN THE PREVENTION OF ALZHEIMER’S DISEASE AND ALZHEIMER’S DISEASE RELATED DEMENTIAS | J Prev Alz Dis 2023;4(10):706-717 | 4 |
| PHASE 1/2A INTRAVENOUS AND SUBCUTANEOUS OLIGOMERSPECIFIC ANTIBODY KHK6640 IN MILD TO MODERATE ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;1(11):65-70 | 4 |
| POTENTIAL IMPLICATIONS OF SLOWING DISEASE PROGRESSION IN AMYLOID-POSITIVE EARLY ALZHEIMER’S DISEASE: ESTIMATES FROM REAL-WORLD DATA | J Prev Alz Dis 2024;2(11):310-319 | 4 |
| AT-HOME ADMINISTRATION OF GANTENERUMAB BY CARE PARTNERS TO PEOPLE WITH EARLY ALZHEIMER’S DISEASE: FEASIBILITY, SAFETY AND PHARMACODYNAMIC IMPACT | J Prev Alz Dis 2024;3(11):537-548 | 4 |
| EVALUATING CAUSAL EFFECTS OF GUT MICROBIOME ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;6(11):1843-1848 | 4 |
| NEUROPROTECTIVE EFFECTS OF GUARANA (PAULLINIA CUPANA MART.) AGAINST VINCRISTINE IN VITRO EXPOSURE | J Prev Alz Dis 2018;5(1):65-70 | 3 |
| EFFECTS OF RICE WINE LEES ON COGNITIVE FUNCTION IN COMMUNITY-DWELLING PHYSICALLY ACTIVE OLDER ADULTS: A PILOT RANDOMIZED CONTROLLED TRIAL | J Prev Alz Dis 2020;7(2):95-103 | 3 |
| THE PATIENT IN YOUR ALZHEIMER’S DISEASE STUDY MAY BE IN ANOTHER: DUPLICATION AND DECEPTION IN CLINICAL TRIALS OF ALZHEIMER’S DISEASE | J Prev Alz Dis 2020;7(1):43-46 | 3 |
| EXPLORING FACTORS THAT CONTRIBUTE TO JOINING AND REGULARLY PRACTICING IN COGNITIVE TRAINING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP QUALITATIVE STUDY | J Prev Alz Dis 2020;7(2):75-81 | 3 |
| COMMUNICATING PERSONAL RISK PROFILES OF ALZHEIMER’S DISEASE TO OLDER ADULTS: A PILOT TRIAL | J Prev Alz Dis 2022;1(9):144-150 | 3 |
| REPRESENTATION OF RACIAL AND ETHNIC MINORITY POPULATIONS IN DEMENTIA PREVENTION TRIALS: A SYSTEMATIC REVIEW | J Prev Alz Dis 2022;1(9):113-118 | 3 |
| KETONE ESTER EFFECTS ON BIOMARKERS OF BRAIN METABOLISM AND COGNITIVE PERFORMANCE IN COGNITIVELY INTACT ADULTS ≥ 55 YEARS OLD. A STUDY PROTOCOL FOR A DOUBLEBLINDED RANDOMIZED CONTROLLED CLINICAL TRIAL | J Prev Alz Dis 2022;1(9):54-66 | 3 |
| INTERVENTION FOR COGNITIVE RESERVE ENHANCEMENT IN DELAYING THE ONSET OF ALZHEIMER’S SYMPTOMATIC EXPRESSION (INCREASE) STUDY: RESULTS FROM A RANDOMIZED CONTROLLED STUDY OF MEDICATION THERAPY MANAGEMENT TARGETING A DELAY IN PRODROMAL DEMENTIA SYMPTOM PROGRESSION | J Prev Alz Dis 2022;4(9):646-654 | 3 |
| A HIERARCHICAL BAYESIAN LATENT CLASS MODEL FOR THE DIAGNOSTIC PERFORMANCE OF MINI-MENTAL STATE EXAMINATION AND MONTREAL COGNITIVE ASSESSMENT IN SCREENING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;4(9):589-600 | 3 |
| LETTER TO THE EDITOR: GENETICALLY DETERMINED ALZHEIMER’S DISEASE IS ASSOCIATED WITH INCREASED RISK OF VARICOSE VEIN: A MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2022;4(9):816-817 | 3 |
| WHITE MATTER HYPERINTENSITY AS A VASCULAR CONTRIBUTION TO THE AT(N) FRAMEWORK | J Prev Alz Dis 2023;3(10):387-400 | 3 |
| HIGH INTAKE OF DIETARY CHOLESTEROL DECREASES THE RISK OF ALL-CAUSE DEMENTIA AND AD DEMENTIA: A RESULTS FROM FRAMINGHAM OFFSPRING COHORT | J Prev Alz Dis 2023;4(10):748-755 | 3 |
| PLASMA OLIGOMER Β-AMYLOID AND WHITE MATTER MICROSTRUCTURAL INTEGRITY IN COGNITIVELY NORMAL OLDER ADULTS ACCORDING TO CEREBRAL AMYLOID DEPOSITION | J Prev Alz Dis 2023;4(10):837-846 | 3 |
| ETHICAL CONSIDERATIONS AT THE INTERSECTION OF SOCIAL MEDIA AND DEMENTIA PREVENTION RESEARCH | J Prev Alz Dis 2024;2(11):274-284 | 3 |
| ALZHEIMER’S DISEASE BIOMARKER DECISION-MAKING AMONG PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND THEIR CARE PARTNERS | J Prev Alz Dis 2024;2(11):285-293 | 3 |
| DOMINANTLY INHERITED ALZHEIMER NETWORK TRIALS UNIT (DIAN-TU): TRIAL SATISFACTION AND ATTITUDES TOWARDS FUTURE CLINICAL TRIALS | J Prev Alz Dis 2024;3(11):558-566 | 3 |
| PREDICTING COGNITIVE DECLINE FOR NON-DEMENTED ADULTS WITH HIGH BURDEN OF TAU PATHOLOGY, INDEPENDENT OF AMYLOID STATUS | J Prev Alz Dis 2024;4(11):908-916 | 3 |
| DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND DEMENTIA PREVENTION: A SYSTEMATIC REVIEW OF OBSERVATIONAL EVIDENCE IN RHEUMATOID ARTHRITIS | J Prev Alz Dis 2024;5(11):1339-1347 | 3 |
| META ANALYSIS OF THE CORRELATION BETWEEN PERIODONTAL HEALTH AND COGNITIVE IMPAIRMENT IN THE OLDER POPULATION | J Prev Alz Dis 2024;5(11):1307-1315 | 3 |
| SEMORINEMAB PHARMACOKINETICS AND THE EFFECT ON PLASMA TOTAL TAU PHARMACODYNAMICS IN CLINICAL STUDIES | J Prev Alz Dis 2024;5(11):1241-1250 | 3 |
| THE CAUSAL RELATIONSHIP BETWEEN GENETICALLY PREDICTED BIOLOGICAL AGING, ALZHEIMER’S DISEASE AND COGNITIVE FUNCTION: A MENDELIAN RANDOMISATION STUDY | J Prev Alz Dis 2024;6(11):1826-1833 | 3 |
| EFFECTS OF VITAMIN D3 COMBINED WITH FOLIC ACID ON DOMAIN AND SPECIFIC COGNITIVE FUNCTION AMONG PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CLINICAL TRIAL | J Prev Alz Dis 2024;6(11):1626-1633 | 3 |
| EDITORIAL : ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA? | | 2 |
| EFFECTS ON COGNITION OF BERRY, POMEGRANATE, GRAPE AND BIOPHENOLS: A GENERAL REVIEW | | 2 |
| INTEGRATING BIOMARKER OUTCOMES INTO CLINICAL TRIALS FOR ALZHEIMER’S DISEASE IN DOWN SYNDROME | J Prev Alz Dis 2021;1(8):48-51 | 2 |
| MENTAL COMPONENT SCORE (MCS) FROM HEALTH-RELATED QUALITY OF LIFE PREDICTS INCIDENCE OF DEMENTIA IN U.S. MALES | J Prev Alz Dis 2021;2(8):169-174 | 2 |
| A SYSTEMATIC REVIEW ON THE FEASIBILITY OF SALIVARY BIOMARKERS FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;1(8):84-91 | 2 |
| EXECUTIVE FUNCTION PREDICTS THE VALIDITY OF SUBJECTIVE MEMORY COMPLAINTS IN OLDER ADULTS BEYOND DEMOGRAPHIC, EMOTIONAL, AND CLINICAL FACTORS | J Prev Alz Dis 2021;2(8):161-168 | 2 |
| DOES TEA DRINKING PROMOTE HEALTH OF OLDER ADULTS: EVIDENCE FROM THE CHINA HEALTH AND NUTRITION SURVEY | J Prev Alz Dis 2021;2(8):194-198 | 2 |
| DETERMINANTS OF MEDICAL DIRECT COSTS OF CARE AMONG PATIENTS OF A MEMORY CENTER | J Prev Alz Dis 2021;3(8):351-361 | 2 |
| MAIL AND TELEPHONE OUTREACH FROM ELECTRONIC HEALTH RECORDS FOR RESEARCH PARTICIPATION ON COGNITIVE HEALTH AND AGING | J Prev Alz Dis 2021;3(8):292-298 | 2 |
| SENOLYTIC THERAPY TO MODULATE THE PROGRESSION OF ALZHEIMER’S DISEASE (STOMP-AD): A PILOT CLINICAL TRIAL | J Prev Alz Dis 2022;1(9):22-29 | 2 |
| IS “PRE-PRECLINICAL AD” HELPFUL TO THE EU/US CTAD TASK FORCE? | J Prev Alz Dis 2022;1(9):184 | 2 |
| ANXIETY AND DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID-Β BURDEN IN COGNITIVELY UNIMPAIRED OLDER ADULTS | J Prev Alz Dis 2022;2(9):286-296 | 2 |
| EVERYDAY FUNCTIONING AND ENTORHINAL AND INFERIOR TEMPORAL TAU BURDEN IN COGNITIVELY NORMAL OLDER ADULTS | J Prev Alz Dis 2022;4(9):801-808 | 2 |
| ASSOCIATION OF A MIND DIET WITH BRAIN STRUCTURE AND DEMENTIA IN A FRENCH POPULATION | J Prev Alz Dis 2022;4(9):655-664 | 2 |
| ALZHEIMER’S DISEASE CLINICAL TRIAL RESEARCH ADAPTATION FOLLOWING COVID-19 PANDEMIC ONSET: NATIONAL SAMPLE OF ALZHEIMER’S CLINICAL TRIAL CONSORTIUM SITES | J Prev Alz Dis 2022;4(9):665-671 | 2 |
| AGE, SEX, HYPERTENSIONANDHDL-CALTERSERUMBACE1ACTIVITY IN COGNITIVELY NORMAL SUBJECTS: IMPLICATIONS FOR ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;4(9):708-714 | 2 |
| PROGRAMMED DEATH OF MICROGLIA IN ALZHEIMER’S DISEASE: AUTOPHAGY, FERROPTOSIS, AND PYROPTOSIS | J Prev Alz Dis 2023;1(10):95-103 | 2 |
| RISK ESTIMATES OF DEMENTIA AND ALZHEIMER’S DISEASE AMONG DIFFERENT WHOLE GRAIN FOOD CONSUMPTION CATEGORIES: A PILOT STUDY | J Prev Alz Dis 2023;1(10):133-136 | 2 |
| MEDICAL AND PSYCHIATRIC RISK FACTORS FOR DEMENTIA IN VETERANS WITH AND WITHOUT TRAUMATIC BRAIN INJURY (TBI): A NATIONWIDE COHORT STUDY | J Prev Alz Dis 2023;2(10):244-250 | 2 |
| A GENETIC VALIDATION OF THE NEURODEGENERATION BIOMARKERS TAU-A AND TAU-C - A MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2023;3(10):536-542 | 2 |
| GENOTYPIC EFFECTS OF THE TOMM40’523 VARIANT AND APOE ON LONGITUDINAL COGNITIVE CHANGE OVER 4 YEARS: THE TOMMORROW STUDY | J Prev Alz Dis 2023;4(10):886-894 | 2 |
| RELATIONSHIPS OF HYPNOTICS WITH INCIDENT DEMENTIA AND ALZHEIMER’S DISEASE: A LONGITUDINAL STUDY AND META-ANALYSIS | J Prev Alz Dis 2024;1(11):117-129 | 2 |
| ALZHEIMER’S DISEASE AND AGING ASSOCIATION: IDENTIFICATION AND VALIDATION OF RELATED GENES | J Prev Alz Dis 2024;1(11):196-213 | 2 |
| THE THERAPEUTIC EFFECTS OF NONINVASIVE BRAIN STIMULATION COMBINED WITH COGNITIVE TRAINING IN ELDERS WITH ALZHEIMER’S DISEASE OR AMNESIC MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2024;1(11):222-229 | 2 |
| ERRATUM TO: CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL | J Prev Alz Dis 2024;1(11):264 | 2 |
| LETTER TO THE EDITOR: ALZHEIMER’S DISEASE-ASSOCIATED APOE Ε4 FREQUENCIES IN INDIAN POPULATION GENOMES MAY SUGGEST IMPLICATIONS IN LECANEMAB TREATMENT | J Prev Alz Dis 2024;2(11):525-526 | 2 |
| IMPACT OF DIFFERENTIAL RATES OF DISEASE PROGRESSION IN AMYLOID-POSITIVE EARLY ALZHEIMER’S DISEASE: FINDINGS FROM A LONGITUDINAL COHORT ANALYSIS | J Prev Alz Dis 2024;2(11):320-328 | 2 |
| EXAMINING THE DIAGNOSTIC ACCURACY OF A NOVEL PERFORMANCE-BASED TEST FOR ALZHEIMER’S DISEASE SCREENING | J Prev Alz Dis 2024;4(11):903-907 | 2 |
| ASSOCIATION BETWEEN CEREBROSPINAL FLUID STREM2 LEVELS AND DEPRESSION: THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE STUDY | J Prev Alz Dis 2024;4(11):1087-1092 | 2 |
| LEFT FRONTOPARIETAL CONTROL NETWORK CONNECTIVITY MODERATES THE EFFECT OF AMYLOID ON COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER’S DISEASE: THE A4 STUDY | J Prev Alz Dis 2024;4(11):881-888 | 2 |
| ALZHEIMER’S DISEASE LINKAGE TO REAL-WORLD EVIDENCE (AD-LINE) STUDY: LINKING CLAIMS DATA TO PHASE 3 GRADUATE STUDY OF GANTENERUMAB | J Prev Alz Dis 2024;5(11):1251-1259 | 2 |
| MULTIDOMAIN INTERVENTION FOR THE REVERSAL OF COGNITIVE FRAILTY USING A PERSONALIZED APPROACH (AGELESS TRIAL): RECRUITMENT AND BASELINE CHARACTERISTICS OF PARTICIPANTS | J Prev Alz Dis 2024;5(11):1291-1306 | 2 |
| ASSOCIATIONS OF LATER-LIFE EDUCATION, THE BDNF VAL66MET POLYMORPHISM AND COGNITIVE CHANGE IN OLDER ADULTS | J Prev Alz Dis 2020;7(1):37-42 | 1 |
| ASSOCIATION OF VITAMIN D LEVELS WITH INCIDENT ALLCAUSE DEMENTIA IN LONGITUDINAL OBSERVATIONAL STUDIES: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2020;7(1):14-20 | 1 |
| Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA | | 1 |
| Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA | | 1 |
| KNOWLEDGE, ATTITUDE AND PREVENTIVE PRACTICE ON DEMENTIA CARE AMONG PRIMARY HEALTH PROFESSIONALS IN MACAO | J Prev Alz Dis 2020;7(2):83-86 | 1 |
| THE EFFECT OF BASELINE PERFORMANCE AND AGE ON COGNITIVE TRAINING IMPROVEMENTS IN OLDER ADULTS: A QUALITATIVE REVIEW | J Prev Alz Dis 2021;1(8):100-109 | 1 |
| PHYSICAL FITNESS AND APOLIPOPROTEIN E GENOTYPE INFLUENCE CORTICAL NETWORKING AND INTELLIGENCE IN ADOLESCENTS | J Prev Alz Dis 2021;1(8):92-99 | 1 |
| COMPARATIVE EFFECTIVENESS OF BEHAVIORAL INTERVENTIONS TO PREVENT OR DELAY DEMENTIA: ONEYEAR PARTNER OUTCOMES | J Prev Alz Dis 2021;1(8):33-40 | 1 |
| MOLECULAR SUBTYPING OF MILD COGNITIVE IMPAIRMENT BASED ON GENETIC POLYMORPHISM AND GENE EXPRESSION | J Prev Alz Dis 2021;2(8):224-233 | 1 |
| CHINESE VERSION OF THE BAYLOR PROFOUND MENTAL STATUS EXAMINATION: A BRIEF STAGING MEASURE FOR PATIENTS WITH SEVERE ALZHEIMER’S DISEASE | J Prev Alz Dis 2021;2(8):175-180 | 1 |
| CHILDHOOD SECONDHAND SMOKE EXPOSURE AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE IN ADULTHOOD: A PROSPECTIVE COHORT STUDY | J Prev Alz Dis 2021;3(8):345-350 | 1 |
| DETERMINANTS OF POST-OPERATIVE COGNITIVE DECLINE IN ELDERLY PEOPLE | J Prev Alz Dis 2021;3(8):322-328 | 1 |
| DEVELOPMENT, VALIDATION AND FIELD EVALUATION OF THE SINGAPORE LONGITUDINAL AGEING STUDY (SLAS) RISK INDEX FOR PREDICTION OF MILD COGNITIVE IMPAIRMENT AND DEMENTIA | J Prev Alz Dis 2021;3(8):335-344 | 1 |
| ASSOCIATION OF SUBJECTIVE COGNITIVE DECLINE WITH RISK OF COGNITIVE IMPAIRMENT AND DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF PROSPECTIVE LONGITUDINAL STUDIES | J Prev Alz Dis 2021;3(8):277-285 | 1 |
| A FAY-HERRIOT MODEL FOR ESTIMATING SUBJECTIVE COGNITIVE DECLINE AMONG MILITARY VETERANS | J Prev Alz Dis 2021;4(8):457-461 | 1 |
| EARLY-ONSET SUBGROUP OF TYPE 2 DIABETES AND RISK OF DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A COHORT STUDY | J Prev Alz Dis 2021;4(8):442-447 | 1 |
| DIVERSIFYING RECRUITMENT REGISTRIES: CONSIDERING NEIGHBORHOOD HEALTH METRICS | J Prev Alz Dis 2022;1(9):119-125 | 1 |
| EVALUATION OF MEMANTINE IN AAV-AD RAT: A MODEL OF LATEONSET ALZHEIMER’S DISEASE PREDEMENTIA | J Prev Alz Dis 2022;2(9):338-347 | 1 |
| THE SINGAPORE GERIATRIC INTERVENTION STUDY TO REDUCE COGNITIVE DECLINE AND PHYSICAL FRAILTY (SINGER): STUDY DESIGN AND PROTOCOL | J Prev Alz Dis 2022;1(9):40-48 | 1 |
| AT A GLANCE: AN UPDATE ON NEUROIMAGING AND RETINAL IMAGING IN ALZHEIMER’S DISEASE AND RELATED RESEARCH | J Prev Alz Dis 2022;1(9):67-76 | 1 |
| STUDY PROTOCOL OF A COMPREHENSIVE ACTIVITY PROMOTION | J Prev Alz Dis 2022;2(9):376-384 | 1 |
| CEREBRAL PHOSPHO-TAU ACTS SYNERGISTICALLY WITH SOLUBLE AΒ42 LEADING TO MILD COGNITIVE IMPAIRMENT IN AAV-AD RATS | J Prev Alz Dis 2022;3(9):480-490 | 1 |
| INCREASED INCIDENT ALZHEIMER’S DISEASE AMONG INDIVIDUALS WITH VARICOSE VEINS: A POPULATION-BASED COHORT STUDY | J Prev Alz Dis 2022;3(9):441-448 | 1 |
| SUBJECTIVE COGNITIVE DECLINE IN A REGISTRY SAMPLE: RELATION TO PSYCHIATRIC HISTORY, LONELINESS, AND PERSONALITY | J Prev Alz Dis 2022;3(9):435-440 | 1 |
| EFFECTS OF NON-INVASIVE BRAIN STIMULATION ON ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;3(9):410-424 | 1 |
| LETTER TO THE EDITOR: EARLY-ONSET TYPE 2 DIABETES AND RISK OF DEMENTIA | J Prev Alz Dis 2022;3(9):561 | 1 |
| ALZHEIMER\'S DISEASE PREVENTION HEALTH COACHING | J Prev Alz Dis 2022;2(9):277-285 | 1 |
| SALIVARY ALPHA-AMYLASE ACTIVITY AND MILD COGNITIVE IMPAIRMENT AMONG JAPANESE OLDER ADULTS: THE TOON HEALTH STUDY | J Prev Alz Dis 2022;4(9):752-757 | 1 |
| VALIDATION OF THE SAINT LOUIS UNIVERSITY QUALITY OF LIFE QUESTIONNAIRE IN OLDER ADULTS WITH ALZHEIMER’S DISEASE | J Prev Alz Dis 2022;4(9):809-812 | 1 |
| OBESITY AND BRAIN HEALTH: THE IMPACT OF METABOLIC SYNDROME AND CARDIORESPIRATORY FITNESS ON COGNITIVE PERFORMANCES IN MIDDLE-AGED OBESE WOMEN | J Prev Alz Dis 2022;4(9):701-707 | 1 |
| ASSOCIATION OF PREECLAMPSIA WITH INCIDENT DEMENTIA AND ALZHEIMER’S DISEASE AMONG WOMEN IN THE FRAMINGHAM OFFSPRING STUDY | J Prev Alz Dis 2022;4(9):725-730 | 1 |
| OBJECTIVE AND SUBJECTIVE MEASUREMENTS OF MOTOR FUNCTION: RESULTS FROM THE HELIAD STUDY | J Prev Alz Dis 2022;4(9):743-751 | 1 |
| SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ICAPAMESPIB, A SELECTIVE EPICHAPEROME INHIBITOR, IN HEALTHY ADULTS | J Prev Alz Dis 2022;4(9):635-645 | 1 |
| DELAYED DECLINE OF COGNITIVE FUNCTION BY ANTIHYPERTENSIVE AGENTS: A COHORT STUDY LINKED WITH GENOTYPE DATA | J Prev Alz Dis 2022;4(9):679-691 | 1 |
| SOCIOECONOMIC STATUS AND RISKS OF COGNITIVE IMPAIRMENT AND DEMENTIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF 39 PROSPECTIVE STUDIES | J Prev Alz Dis 2023;1(10):83-94 | 1 |
| AGE- AND SEX-DIFFERENT ASSOCIATIONS BETWEEN COGNITIVE PERFORMANCE AND INFLAMMATORY BIOMARKERS IN COMMUNITY DWELLING OLDER ADULTS: TOWARDS PRECISION PREVENTIVE STRATEGIES | J Prev Alz Dis 2023;1(10):104-111 | 1 |
| EMBRYO SELECTION FOR A CARRIER OF AN EARLY-ONSET ALZHEIMER’S DISEASE-ASSOCIATED MUTATION IN THE PSEN1 GENE | J Prev Alz Dis 2023;1(10):144-147 | 1 |
| ERRATUM TO: CEREBRAL PHOSPHO-TAU ACTS SYNERGISTICALLY WITH SOLUBLE AΒ42 LEADING TO MILD COGNITIVE IMPAIRMENT IN AAV-AD RATS | J Prev Alz Dis 2023;1(10):150 | 1 |
| ERRATUM TO: ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASE | J Prev Alz Dis 2023;1(10):151 | 1 |
| SUBJECTIVE COGNITIVE COMPLAINTS: COMPARING THE RELATION BETWEEN SELF-REPORTED VERSUS INFORMANTREPORTED SUBJECTIVE COGNITIVE COMPLAINTS AND COGNITIVE PERFORMANCES IN COGNITIVELY UNIMPAIRED, MILD COGNITIVE IMPAIRMENT AND POPULATIONS WITH DEMENTIA | J Prev Alz Dis 2023;3(10):562-570 | 1 |
| LIFESTYLE AND SOCIOECONOMIC TRANSITION AND HEALTH CONSEQUENCES OF ALZHEIMER’S DISEASE AND OTHER DEMENTIAS IN GLOBAL, FROM 1990 TO 2019 | J Prev Alz Dis 2024;1(11):88-96 | 1 |
| ASSOCIATION OF LONELINESS WITH COGNITIVE FUNCTIONS | J Prev Alz Dis 2023;4(10):903-908 | 1 |
| ADULT RENAL DYSFUNCTION AND RISK OF DEMENTIA OR COGNITIVE DECLINE: BRAIN-KIDNEY AXIS HYPOTHESIS BASED ON A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2023;3(10):443-452 | 1 |
| USEFULNESS OF COMMUNITY PHARMACY FOR EARLY DETECTION OF COGNITIVE IMPAIRMENT IN OLDER PEOPLE USING THE IQCODE QUESTIONNAIRE | J Prev Alz Dis 2023;3(10):488-496 | 1 |
| TEN YEARS AFTER THE NATIONAL ALZHEIMER’S PLAN: DEMENTIA REMAINS A HIDDEN SYNDROME IN FRANCE | J Prev Alz Dis 2023;3(10):600-606 | 1 |
| HIGH-FAT DIET-INDUCED DIABETIC CONDITIONS EXACERBATE COGNITIVE IMPAIRMENT IN A MOUSE MODEL OF ALZHEIMER’S DISEASE VIA A SPECIFIC TAU PHOSPHORYLATION PATTERN | J Prev Alz Dis 2024;1(11):138-148 | 1 |
| A RANDOMIZED PROSPECTIVE SURVEY TARGETING KNOWLEDGE, BARRIERS, FACILITATORS AND READINESS TO PARTICIPATION IN DEMENTIA RESEARCH | J Prev Alz Dis 2023;4(10):790-799 | 1 |
| SOCIAL DETERMINANTS OF HEALTH AMONG OLDER ADULTS WITH DEMENTIA IN URBAN AND RURAL AREAS | J Prev Alz Dis 2023;4(10):895-902 | 1 |
| INVESTIGATING THE FACTOR STRUCTURE OF THE PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE AND COGNITIVE FUNCTION INDEX ACROSS RACIAL/ETHNIC, SEX, AND AΒ STATUS GROUPS IN THE A4 STUDY | J Prev Alz Dis 2024;1(11):48-55 | 1 |
| ASSOCIATION OF BALANCE IMPAIRMENT WITH RISK OF INCIDENT DEMENTIA AMONG OLDER ADULTS | J Prev Alz Dis 2024;1(11):130-137 | 1 |
| THE IMPACT OF TESTOSTERONE ON ALZHEIMER’S DISEASE ARE MEDIATED BY LIPID METABOLISM AND OBESITY: A MENDELIAN RANDOMIZATION STUDY | J Prev Alz Dis 2024;2(11):507-513 | 1 |
| INTEGRATED BIOINFORMATIC ANALYSIS AND VALIDATION IDENTIFIES IMMUNE MICROENVIRONMENT-RELATED POTENTIAL BIOMARKERS IN ALZHEIMER’S DISEASE | J Prev Alz Dis 2024;2(11):495-506 | 1 |
| PERSONALIZED COMPUTATIONAL CAUSAL MODELING OF THE ALZHEIMER DISEASE BIOMARKER CASCADE | J Prev Alz Dis 2024;2(11):435-444 | 1 |
| FRUIT INTAKE AND ALZHEIMER’S DISEASE: RESULTS FROM MENDELIAN RANDOMIZATION | J Prev Alz Dis 2024;2(11):445-452 | 1 |
| CARDIOVASCULAR RISK SCALES ASSOCIATION WITH CEREBROSPINAL FLUID ALZHEIMER’S DISEASE BIOMARKERS IN CARDIOVASCULAR LOW CARDIOVASCULAR RISK REGIONS | J Prev Alz Dis 2024;2(11):453-462 | 1 |
| ASSOCIATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS WITH RISK OF ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS | J Prev Alz Dis 2024;3(11):721-729 | 1 |
| POLYGENIC RISK SCORE REVEALS GENETIC HETEROGENEITY OF ALZHEIMER’S DISEASE BETWEEN THE CHINESE AND EUROPEAN POPULATIONS | J Prev Alz Dis 2024;3(11):701-709 | 1 |
| FISH AND SHELLFISH CONSUMPTION, COGNITIVE HEALTH AND MORTALITY FROM ALZHEIMER’S DISEASE AMONG US ADULTS AGED 60 AND OLDER | J Prev Alz Dis 2024;3(11):632-638 | 1 |
| SERUM TAU-A AND TAU-C LEVELS AND THEIR ASSOCIATION WITH COGNITIVE IMPAIRMENT AND DEMENTIA PROGRESSION IN A MEMORY CLINIC DERIVED COHORT | J Prev Alz Dis 2024;3(11):730-738 | 1 |
| MAGNETIC RESONANCE IMAGING-NEGATIVE CEREBRAL AMYLOID ANGIOPATHY: CEREBROSPINAL FLUID AMYLOID-Β42 OVER AMYLOID POSITRON EMISSION TOMOGRAPHY | J Prev Alz Dis 2024;4(11):1041-1046 | 1 |
| VALUE OF KNOWING: HEALTH-RELATED BEHAVIOR CHANGES FOLLOWING AMYLOID PET RESULTS DISCLOSURE IN MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2024;4(11):958-965 | 1 |
| LONGITUDINAL EVOLUTION OF FINANCIAL CAPACITY AND CEREBRAL TAU AND AMYLOID BURDEN IN OLDER ADULTS WITH NORMAL COGNITION OR MILD COGNITIVE IMPAIRMENT | J Prev Alz Dis 2024;4(11):966-974 | 1 |
| INTEREST IN AND EXPERIENCE WITH GENETIC TESTING FOR LATE-ONSET MEDICAL CONDITIONS: RESULTS FROM THE NATIONAL POLL ON HEALTHY AGING | J Prev Alz Dis 2024;4(11):1079-1086 | 1 |
| LETTER TO THE EDITOR: HYPNOTICS AND INCIDENT DEMENTIA: A RISK ASSESSMENT | J Prev Alz Dis 2024;4(11):1177 | 1 |
| EVALUATING THE PERFORMANCE OF DIFFERENT CRITERIA IN DIAGNOSING AD AND PRECLINICAL AD WITH THE BAYESIAN LATENT CLASS MODEL | J Prev Alz Dis 2024;5(11):1316-1324 | 1 |
| EVALUATING THE CAUSAL EFFECT OF TYPE 2 DIABETES ON ALZHEIMER’S DISEASE USING LARGE-SCALE GENETIC DATA | J Prev Alz Dis 2024;5(11):1280-1282 | 1 |
| UNVEILING POTENTIAL BIOMARKERS IN CEREBROSPINAL FLUID FOR AMYLOID PATHOLOGICAL POSITIVITY IN NON-DEMENTED INDIVIDUALS | J Prev Alz Dis 2024;6(11):1759-1766 | 1 |